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General Protocol 
 
 
 
1. 1H NMR spectra were recorded on Bruker avance II 400 MHz NMR 
spectrometer using TMS as an internal reference.  
 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FR-IR-8400 spectrometer using 
KBr pellet method.  
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from 
Spectrochem, Merck, Thomas-baker and SD fine chemical. 
 
7. MPs were taken in open capillary and are uncorrected. 
 
8. Microwave assisted reaction were carried out in QPro-M microwave 
synthesizer.  
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1.1 INTRODUCTION  
 
Though Bayer1 determined its constitution in 1900, Runge2 was first to 
discovered pyrrole in 1834 as a certain coal tar fraction which was presumably 
responsible for this by hydrochloric acid of pine shaving previously dipped in 
them. 
Anderson3 characterized the structure of pyrrole in 1857 and was later 
synthesized by heating the ammonium salt of music acid.  
Pyrrole is an important π-electron excessive aromatic heterocycle. This ring 
system is incorporated as a basic structural unit in several natural pigment 
porphyrins, porphin (heme), chlorine (chlorophyll), and corrins (vitamin B12). 
Moreover the presence of pyrrole ring in porphobolinogen (I) (intermediate in 
biosynthesis of porphyrins and vitamin B12) has provided an impetus to the 
pyrrole chemistry.     
 
 
 
 
 
 
Many alkaloids and amino acids namely, proline and hydroxyl proline also contain 
the reduce pyrrole system (pyrrolidine)4. Many natural products containing pyrrole 
ring are also known5-8.  
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Their biological functions are as varied as are their structures9-11. Some natural 
pyrrole are pheromones12-13, plant hormones14, or act as antibiotics15. An 
important class of pyrrole derived natural products containing more than one 
pyrrole ring are Neotropsin (VII) and Distamysin (VIII), which bind to the groove of 
DNA16.                                                                    
                                                                                   
 
  
 
 
 
 
 
 
                                         
 
 
                           
 
                   
              
                                      
 
 
 
                                                                                                                                                        
1.1.1 Different method for synthesis of pyrrole 
 
Various methods for synthesis of pyrrole are as follows: 
 
1. Knorr Pyrrole synthesis17: 
This is the most widely used method and involves the cyclizative condensation of 
α- amino ketones or α- amino β- keto esters with β- diketones or β-ketones with 
formation of N-C2 and C3-C4 bonds. 
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2. α-amino ketones react with alkynes, undergoes nucleophilic-electrophilic 
interaction to provide pyrrole18. 
             
                                                              
 
                                     
 
 
 
 
 
 
3. Piloty- Robinson Pyrrole synthesis19 
The condensation of aliphatic aldehyde or ketones with hydrazine under strongly 
acidic conditions affords pyrrole. This reaction can also be applied for the 
preparation of N-substituted pyrroles by condensing ketones with methyl 
hydrazine or N,N-Dimethyle hydrazine. 
 
 
 
 
 
 
 
 
 
 
4. Hantsch Pyrrole synthesis20 
The reaction of β- keto or β- keto esters with α-halo ketones or aldehyde in the 
presence of ammonia or primary amine affords pyrroles. 
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5. The reaction of β-amino-α, β-unsaturated esters with nitro alkenes provides 
substituted pyrroles21. 
 
  
 
 
 
 
 
 
 
 
 
6. Condensation of α- diketones with amines substituted with electron-
withdrawing   species at β’-position, results in the corresponding pyrrole22. 
 
 
 
 
 
 
 
 
 
 
 
1.1.2 RECENT LETRATURE SURVEY  
1. An efficient, solvent-free, microwave-assisted coupling of chloroenones and 
amines on the surface of silica gel gave 1,2-disubstituted homochiral pyrroles in 
good yields23. 
 
 
 
 
2. A mild, gold (I)-catalyzed acetylenic Schmidt reaction of homopropargyl azides 
gave regiospecific substituted pyrroles. A mechanism in which azides serve as 
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nucleophiles toward gold (I)-activated alkynes with subsequent gold (I)-aided 
expulsion of dinitrogen is proposed24. 
 
 
 
 
 
 
 
 
 
3. An efficient and regioselective palladium-catalyzed cyclization of internal 
alkynes and 2-amino-3-iodoacrylates gave good yields of highly functionalized 
pyrroles25. 
 
 
 
 
4. Silver (I)-promoted oxidative cyclization of homopropargylamines at room 
temperature provides pyrroles. Homopropargylamines are readily available by the 
addition of a propargyl Grignard reagent to Schiff bases26. 
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5. A general, highly flexible Cu-catalyzed domino C-N coupling/hydroamination 
reaction constitutes a straightforward alternative to existing methodology for the 
preparation of pyrroles and pyrazoles27. 
 
  
 
 
6. An efficient and highly versatile microwave-assisted Paal-Knorr condensation 
of various 1,4-diketones gave furans, pyrroles and thiophenes in good yields. In 
addition, transformations of the methoxycarbonyl moiety, such as Curtius 
rearrangement, hydrolysis to carboxylic acid, or the conversion into amine by 
reaction with a primary amine in the presence of Me3Al, are studied28. 
  
 
 
 
 
7. The synthesis of N-acylpyrroles from primary aromatic amides and excess 2,5-
dimethoxytetrahydrofuran in presence of one equivalent of thionyl chloride offers 
short reaction times, mild reaction conditions, and easy workup29. 
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8. Propargyl vinyl ethers and aromatic amines are effectively converted into tetra- 
and pentasubstituted 5-methylpyrroles through a silver(I)-catalyzed propargyl-
Claisen rearrangement, an amine condensation, and a gold(I)- catalyzed 5-exo-
dig heterocyclization in a convenient one-pot process30. 
 
 
 
 
 
9. Various 2,3,4-trisubstituted pyrroles are easily accessible in one step from 
readily available acetylenes and acceptor-substituted methyl isocyanides by 
base-mediated or copper-catalyzed cycloadditions. Scope and limitations of both 
pyrrole syntheses are discussed31. 
 
 
 
  
10. A novel and efficient multicomponent reaction of N-tosylimines, DMAD, and 
isocyanides for the synthesis of 2-aminopyrrole systems was uncovered32. 
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11. A new microwave-assisted rearrangement of 1,3-oxazolidines scaffolds is the 
basis for a new, metal-free, direct, and modular construction of tetra substituted 
pyrroles from terminal-conjugated alkynes, aldehyde, and primary amines under 
very simple and environmental-friendly experimental conditions33. 
 
 
 
 
 
 
12. Coupling of acetylene, nitrile, and a titanium reagent generated new 
azatitanacyclopentadienes in a highly regioselective manner. The subsequent 
reaction with sulfonylacetylene and electrophiles gave substituted pyridines 
virtually as a single isomer. Alternatively, the reaction of 
azatitanacyclopentadienes with an aldehyde or another nitrile gave furans or 
pyrroles having four different substituents again in a regioselective manner34. 
 
 
  
 
 
 
 
 
13. An efficient synthesis of 2,3,4-trisubstituted pyrroles via intermolecular 
cyclization of alkylidenecyclopropyl ketones with amines were observed. A 
mechanism involving a distal cleavage of the C-C bond of the cyclopropane ring 
is discussed35. 
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14. Several aryl-substituted pyrrole derivatives were prepared conveniently in a 
microwave-assisted one pot-reaction from but-2-ene-1,4-diones and but-2-yne-1, 
4-diones via Pd/C-catalyzed hydrogenation of the carbon-carbon double 
bond/triple bond followed by amination-cyclization36. 
 
 
 
 
 
 
 
1.1.3 Biological profile 
 
Ghassan abdalla37 and his coworkers has discovered [3,2-b]-pyridine-6-
carboxylic acid from 2-methyl-3-benzoyl-4-amino pyrrole as potential 
antimicrobial agents. 
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Gaetano Dattolo38 and his research group has proposed a new ring system, 
pyrrolo [3,4-d]-1,2,3-trizine synthesized via diazotization of the 3-amino-4-
carboxamides under different conditions through an intramolecular coupling 
reaction. This molecule is found to be a potential antineoplastic agent. 
 
 
 
 
 
 
 
 
 
 
 
Wilson and group39 recently synthesized a series of pyrazole oxime ether 
derivatives were prepared and examined as cytotoxic agents. In particular, 5-
phenoxypyrazole was comparable to doxorubicin, while exhibiting very potent 
cytotoxicity against XF 498 and HCT15.The antimalarial activity of chloroquine-
pyrazole analogues, synthesized from the reaction of 1,1,1-trifluoro-4-methoxy-3-
alken-2-ones with 4-hydrazino-7-chloroquinoline, has been evaluated in vitro 
against a chloroquine resistant Plasmodium falciparum clone. Parasite growth in 
the presence of the test drugs was measured by incorporation of [3H] 
hypoxanthine in comparison to controls with number of drugs. Zhong Jin and co-
workers40 prepared novel ferrocene-containing propenones have been 
synthesized from acetylferrocene via a Mannich-type intermediate. Sequential 
condensation cyclization of these propenones with phenyl hydrazine afforded 
highly substituted 4,5-dihydropyrazole derivatives, which structures have been 
characterized by spectral data and single crystal X-ray diffraction analysis. In 
addition, these new ferrocene-containing derivatives have been evaluated for in 
vitro fungicidal activities against five selected fungi.  
Jenny L. and coworkers41 have described Novel Pyrazoles Cannabinoids: 
Insights into CB1 Receptor Recognition and Activation. Synthesis of an antagonist, 
SR141716A, that selectively binds to brain cannabinoid (CB1) receptors without 
producing cannabimimetic activity in vivo, suggests that recognition and activation  
N
NN
NH
CH3
O
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of cannabinoid receptors are separable events. In the present study, a series of 
SR141716A analogoues were synthesized and were tested for CB1 binding 
affinity and in a battery of in vivo tests, including hypo mobility, antinociception, 
and hypothermia in mice. These analogoues retained the central pyrazole 
structure of SR141716A with replacement of the 1-, 3-, 4-, and/or 5-substituents 
by alkyl side chains or other substituents known to impart potent agonist activity in 
traditional tricyclic cannabinoid compounds. Although none of the analogoues  
alone produced the profile of cannabimimetic effects seen with full agonists, 
several of the 3-substituent analogoues with higher binding affinities showed 
partial agonism for one or more measures. Cannabimimetic activity was most 
noted when the 3-substituent of SR141716A was replaced with an alkyl amide or 
ketone group (B). None of the 3-substituted analogoues produced antagonist 
effects when tested in combination with 3 mg/kg 9-tetrahydrocannabinol ( 9-
THC). In contrast, antagonism of 9-THC's effects without accompanying agonist 
or partial agonist effects was observed with substitutions at positions 1, 4, and 
5. These results suggest that the structural properties of 1- and 5-substituents are 
primarily responsible for the antagonist activity of SR141716A. 
 
     
 
 
 
 
 
 
 
 
 
 
 
Antonello and silvio42 synthesized 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-
2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. 
Effect of Pyrrole-C2 and/or -C4Substitutions on Biological Activity. 
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They investigated the effect on anti-HD2 activity of chemical substitutions 
performed on the pyrrole-C2 ethene chains of 1a-c, which were replaced with 
methylene, ethylene, substituted ethene, and 1,3-butadiene chains (compounds 
2). Biological results clearly indicated the unsubstantiated ethene chain as the 
best structural motif to get the highest HDAC inhibitory activity, the sole exception 
to this rule being the introduction of the 1,3-butadienylmoiety into the 1a chemical 
structure (IC50(2f) ) 0.77 íM; IC50(1a) ) 3.8 íM). IC50 values of compounds 3a-3f, 
prepared as 1b homologues, revealed that between benzene and carbonyl group 
sat the pyrrole-C4 position a hydrocarbon spacer length ranging from two to five 
methylenes is well accepted by the APHA template, being that two methylenes 
and five methylenes are more potent (2.3- and 1.4-fold, respectively) than 1b, 
while the introduction of a higher number of methylene units (see 3e, f) 
decreased the inhibitory activities of the derivatives. Particularly, 3a (IC50 ) 0.043 
íM) showed the same potency as SAHA in inhibiting HD2 invitro, and it was 3000- 
and 2.6-fold more potent than sodium valproate and HC-toxin and was4.3- and 6-
fold less potent than trapoxin and TSA, respectively. Finally, conformational 
constrained forms of 1b-1c, prepared with the aim to obtain some information 
potentially useful for a future 3D-QSAR study, showed the same (4a, b) or higher 
(4c, d) HD2inhibiting activities in comparison with those of the reference drugs. 
X
O
N
CH3
Y NHOH
O
X
O
N
CH3
NHOH
O
X
O
N
CH3
COOH
COOH
O
N
CH3
NHOH
O
n
N
CH3
OCH3
O
R
X=none, CH2, CH=CH
Y=CH2, CH2CH2, CH=C(CH3)
X= none, CH2 X=none, CH2
2b 2g
3a -f
4a-dn=2-7
CH3
CH3
CH3R =
2a,2f
CH3
 14
Molecular modeling and docking calculations on the designed compounds 
performed in parallel with the chemistry work fully supported the synthetic effort 
and gave insights into the binding mode of the more flexible APHA derivatives 
(i.e., 3a). Despite the difference of potency between 1b and 3a in the enzyme 
assay, the two APHA derivatives showed similar antiproliferative and cyto 
differentiating activities in vivo on Friends MEL cells, being that 3a is more potent 
than 1b in the differentiation assay only at the highest tested dose (48 íM). 
Mark player43 et al has synthesized 2, 7 disubstituted-5,6-dimethyl-[2,3-d]-1,3 
oxazine-4-ones from 2-amino-3-tert-butoxycarbonyl-4,5-dimethyl pyrrole, which 
are found to be the antifungal agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Said bayomi44 found that 2-amino-3-cyno-4-(substituted phenyl)-pyrroles acts as 
an antimicrobial agents. 
 
 
 
 
 
 
 
 
 
 
 
 
Carsin and John45 and his group found that pyrrolyl heteroaryl methanones and 
methanols are useful as treating or modulating central nervous system disorders. 
The preparation of these molecules was carried out by Friedel-Crafts acylation of 
(4-choro phenyl, 1-methyl-1H-pyrrole-2-yl) methanones with isonicotinoyl chloride 
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in the presence of AlCl3 in dichloro ethane for 16 hrs. This compounds exhibited 
anticonvulsant activity on the mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaizeman46 et al has discovered potent DNA groove binding antibacterials which 
has shown improved tolerability in vivo and in vitro with excellent antibacterial 
potency against broad  Gram positive pathogens, including drug resistant strains 
such as methicillin-resistant Staphylococcus aureus, penicillin-resistant 
Streprococcus pneumonia and vancomycin-resistant Enterococcus faecalis. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Pyrrole derivatives and their salts having structure type, shown below are useful 
as inhibitors of the human immunodeficiency virus (reverse transcriptase) 
enzyme which is involved in viral replication and consequently may be 
advantageously used as therapeutics agents for HIV mediated process.47 
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Reduced pyrrole derivatives such as pyrrolidine-2-carboxilic acid hydrazide 
derivatives for use as metalloprotease inhibitors48. 
 
 
 
 
 
 
 
 
 
 
 
Febrizio and group have synthesized 2,4-dicarboxy-pyrroles and tested as 
selective non-competitive mGluR1 antagonists49. 
 
 
 
 
 
 
 
 
 
Various reduce pyrrole derivatives such as pyrroline, pyrrolidine are active on the 
cardiovascular apparatus and useful for preparation of structurally modified 
bioactive peptides50. 
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Wijngaarden51 and research group have synthesized a series of 2-phenylpyrrole 
Mannich bases and screened in pharmacological models for antipsychotic activity 
and extrapyramidal effects. They made structure modification of 5-(4-
flourophenyl)-2-[4-(2-methoxyphenyl)-I-piperazinyl] methyl pyrrole, the prototype 
of new class of sodium independent atypical dopamine D-2 anganosits and 
resulted in 2-[4-(7-benzofuranyl)-I-piperazinyl] methyl-5-(flouro phenyl) pyrrole, 
which was an even more potent and selective D-2 anganosits than the parent 
compound. They found excellent oral activity in the apomorphine induced 
climbing behavior and the conditioned avoidance response tests and the absence 
of catalepsy make this compound particularly promising as a potential 
antipsychotic with low propensity to induce acute extrapyramidal side effect. 
 
 
 
 
 
 
 
 
 
 
 
 
Demetri52 has suggest, GIST is the most common mesenchymal cancer of the 
gastrointestinal tract. Activating mutations in KIT are common in GIST, and 
imatinib, which also inhibits KIT, was found to be the first RTK inhibitors to show 
efficacy in this cancer, dramatically improving disease outcome43. However, 
resistance to imatinib resulting from subsequent mutations in KIT has emerged.  
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1.1.4 NEW DRUG MOLECULE INTRODUCE UNDER CLINICAL STUDY 
 
New drug molecules which are related to the pyrrole ring structure, are under 
study for phase-I to phase- IV clinical trial for different pharmacological action. 
Few selected example are showed under. 
 
532545-A  :       Drug Name                     
Chemical Structure               : 
 
 
 
 
 
 
Chemical Name                    :  2,2,5,5-Tetra Methyl-N-(3-pthalimidopropyl)-2,5- 
                                                dihyro-1H-pyrrole-3-carboxamide hydrochloride 
Phase                                   :  Preclinical  
Activity                                  :  Antiarrhythnic Drug; Sodium Channel Blockers; 
                                                Calcium antagonists 
 
5437326-Anirolac, RS  :    Drug Name                         
Chemical Structure               : 
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Chemical Name                    :  (+)-5-(4-methoxybenzoyl)-1,2-dihyro-3H- 
                                                pyrrolo[1,2-a]pyrrole-1-carboxylic acid 
Phase                                   :  Phase II 
Activity                                  :  Non-steroidal anti-inflammatory Drug 
 
5537619-Cketorolac, R  :  ame                          Drug N 
Chemical Structure               :  
 
 
 
 
 
Chemical Name                     :  (+)-5-Benzoyl-1, 2-dihydro-3H-pyrrolo [1,2-a] 
                                                  pyrrole -1-carboxylic acid 
Phase                                    :   Launched-1990 
Activity                                   :   Non-Opioid Analgesic; Non-steroidal 
                                                  Antiinflammatory  
 
562507- OP   :   Drug Name                          
Chemical Structure                :   
 
 
 
 
 
Chemical Name                      :  15-cis-(4-N-propylcyclohexyl)- 
                                                   16,17,18,19,20-pentanor-9-deoxy-6,9-alpha- 
                                                   nitrilo  PGF1 methyl ester 
Phase                                     :   Phase II 
Activity                                    :   Cognition-enhancing Drug; Cerebral 
                                                   Antiischemics ; Hepatoprotectants 
 
 
N
O
OH
O
CH3
HO H
OH
N
O
O
CH3
 20
5727- Medosan : Drug Name                              
Chemical Structure                 :  
 
 
 
 
 
 
Chemical Name                      : 1-Methyl-5-(4-methylbenzoyl)pyrrole-2-acetic 
acid-                                          2-(thiophylline-7-yl)ethyl ester 
Phase                                     :  Phase I 
Activity                                    :  Aantiplatelet Therapy; Bronchodilators; 
                                                  Thromboxane A2 Antagonists; Non-steroidal 
                                                  Antiinflammatory Drug; Thromboxane Synthase 
                                                  Inhibitors; Methylxanthines 
                                      
585222- Org :  ame                           Drug N 
  Chemical Structure                 : 
 
 
 
 
 
Chemical Name                      : Transe-5-chloro-2-methyl-2,3,3a-tetrahydro-                                
                                                  1H-dibenz [2,3:6,7] oxepine[4,5-c]pyrrole                                     
                                                  Maleate (1:1) 
Phase                                     :  Phase II 
Activity                                    :  Antipsychotic Drugs; 5-HZ2A antagonists;                                   
                                                  Dopamine D2 Antagonists 
 
 
 
Drug Name                              : Pamicogrel, KB-302259 
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Chemical Structure                  :  
 
 
 
 
 
Chemical Name                       :  2-[4,5-Bis(4-methoxyphenyl)thiazol-2-yl]       
                                                    Pyrrole-1-aceticacid ethyl ester 
Phase                                      :  pre-registered 
Activity                                     :  Antiplatelet Therapy; Cyclooxygenase   
                                                    Inhibitors 
 
1.2 SYNTHETIC ASPECT 
 
In the present chapter, the aspect was to develop the molecules of 
pharmacological interest, encircled different heterocyclic ring system with pyrrole 
ring which is documented as significant pharmacophore for treatment of 
tuberculosis, HIV, schizophrenia, anxiety, depression, circadiac rhythm disorders, 
diabetes, impaired glucose tolerance tumors, autoimmune disease and many 
others.  
 
Serving as an excellent intermediate with other chemical structures leading to 
large number of heterocycles, pyrrole it self is very well explored in analytical and 
pharmaceutical chemistry and their biological properties are also documented in 
last few years. This data promoted us to investigate the biological properties of 
this structure class. 
 
Earlier in our laboratory, pyrrole derivatives with oxadiazole ring on side chain are 
synthesized and their biological profile showed promising results. In continuation 
of this work pyrrole derivatives with pyrazol ring on side chain are synthesized in 
current chapter. The physical data and spectral data of synthesized compounds 
are given in Section 1.6 and 1.7. 
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1.3 REACTION SCHEMES  
 
1.3.1 Scheme 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2 Scheme 2  
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1.3.3 Scheme 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.4 REACTION MECHANISM 
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1.4         Experimental Protocols 
Commercial ethylacetoacetate was used only after distillation. The zinc dust used 
of minimum 80 % pure. Before the reaction mixture is refluxed, enough time 
should be allowed for the zinc dust react totally; or else considerable problem 
with foaming may be encountered. While addition of zinc is done in small portion 
to ensure proper temperature control otherwise foaming will occur and 
temperature will shoot up. 
 
Thin layer chromatography 
It was carried out on silica Gel-G as a stationary phase. The slurry was prepared 
by adding 20 ml distilled water to 10 gm Silica Gel in 250 ml beaker with 
continues stirring and the slurry was poured over glass plate and uniform thin 
layer was prepared. The plate was kept dried at 105 oC and activated before 
used. The reactions of all newly synthesized compounds and intermediate were 
monitories and the purity was checked by TLC. 
Mobile phase: 1. Ethyl acetate  : Hexane 
                        2. Chloroform    : Methanol 
 
Melting point 
All the melting points were taken in open end capillary by using paraffin bath with 
standard Zeal thermometer and they were uncorrected. 
 
1.5      EXPERIMENTAL 
 
1.5.1 Preparation of 1-{5-[ethoxy (hydroxy) methyl]-2, 4-dimethyl-1H-pyrrol-
3-yl} ethanone (Scheme-1) 
In 250 ml conical flask provided with magnetic needle and surrounded by an ice 
bath are placed 13 ml of ethyl acetoacetate and 40 ml of glacial acetic acid. To 
this, then added drop wise with stirring a solution of (0.11 mole) of sodium nitrite 
in 13 ml of water. The rate of addition is controlled so that the temperature does 
not rise above 10 oC. After the sodium nitrite solution has been added, the 
mixture is stirred for 2-3 hrs more. It is then allow to warm up to room 
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temperature and stand about 12 hrs, after which (0.12 mole) of acetyl acetone 
added at one time. To the reaction mixture, 15 gm of zinc dust is added in 
portions of about 2-3 gm with vigorous stirring. The rate of addition is regulated 
so that temperature never rises above 60 oC. After the addition is complete, the 
mixture is refluxed for 2-3 hrs on water bath until the unreacted zinc dust 
collected in balls. The hot solution is then filtered and poured into ice water. The 
creamy white product obtained is filtered and dried. Crude product is crystallized 
from alcohol. M.P.-142-144 oC (reported M.P.-143 oC)A, Yield 45-60 %. 
 
1.5.2 Preparation of (2E)-1-{5-[ethoxy (hydroxy) methyl]-2,4-dimethyl-1H-
pyrrol-3-yl}-3-phenylprop-2-en-1-one (Scheme-2) 
General method: 
In 100 ml conical flask, 1-{5-[ethoxy (hydroxy) methyl]-2,4-dimethyl-1H-pyrrol-3-
yl} ethanone (0.01 mole) and substituted aromatic aldehyde (0.01 mole) were 
dissolved in chloroform. The catalytic amount of potassium hydroxide (2-3) drops 
was added and the reaction mixture was refluxed for 2 hrs. The reaction progress 
was monitored by TLC. After completetion of the reaction, chloroform was 
distilled out completely and 10 ml methanol was added. Stirred for 20 min at 25-
30 oC. The product was filtered and dried in air oven. It was recrystallised from 
methanol. Yield 50-60 %. 
 
1.5.3 Preparation of [3, 5-dimethyl-4-(5-phenyl-4, 5-dihydro-1H-pyrazol-3-
yl)-1H-pyrrol-2-yl] (ethoxy) methanol (Scheme-3) 
General method: 
In 100 ml conical flask, 10 ml (0.32 mole) of hydrazine hydrate is added to the 
solution of (2E)-1-{5-[ethoxy (hydroxy) methyl]-2,4-dimethyl-1H-pyrrol-3-yl}-3-
phenylprop-2-en-1-one (0.01 mole) in 20 ml ethanol and reflux with stirring  in 
water bath for 6-8 hrs. Pour the contain into crushed ice with stirring. The solid 
obtained was filtered and washed with water. It was dried and recrystallized from 
ethanol. Yield 65-70 %. 
 
Physical data of the newly synthesized compounds are given in Table 1.6. 
ARaval, K.; Ph.D. Thesis.; Saurashtra University, Rajkot, 2005.  
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1.6 Physical data of Ethyl 4-[5-(4-methoxyphenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM 1-18) 
 
 
 
 
 
 
 
 
 
 
 
Code No. R MW MP oC Yield 
in % 
RF 
Value 
VGM-1 4-F 329.36 184-186 54 0.36 
VGM-2 3-NO2 356.37 156-157 68 0.39 
VGM-3 4-OCH3 341.40 196-198 48 0.51 
VGM-4 2-Cl 345.82 210-212 51 0.42 
VGM-5 3-OCH3 341.40 246-248 44 0.48 
VGM-6 4-NO2 356.37 188-190 56 0.37 
VGM-7 2-NO2 356.37 176-178 48 0.46 
VGM-8 4-Cl 345.82 212-214 56 0.33 
VGM-9 2,3,5,6-dibenzo 411.49 276-278 43 0.53 
VGM-10 H 311.37 222-224 54 0.38 
VGM-11 2-F 329.36 189-191 47 0.41 
VGM-12 2-OCH3 341.40 256-258 39 0.50 
VGM-13 3-Cl 345.82 156-158 58 0.48 
VGM-14 2-OH 327.37 179-181 49 0.36 
VGM-15 3-F 329.36 245-247 51 0.44 
VGM-16 4-OH 327.37 168-170 53 0.38 
VGM-17 2,3-benzo 361.43 198-200 56 0.47 
VGM-18 3-OH 327.37 246-248 46 0.52 
 
TLC solvent system               :       EA             :  Hexane           4.5   :  5.5 (ml) 
Visualization: UV light (long)        Chloroform : Methanol          9.4   :  0.6 (ml) 
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1.7 SPECTRAL ANALYSIS  
 
1.7.1 IR SPECTRAL ANALYSIS  
 
The IR spectral data of newly synthesized pyrrole derivatives have many 
significant characteristic IR peaks which are identified. 
Looking to the IR spectra of newly synthesized compounds, the carbonyl group of 
ester was observed at 1695-1660 cm-1. Two methyl groups illustrate stretching 
vibration at 2975-2950 cm-1 and deformation at 1485-1445 cm-1. The -C-O 
stretching of ester group observed at 1100-1001 cm-1. The –NH deformation and 
C-N stretching of secondary bonded observed at 1205-1310 cm-1. The –CH 
stretching of five member ring observed in the region of 1610-1660 cm-1.  Chloro 
group was confirmed due to their frequencies which come out at 800-650 cm-1. 
The –NH stretching of pyrrole ring observed at 3230-3400 cm-1 and bending 
vibration suggest itself 1580-1640 cm-1 region. 
The informative bands in the spectra due to aromatic moiety occur in the low 
frequency range between 900 and 675 cm-1. These strong absorption bands 
consequence from the out-of-plan banding of the ring C-H bonds. In plane 
banding emerge in the region of 1300-1000 cm-1. Skeletal vibration, involving 
carbon-carbon stretching with the ring, absorb in the 1600-1585 cm-1 and 1500-
1400 cm-1 regions. Aromatic C-H stretching bands occur between 3100-3000 cm-
1. IR spectra of the newly synthesized compounds are given on Pages 36-37. 
 
1.7.2 1HNMR  SPECTRAL ANALYSIS  
 
Study of the 1H NMR spectra of newly synthesized compounds shows 
characterization pattern of triplet-quartet of CH3-CH2 group, in which quartet of 
CH2 group was observed at 2.50-4.55 δ ppm, while that of triplet of methyl 
protons 1.38-2.55 δ ppm. The two methyl groups present at 2 and 5 position of 
pyrrole ring explain presence of mostly two distinct singlets at 2.20 – 4.10 δ ppm. 
The aromatic protons were observed at 6.99 to 7.75 δ ppm. The –NH group of 
pyrrole ring structure and –CO-NH was observed at 6.65 to 10.55 δ ppm 
respectively. In case of 5-phenyl-4, 5-dihydro-1H-pyrazole ring own two types of 
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methylenic protons at dissimilar C4 positions, as these two protons are chemically 
equivalent but magnetically non equivalent. Thus these two protons establish 
different region in the spectrum. Thereby these protons give multiple signals at 
2.50 – 3.70 δ ppm, in place of doublet due to steric hindrance of entire ring 
protons. At C5 position 1H protons offer triplet at 4.52 to 4.68 δ ppm, outstanding 
to the neighboaring two protons in the pyrazole ring at C4 position. Although, in 
case of VGM-1, due to attendance of fluorine atom in aromatic ring, nearby two 
protons give triplet- triplet at 7.34-7.38 δ ppm. NMR spectra of the newly 
synthesized compounds are given on Pages 38-41.     
 
1.7.3 Elemental Analysis 
 
Elemental analysis of the all the synthesized compounds was carried out on 
Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
(within range of  theoretical value) with the structures assigned. 
 
1.7.4 Mass spectral Analysis 
 
Molecular ion peak (M+) of the Ethyl 4-[5-(substituted phenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-3, 5-dimethyl-1H-pyrrole-2-carboxylate was in total agreement with 
their molecular weight.  
In case of VGM-2 and VGM-6, molecular ion peak relevant to its molecular 
weight. Base peak observed at 310 m/z due to lost of one methyl group from 
pyrrole ring and two oxygen atoms from the nitro group, 207 peak is relevant to 
subsequent loss of phenyl ring from the left behind molecular part. 
In case of VGM-3 and VGM-5, base peak is observed at 327 m/z with upper limit 
intensity owing to loss of one methyl group from the pyrrole ring. An additional 
peak is observed at 313 m/z due to loss of second methyl group from pyrrole 
nucleus.  
For the Mass spectrum of VGM-7, base peak is observed at 147 m/z. M+ peak is 
relevant to its molecular weight. While 342 m/e peak is also observed cause of 
the loss of the methyl group. In Mass spectrum, 207 peak  was observed by loss 
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of phenyl ring from molecule, base peak is observed because of subsequently 
loss of ester linkage at C5 position from the pyrrole ring.  
In case of VGM-8,  M+ in total agreement with its molecular weight, while base 
peak is observed at 299 m/z down due to loss of one methyl group from pyrrole 
focus and Cl atom from the aromatic nucleus at C4 position. 283 m/z is moreover 
revealed caused by subsequently loss of second methyl group from the pyrrole 
ring.  
In case of ethyl 3, 5-dimethyl-4-(5-phenyl-4, 5-dihydro-1H-pyrazol-3-yl)-1H-
pyrrole-2-carboxylate base peak observed 148 m/e. 297 m/e and 283 m/e were 
observed due to loss of two methyl group from the pyrrole ring. Mass spectra of 
the newly synthesized compounds are given on Pages 42-45. 
 
Mass fragmentation of Ethyl 4-[5-(4-methoxyphenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-3). 
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Mass fragmentation of Ethyl 4-[5-(4-chlorophenyl)-4, 5-dihydro-1H-pyrazol-
3-yl]-3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-8): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPECTRAL DATA 
Ethyl 4-[5-(4-Fluorophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-1) 
IR (KBr) cm-1 :  3206, 3145 (-NH, str.), 1556 (-NH, def.), 1392 (-C-N, str.), 1681 
(-C=O, str.), 1510 (-C=C, str. of pyrrole), 1492 (-CH2 def.), 1437 (-CH3, C-H def.), 
2924 (-CH, asym. str. ), 2856 (-CH, sym. str.), 1238 (-CH2, ipd.), 796 (-CH2, 
oopd.), 1014-1089 (-C-O-C, sym, str.)  
1H NMR (δ ppm): 2.39 (3H,s), 2.46 (3H, s), 2.55 (2H, qt), 2.96 (1H, m), 3.86 (1H, 
m), 4.48 (1H, t), 7.0-7.05 (2H, m), 7.34-7.38 (2H, t-t, J= 2.08, 2.08 Hz) 
C, H, N (in %): Found:  65.67(C), 6.10(H), 12.72 (N), Cacld: 65.64(C), 6.12(H), 
12.76 (N) 
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Ethyl 3,5-dimethyl-4-[5-(3-nitrophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-1H-
pyrrole-2-carboxylate (VGM-2) 
IR (KBr) cm-1 :  3192, 3142 (-NH, str.), 1539 (-NH, def.), 1392 (-C-N, str.), 1681 
(-C=O, str.), 1521 (-C=C, str. of pyrrole), 1491 (-CH2 def.), 1440 (-CH3, C-H def.), 
2937 (-CH, asym. str. ), 2851, 2835 (-CH, sym. str.), 1240 (-CH2, ipd.), 794 (-CH2, 
oopd.), 1028-1087 (-C-O-C, sym, str.)  
Mass (m/e value): 356 (40), 342 (35), 324 (2), 310 (100), 307 (20, 281 (20), 279 
(10), 264 (4), 249 (2), 234 (5), 220 (3), 206 (3), 188 (24), 180 (2), 161 (10), 148 
(8), 133 (11), 117 (5), 104 (5), 91 (7), 77 (7), 65 (8), 44 (14), 41 (3). 
C, H, N (in %):  Found: 60.64(C), 5.68(H), 15.71 (N), Cacld: 60.66(C), 5.66(H), 
15.72 (N) 
Ethyl 4-[5-(4-methoxyphenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-3) 
IR (KBr) cm-1 :  3277, 3255 (-NH, str.), 1398 (-C-N, str.), 1699 (-C=O, str.), 1512 
(-C=C, str. of pyrrole), 1491 (-CH2 def.), 1429 (-CH3, C-H def.), 2949, 2916 (-CH, 
asym. str. ),  1249 (-CH2, ipd.), 771 (-CH2, oopd.), 1010 (-C-O-C, sym, str.)  
Mass (m/e value): 341 (3), 327 (100), 313 (30), 295 (80), 293 (24), 264 (14), 250 
(5), 225 (4), 220 (3), 206 (3), 188 (10), 180 (23), 161 (23), 148 (57), 135 (32), 121 
(25), 107 (5), 91 (15), 77 (16), 65 (16), 44 (11), 41 (3). 
C, H, N (in %):  Found: 66.80(C), 6.76(H), 12.28 (N), Cacld: 66.84(C), 6.79(H), 
12.31 (N) 
Ethyl 4-[5-(2-chlorophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-4) 
IR (KBr) cm-1 :  3377, 3286 (-NH, str.), 1346 (-C-N, str.), 1685 (-C=O, str.), 1516 
(-C=C, str. of pyrrole), 1491 (-CH2 def.), 2939, 2910 (-CH, asym. str.), 1242 (-
CH2, ipd.), 740 (-CH2, oopd.), 1101 (-C-O-C, sym, str.)  
C, H, N (in %): Found:  62.50 (C), 5.80 (H), 10.21 (N), Cacld: 62.52 (C), 5.83 
(H), 10.25 (N) 
Ethyl 4-[5-(3-methoxyphenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-5) 
IR (KBr) cm-1 :  3245, 3210 (-NH, str.), 1542 (-NH, def.), 1388 (-C-N, str.), 1684 
(-C=O, str.), 1530 (-C=C, str. of pyrrole), 1481 (-CH2 def.), 1435 (-CH3, C-H def.), 
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3054 (Ar-CH, str),  2940 (-CH, asym. str. ), 2862, 2810 (-CH, sym. str.), 1244 (-
CH2, ipd.), 782 (-CH2, oopd.), 1010-1090 (-C-O-C, sym, str.)  
Mass (m/e value): 341 (5), 325 (100), 313 (70), 295 (71), 293 (84), 264 (48), 266 
(20), 250 (16), 224 (5), 210 (8), 206 (16), 195 (24), 180 (86), 160 (23), 148 (100), 
135 (46), 121 (20), 107 (18), 92 (24), 77 (33), 65 (37), 44 (24), 41 (5).  
C, H, N (in %):  Found: 66.82 (C), 6.83 (H), 12.30 (N), Cacld: 66.84 (C), 6.79 
(H), 12.31 (N) 
Ethyl 3,5-dimethyl-4-[5-(4-nitrophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-1H-
pyrrole-2-carboxylate (VGM-6) 
IR (KBr) cm-1 :  3312, 3214 (-NH, str.), 1389 (-C-N, str.), 1690 (-C=O, str.), 1520 
(-C=C, str. of pyrrole), 1496 (-CH2 def.), 1440 (-CH3, C-H def.), 2965, 2921 (-CH, 
asym. str. ),  1251 (-CH2, ipd.), 774 (-CH2, oopd.), 1010-1086 (-C-O-C, sym, str.)  
1H NMR (δ ppm): 1.34 (3H,s), 2.38 (3H, s), 2.53 (3H, s), 3.50 (1H, m), 4.29 (2H, 
qt), 4.92 (1H, t), 6.42 (-NH, s), 7.64 (2H, t, J= 1.92, 8.68 Hz), 8.17 (2H, d, J= 8.72 
Hz ), 10.82 (-NH, s)  
Mass (m/e value): 356 (100), 342 (14), 326 (7), 310 (100), 294 (3), 281 (39), 279 
(10), 264 (10), 250 (2), 235 (8), 220 (2), 207 (3), 188 (37), 178 (3), 161 (20), 146 
(10), 133 (22), 119 (8), 106 (8), 91 (11), 77 (8), 65 (12),44 (7), 41 (3).  
C, H, N (in %): Found: 60.62 (C), 5.63 (H), 15.70 (N), Cacld: 60.66 (C), 5.66 (H), 
15.72 (N) 
Ethyl 3,5-dimethyl-4-[5-(2-nitrophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-1H-
pyrrole-2-carboxylate (VGM-7) 
IR (KBr) cm-1 :  3224, 3186 (-NH, str.), 1540 (-NH, def.), 1387 (-C-N, str.), 1686 
(-C=O, str.), 1520 (-C=C, str. of pyrrole), 1480 (-CH2 def.), 1435 (-CH3, C-H def.), 
2956, 2914 (-CH, asym. str. ), 2851, 2810 (-CH, sym. str.), 1244 (-CH2, ipd.), 776 
(-CH2, oopd.), 1005-1084 (-C-O-C, sym, str.)  
1H NMR (δ ppm): 1.34-1.38 (3H, t), 2.41 (3H, s), 2.98 (1H, m), 3.49 (3H, s), 3.73 
(1H, m), 4.30-4.34 (2H, qt), 5.29-5.34 (1H, t), 7.42 – 7.46 (1H, m, 1.40, 7.08 Hz), 
7.62 – 7.66 (1H, t-t,  J= 1.24, 6.64 Hz), 7.95 -8.00 (2H, t-t, J= 0.96, 1.16 Hz), 8.8 
(1H, s)   
Mass (m/e value): 356 (69), 342 (74), 322 (5), 307 (14), 292 (5), 275 (69), 263 
(300, 247 (27), 235 (60), 221 (32), 207 (29), 188 (22), 180 (14), 167 (18), 147 
(100), 131 (20), 119 (30), 104 (20), 91 (26), 77 (25), 65 (28), 44 (15), 41 (4).  
 33
C, H, N (in %):  Found: 60.62(C), 5.67(H), 15.70 (N), Cacld: 60.66(C), 5.66(H), 
15.72 (N) 
Ethyl 4-[5-(4-chlorophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-8) 
IR (KBr) cm-1 :  3364, 3246 (-NH, str.), 1374 (-C-N, str.), 1684 (-C=O, str.), 1510 
(-C=C, str. of pyrrole), 1494 (-CH2 def.), 2956, 2914 (-CH, asym. str.), 1240 (-
CH2, ipd.), 779 (-CH2, oopd.), 1080 (-C-O-C, sym, str.)  
1H NMR (δ ppm): 2.46 (3H,t), 2.51 (3H, s), 2.75 (1H, m), 3.69 (1H, m), 3.86 
(2H,qt), 4.33 (3H, m), 4.63 (1H, t), 7.24 (1H, t, J= 8.64, 8.04 Hz ), 7.32 (2H, m, J= 
2.62 Hz), 7.38-7.40 (1H, m, J= 6.52 , 2.62 Hz), 8.65 (1H, s) 
Mass (m/e value): 345 (58), 331 (32), 311 (20), 299 (100), 283 (41), 270 (14), 
256 (5), 242 (3), 234 (4), 220 (4), 206 (5), 188 (20), 178 (4), 102 (8), 91 (10), 77 
(10), 65 (14), 44 (15), 41 (3).   
C, H, N (in %): Found:  62.54(C), 5.80(H), 10.21 (N), Cacld: 62.52(C), 5.83(H), 
10.25 (N) 
Ethyl 4 - [5 - (4-anthracene) - 4, 5- dihydro- 1H- pyrazol- 3- yl]- 3, 5- dimethyl-
1H-pyrrole-2-carboxylate (VGM-9) 
IR (KBr) cm-1 :  3346, 3274 (-NH, str.), 1540 (-NH, def.), 1389 (-C-N, str.), 1686 
(-C=O, str.), 1524 (-C=C, str. of pyrrole), 1492 (-CH2 def.), 1438 (-CH3, C-H def.), 
3024,3010 (Ar-CH, str.) 2954, 2912 (-CH, asym. str. ), 2860, 2814 (-CH, sym. 
str.), 1242 (-CH2, ipd.), 778 (-CH2, oopd.), 1010-1086 (-C-O-C, sym, str.)  
C, H, N (in %): Found: 75.50 (C), 6.54 (H), 10.12 (N), Cacld: 75.52 (C), 6.58 (H), 
10.16 (N) 
Ethyl 4-(5-cyclohexa-2,5-dien-1-yl-4,5-dihydro-1H-pyrazol-3-yl)-3,5-dimethyl-
1H-pyrrole-2-carboxylate (VGM-10) 
IR (KBr) cm-1 :  3264, 3178 (-NH, str.), 1538 (-NH, def.), 1391 (-C-N, str.), 1688 
(-C=O, str.), 1521 (-C=C, str. of pyrrole), 1475 (-CH2 def.), 1436 (-CH3, C-H def.), 
2940, 2912 (-CH, asym. str. ), 2856, 2814 (-CH, sym. str.), 1240 (-CH2, ipd.), 789 
(-CH2, oopd.), 1014-1096 (-C-O-C, sym, str.) 
Mass (m/e value): 311 (5), 297 (92), 283 (54), 266 (24), 265 (92), 251 (20), 236 
(20), 222 (15), 206 (19), 188 (26), 180 (61), 160 (20), 148 (100), 133 (17), 122 
(19), 105 (47), 91 (28), 77 (57), 65 (37), 51 (21), 41 (6). 
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C, H, N (in %): Found: 69.40 (C), 6.84 (H), 13.45 (N), Cacld: 69.43 (C), 6.80 (H), 
13.49 (N) 
Ethyl 4-[5-(2-flourophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-11) 
IR (KBr) cm-1 :  3314, 3262 (-NH, str.), 1344 (-C-N, str.), 1686 (-C=O, str.), 1520 
(-C=C, str. of pyrrole), 1488 (-CH2 def.), 2940, 2916 (-CH, asym. str.), 1240 (-
CH2, ipd.), 758 (-CH2, oopd.), 1089 (-C-O-C, sym, str.)  
C, H, N (in %): Found:  65.66 (C), 6.10(H), 12.74 (N), Cacld: 65.64 (C), 6.12 (H), 
12.76 (N) 
Ethyl 4-[5-(2-methoxyphenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-12) 
IR (KBr) cm-1 :  3267, 3186 (-NH, str.), 1390 (-C-N, str.), 1689 (-C=O, str.), 1514 
(-C=C, str. of pyrrole), 1490 (-CH2 def.), 1432 (-CH3, C-H def.), 2965 (-CH, asym. 
str. ),  1244 (-CH2, ipd.), 775 (-CH2, oopd.), 1010-1024 (-C-O-C, sym, str.)  
C, H, N (in %):  Found: 66.82 (C), 6.82(H), 12.28 (N), Cacld: 66.84 (C), 6.79 (H), 
12.31 (N) 
Ethyl 4-[5-(3-chlorophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-13) 
IR (KBr) cm-1 :  3326, 3240 (-NH, str.), 1364 (-C-N, str.), 1688 (-C=O, str.), 1521 
(-C=C, str. of pyrrole), 1490 (-CH2 def.), 2940, 2911 (-CH, asym. str.), 1238 (-
CH2, ipd.), 784 (-CH2, oopd.), 1080-1040 (-C-O-C, sym, str.)  
C, H, N (in %): Found: 62.54 (C), 5.80 (H), 10.22 (N), Cacld: 62.52 (C), 5.83 (H), 
10.25 (N) 
Ethyl 4-[5-(2-hydroxycyclohexa-2, 5-dien-1-yl)-4, 5-dihydro-1H-pyrazol-3-yl]-
3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-14) 
IR (KBr) cm-1 :  3586 (-OH, str, ) 3246, 3174 (-NH, str.), 1541 (-NH, def.), 1387 (-
C-N, str.), 1688 (-C=O, str.), 1524 (-C=C, str. of pyrrole), 1474 (-CH2 def.), 1423 
(-CH3, C-H def.), 2954 (-CH, asym. str. ), 2864, 2812 (-CH, sym. str.), 1240 (-
CH2, ipd.), 784 (-CH2, oopd.), 1010-1098 (-C-O-C, sym, str.)  
C, H, N (in %): Found: 66.02 (C), 6.49 (H), 12.80 (N), Cacld: 66.04 (C), 6.47 (H), 
12.84 (N) 
Ethyl 4-[5-(3-flourophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-15) 
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IR (KBr) cm-1 :  3320, 3246 (-NH, str.), 1340 (-C-N, str.), 1680 (-C=O, str.), 1516 
(-C=C, str. of pyrrole), 1480 (-CH2 def.), 2974, 2910 (-CH, asym. str.), 1242 (-
CH2, ipd.), 762 (-CH2, oopd.), 1080-1014 (-C-O-C, sym, str.)  
C, H, N (in %): Found: 65.67 (C), 6.10 (H), 12.73 (N), Cacld: 65.64 (C), 6.12 (H), 
12.76 (N) 
Ethyl 4-[5-(4-hydroxycyclohexa-2, 5-dien-1-yl)-4, 5-dihydro-1H-pyrazol-3-yl]-
3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-16) 
IR (KBr) cm-1 :  3574 (-OH, str, ) 3346, 3214 (-NH, str.), 1380 (-C-N, str.), 1691 (-
C=O, str.), 1520 (-C=C, str. of pyrrole), 1470 (-CH2 def.), 1432 (-CH3, C-H def.), 
3014 (Ar-CH,str.) 2948 (-CH, asym. str. ), 2874, (-CH, sym. str.), 1248 (-CH2, 
ipd.), 781 (-CH2, oopd.), 1098-1012 (-C-O-C, sym, str.)  
C, H, N (in %): Found: 66.05 (C), 6.45 (H), 12.82 (N), Calcld: 66.04 (C), 6.47 
(H), 12.84 (N) 
Ethyl 4-[5-(4-naphthalene)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-dimethyl-1H-
pyrrole-2-carboxylate (VGM-17) 
IR (KBr) cm-1 :  3318, 3240 (-NH, str.), 1538 (-NH, def.), 1392 (-C-N, str.), 1679 
(-C=O, str.), 1521 (-C=C, str. of pyrrole), 1490 (-CH2 def.), 1420 (-CH3, C-H def.), 
3014 (Ar-CH, str.) 2964, 2910 (-CH, asym. str. ), 2864 (-CH, sym. str.), 1242 (-
CH2, ipd.), 784 (-CH2, oopd.), 1088-1014 (-C-O-C, sym, str.)  
C, H, N (in %): Found: 72.72 (C), 6.90 (H), 11.54 (N), Cacld: 72.70 (C), 6.93 (H), 
11.56 (N) 
Ethyl 4-[5-(3-hydroxycyclohexa-2, 5-dien-1-yl)-4, 5-dihydro-1H-pyrazol-3-yl]-
3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-18) 
IR (KBr) cm-1 :  3574 (-OH, str, ) 3346, 3214 (-NH, str.), 1540 (-NH, def.), 1384 (-
C-N, str.), 1690 (-C=O, str.), 1531 (-C=C, str. of pyrrole), 1470 (-CH2 def.), 1430 
(-CH3, C-H def.), 2917 (-CH, asym. str.), 2874, 2810 (-CH, sym. str.), 1244 (-CH2, 
ipd.), 788 (-CH2, oopd.), 1098-1024 (-C-O-C, sym, str.)  
C, H, N (in %):  Found: 66.02 (C), 6.49 (H), 12.81 (N), Cacld: 66.04 (C), 6.47 
(H), 12.84 (N) 
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IR spectrum of Ethyl 4-[5-(4-fluorophenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-3, 5-
dimethyl-1H-pyrrole-2-carboxylate (VGM-1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
IR spectrum of Ethyl 3, 5-dimethyl-4-[5-(3-nitrophenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-2) 
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IR spectrum of Ethyl 4-[5-(4-methoxycyclohexa-1, 5-dien-1-yl)-4, 5-dihydro-
1H-pyrazol-3-yl]-3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of Ethyl 4-[5-(2-chlorocyclohexa-1, 5-dien-1-yl)-4, 5-dihydro-1H-
pyrazol-3-yl]-3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-4) 
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1H NMR spectrum of Ethyl 4-[5-(4-fluorophenyl)-4, 5-dihydro-1H-pyrazol-3-
yl]-3, 5-dimethyl-1H-pyrrole-2-carboxylate (VGM-1). 
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1H NMR spectrum of Ethyl 3, 5-dimethyl-4-[5-(2-nitrophenyl)-4, 5-dihydro-
1H-pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-7). 
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1H NMR spectrum of Ethyl 3, 5-dimethyl-4-[5-(4-chlorophenyl)-4, 5-dihydro-
1H-pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-8). 
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1H NMR spectrum of Ethyl 3, 5-dimethyl-4-[5-(4-nitrophenyl)-4, 5-dihydro-
1H-pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-6). 
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Mass spectrum of Ethyl 3, 5-dimethyl-4-[5-(3-nitrophenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of Ethyl 3, 5-dimethyl-4-[5-(4-methoxyphenyl)-4, 5-dihydro-
1H-pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-3) 
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Mass spectrum of Ethyl 3, 5-dimethyl-4-[5-(3-methoxyphenyl)-4, 5-dihydro-
1H-pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of Ethyl 3, 5-dimethyl-4-[5-(4-nitrophenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-6). 
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Mass spectrum of Ethyl 3, 5-dimethyl-4-[5-(2-nitrophenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of Ethyl 3, 5-dimethyl-4-[5-(4-chlorophenyl)-4, 5-dihydro-1H-
pyrazol-3-yl]-1H-pyrrole-2-carboxylate (VGM-8) 
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Mass spectrum of Ethyl 3, 5-dimethyl-4-[5-(phenyl)-4, 5-dihydro-1H-pyrazol-
3-yl]-1H-pyrrole-2-carboxylate (VGM-10) 
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2.1 INTRODUCTION 
 
1,4-Dihydropyridines is the significant subclass of pyridines, the best known 
heterocyclic compounds which are associated with good number of 
pharmacological activities. 1,4 dihydropyridines whether symmetrical or 
unsymmetrical, are expected for their cardiovascular and other pharmacological 
properties. 
Many drug molecule bearing 1,4-dihydropyridines nucleus are specifically related 
with calcium channel antagonism1 and antihypertensive2. Earlier it was believed 
that, the dihydropyridines is useful only as calcium channel antagonism, but later 
on QSAR and X-ray crystallography study of new synthetic dihydropyridines 
molecules indicates that their therapeutics activities may be broaden to 
ionotrophy to secretary stimulation also. Currently these drugs are target for 
angina, hypertension, hypertropic cardiomyopathy, cerebral vasospasm and 
other smooth muscle disorders. 
Beside these, antitumor3, vasodilator4, coronary vasodilator and cardiopathic5, 
antimayocardiac ischemic6, antiulcer7, antiallergic activity are also reported. 
 
2.1.1 Biological profile  
Dihydropyridine (DHP) chemistry began in 1882 when Hantzsch11-12 published 
the synthesis. The simplest form of the synthesis involves heating an aldehyde 
1,3-diketone ester and ammonia. The reaction almost certainly involves aldol 
condensation to form the benzylidine derivative as the first step. Conjugated 
addition of a second mole of 1,3-diketone ester would then afford the 1,5-
diketone. Reaction of the carbonyl group with ammonia will lead to the formation 
of the dihydropyridine ring. 
The DHP nucleus is common to numerous bioactive compounds which include 
various vasodilator, antihypertensive, bronchodilator, antiatherosclerotic, 
hepatoprotective, antitumor, antimutagenic, geroprotective, and antidiabetic 
agents13-18. 
Dihydropyridines have found commercial utility as calcium channel blockers, as 
exemplified by therapeutic agents such as Nifedipine16, Nitrendipine20 and 
Nimodipine21. Second-generation calcium antagonists include DHP derivatives 
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with improved bioavailability, tissue selectivity, and/or stability, such as the 
antihypertensive/antianginal drugs like Elgodipine22, Furnidipine23-24, 
Darodipine25, Pranidipine26, Lemildipine27, Dexniguldipine28, Lacidipine29, and 
Benidipine30. Number of DHP calcium agonists has been introduced as potential 
drug candidates for treatment of congestive heart failure31, 32. 
The key characteristic of calcium channel blockers is their inhibition of entry of 
calcium ions via a subset of channels, thereby leading to impairment of 
contraction. There are three main groups of calcium channel blockers, i.e. 
dihydropyridines, phenylalkylamines and benzothiazepines, typical examples of 
which are nifidepine, verapamil and diltiazem, respectively33-36. Each has a 
specific receptor on the calcium channel and a different profile of 
pharmacological activity. Dihydropyridines have a less negative inotropic effect 
than phenylalkylamines and benzothiazepines but can sometimes cause reflex 
tachycardia. Dihydropyridines are able to reduce peripheral resistance, generally 
without clinically significant cardio depression. Among DHPs with other types of 
bioactivity, Cerebrocrast37 has been recently introduced as a neuroprotectant and 
cognition enhancer lacking neuronal-specific calcium antagonist properties. In 
addition, a number of DHPs with platelet antiaggregatory activity have also been 
discovered38. These recent examples highlight the level of ongoing interest 
toward new DHP derivatives and have prompted us to explore this 
pharmacophoric scaffold to develop a fertile source of bioactive molecules. 
1,4- DHPs possess different pharmacological activities such as antitumor39, 
vasodilator40, coronary vasodilator and cardiopathic41, antimayocardiac ischemic, 
antiulcer42, antiallergic43, antiinflammatory44 and antiarrhythmic45, PAF 
antagonist46, Adenosine A3 receptor antagonist47 and MDR reversal activity48-49. 
In particular, DHP-CA (calcium channel antagonist DHP) are extensively used for 
the treatment of hypertension,50 subarachnoid hemorrhage,51-52 myocardial 
infarction53-56 and stable57,58 and unstable angina59-60 even though recently their 
therapeutic efficacy in myocardial infarction and angina has been questioned61. 
This class of compounds is also under clinical evaluation for the treatment of 
heart failure62, ischemic brain damage63 nephropathies, and atherosclerosis64. 
1,4-Dihydropyridines are now established as heterocycles having numerous 
applications and having widened scope from its pronounced drug activity like 
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calcium channel antagonism and antihypertensive action. Many other 
cardiovascular activities are associated with such compounds and they can be 
presented in the structure as 2,6-dimethyl-3,5-diacetyl or dicarboxylate or 
dicarbamoyl or many other homoaryl or heteroaryl carbon chain having C2 to C8 
1,4-dihydropyridines substituted at 4-position. Some representative Ca2+ 
antagonists of Dihydropyridine class are as shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A startling revelation is found recently in which the imidazolyl moiety is linked to 
the phenyl ring by means of a methylene bridge, the activity tends to decrease. 
Finally, the replacement of DHP itself by a pyridine ring gives an inactive 
compound 65. 
Cozzi and coworkers66 have synthesized a series of 4-phenyl-1,4-
dihydropyridines bearing imidazol-1-yl or pyridine-3-yl moieties on the phenyl 
ring, with the aim of  
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combining Ca2+ antagonism and thermboxane A2(TxA2) synthases inhibition in 
the same molecules. Some of the compounds showed significant combined 
activity in vitro, while other showed single activity. As far as Ca2+ antagonism is 
concerned, two points deserve comment. First, the SAR, in most cases, does not 
differ substantially from that reported for classic DHP-CA, even though the 
potency is lower than that found with the most potent drugs of this class as, for 
example, reference compound nifidepine. In fact, Ca2+ antagonism is dramatically 
reduced by (a) replacement of DHP by a pyridine ring, (b)    substitution of DHP 
nitrogen N-1 by a methyl group, (c) Para substitution on the phenyl ring, and (d) 
replacement of one ester function by a ketone or carboxy group. All these 
variations are also detrimental in classic DHP-CA.67  
Hernandez-Gallegos and coworkers68 have synthesized new 1,4-dihydropyridines 
and evaluated their relaxant ability (rat aorta), antihypertensive activity in 
spontaneously hypertensive rats and their microsomal oxidation rate (MOR) was 
determined. 
 
 
 
 
 
 
 
R = 3-NO2, 4-F, 3,5-di-F, 3-Br-4-F.
R1 = R2= Me, Et, -CH2-CF3, -CH2CH2-OPh, -(CH2)2-N(CH3)-CH3-Ph  
Christiaans and Timmerman69 studied new molecules like CV-159 for possible 
variation at 3-position. 
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Carlos et al70 reported 1,4-DHPs derivatives with a 1,2-benzothiazol-3-one-1-
sulphoxide group, linked through an alkylene bridge to the C3 carboxylate of the 
DHP ring, with both vasoconstricting and vasorelaxant properties were obtained. 
In blocking Ca2+ evoked contractions of K+ depolarized rabbit aortic strips. Many 
compounds were 10 times more potent than nifidepine. Their vascular versus 
cardiac selectivity was very pronounced. 
 
 
 
 
 
 
 
 
Sonja76 and group have synthesized a new series of calcium channel agonists 
structurally related to Bay K8644, containing NO donor furoxans and the related 
furazans unable to release NO. The racemic mixtures were studied for their 
action on L-type Ca2+ channels expressed in cultured rat insulinoma RINm5F 
cells. All the products proved to be potent calcium channel agonists 
 
 
 
 
 
 
 
 
Recent reports show that efonidipine, a dihydropyridine Ca2+ antagonist, has 
blocking action on T-type Ca channels, which may produce favorable actions on 
cardiovascular systems. However, the effects of other dihydropyridine Ca 
antagonists on T-type Ca channels have not been investigated yet. Therefore, 
Furukawa and group77 have examined the effects of dihydropyridine compounds 
clinically used for treatment of hypertension on a T-type Ca channel subtype, 
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alpha1G, expressed in Xenopus oocytes. Twelve DHPs (amlodipine, barnidipine, 
benidipine, cilnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, 
nilvadipine, nimodipine, nitrendipine) and mibefradil were tested. Cilnidipine, 
felodipine, nifidipine, nilvadipine, minodipine, and nitrendipine had little effect on 
the T-type channel. The blocks by drugs at 10 uM were less than 10% at a 
holding potential of -100 mV. The remaining 6 drugs had blocking action on the 
T-type channel comparable to that on the L-type channel. These results show 
that many dihydropyridine Ca2+ antagonists have blocking action on the alpha1G 
channel subtype. 
Labedipinedilol-A (II), a novel dihydropyridine-type calcium antagonist, has been 
shown to induce hypotension and vasorelaxation. Liou78 and co-workers have 
studied to investigate the effect of labedipinedilol-A on vascular function of rat 
aortic rings and cultured human umbilical vein endothelial cells (HUVECs).  
2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylicacid esters 
(I), which lack  the potential C3 symmetry of dihydropyridine calcium channel 
blockers, were  evaluated for biological  activity. Biological assays using 
potassium-depolarized rabbit aorta and radioligand binding techniques showed 
that some of these compounds are potent mimics of dihydropyridine calcium 
channel blockers. The combination of a branched ester (e.g. isopropyl, sec-butyl) 
and an alkylthio group (e.g. SMe) was found to be optimal for biological activity79.  
 
 
 
 
 
 
 
2.1.2 Recent Literature survey  
Synthesis of New Dihydropyridine Glycoconjugates85 is recently established by in 
situ generated HCl as an efficient catalyst for solvent free Hantzsch rection at 
room temprarute. 
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Yb(OTf)3 catalyzed an efficient, operationally simple and environmentally benign 
Hantzsch reaction via a four-component coupling reaction of aldehydes, 
dimedone, ethyl acetoacetate and ammonium acetate at ambient temperature 
also gave polyhydroquinoline derivatives in excellent yield86. 
 
 
 
 
2.2 SYNTHETIC ASPECTS 
In last few years, 1,4-dihydropyridine skeleton is extensively modified in our 
laboratory and very interesting results are obtained with these modification to 
various positions of 1,4-dihydropyridine skeleton and can be discussed as below. 
3,5-dibenzoyl-1,4-dihydropyridines (BzDHPs) substituted at 4-phenyl ring were 
synthesized and compared for their cytotoxic activity and multidrug resistance 
reverting activity in in vitro assay systems. Among fifteen BzDHPs, 2-
trifluoromethyl, 2-chloro and 3-chloro derivatives showed the highest cytotoxic 
activity80.  
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3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydropyridine-2,6-dimethylpyridine, DP-
7 a dibenzoyl dihydropyridines derivative as mdr inhibitor,  was investigated for 
cardiac effects in Langendorff-perfused rat heart and compared with nifidepine. It 
was found that this molecule represent a lead for development of potent DHP 
mdr chemosensitisers devoid of cardiac effect81.  
Dibenzoyl-DHPs, tested for their mdr reversing activity, were found to show one 
or two orders higher tumor-specific cytotoxic activity against human tumor cell 
lines than human normal cells82. Dihydropyridine derivatives with phenyl 
carbamoyl side chain on 3 and 5 positions were synthesized and evaluated for 
their anti-tubercular activity. The results of anti-tubercular activity for dicarbamoyl 
derivatives were studied for 2D QSAR. The study indicates the presence of 
bulkier group on 4-phenyl ring contributes for the activity. The electronic influence 
of substituents at carbamoyl phenyl ring is important for activity8.  
To find out structural requirement of dicarbamoyl DHPs for anti tubercular activity, 
CoMFA and CoMSIA methods were applied on a set of 33 dicarbamoyl 
derivatives. The QSAR models reveal the importance of spatial properties and 
conformational flexibility of side chains for anti tubercular activity9.  
 
 
 
 
 
 
 
Dihydropyridines with N-phenyl substitution were synthesized and tested for 
tumor specific cytotoxicity and mdr reversal activity to find out the effects of N-
phenyl substitution on activity. Asymmetric benzoyl DHPs with different 
substitution on benzoyl aromatic ring were synthesized and evaluated for tumor 
specific cytotoxicity. In continuation, dihydropyridines with phenyl carbamoyl side 
chain on one arm and –CN, -COOEt, -COOMe side chain on other arm were also 
synthesized and evaluated as MDR reversal dihydropyridines83. In continuation of 
skeleton modification,  
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dihydropyridines with heterocyclic systems on side chain were synthesized and 
evaluated for anti tubercular activity. These derivatives showed moderate activity 
and it was found that aromatic heterocyclic systems on side chain do not 
enhance anti tubercular activity84.   
 
 
 
 
 
 
Schramm and coworker71 have proved that phenyl carbamoyl moiety in 
dihydropyridines affords for cardiovascular selective activity. 
 
 
 
 
 
 
Similarly Kelvin Cooper (Pfitzer, USA) et al72 found that DHP can be highly 
selective as platelet activating factor (PAF) antagonist. They found potent 
compounds and prove that platelet aggregating activity (PAF) exhibits a wide 
spectrum of biological activities elicited either directly or via the release of other 
powerful mediator such as Thromboxane A2 or the Leukotrienes. In vitro PAF 
stimulates the movement and aggregation and the release there from of tissue 
damaging enzymes and oxygen radicals. Accordingly compounds like UK-74505, 
antagonize the action of PAF and consequently also prevent mediator release by 
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PAF, will have clinical utilities in the treatment of the variety of the allergic, 
inflammatory and hypersecretory conditions such as asthama, arthritis, rhinitis, 
bronchitis and utricaria73 in future.   
 
 
 
 
 
 
 
Reddy and coworkers74 synthesized 4-aryl hetroaryl-2,6-dimethyl-3,5-bis-N-(2-
methyl phenyl)carbamoyl-1,4-dihydropyridines through one-pot synthesis using 
appropriate aromatic aldehydes and liquid ammonia. Pharmacological screening 
of the new 1,4-dihyropyridines were also carried out for CNS depressant 
(anticonvulsant and analgesic) and cardiovascular (inotropic and blood pressure) 
activities by standard methods. They recently tested bronchodilatory acitivity on 
2-chlorophenyl substitutents of such compounds75. 
 
 
 
 
 
 
 
Neamati and coworkers75 reported that a 1,4-dihydorpyridine NCS-372643 is 
showing anti-HIV activity, which has opened up the synthetic as well as 
pharmacological importance in antiviral area also. 
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QSAR STUDY 
Recently Shah et al8 synthesized and studied 2D QSAR of substituted phenyl-
2,6-dimethyl-3,5-bis-N-substituted phenyl carbamoyl-1,4-dihyropyridines as 
potent antitubercular agents. It was explained that these dihydropyridines may 
act as precursors and after penetration into cell wall may lead to the 3,5-
carboxylate anions by enzymatic hydrolysis. All these derivatives were screened 
for their antitubercular activity against M. tuberculosis H37 Rv, among them some 
derivatives showed >90% inhibition comparable to Riampicin. 
 
 
 
 
 
 
 
 
 
 
 
 
The result of QSAR studies of all these derivatives indicates that the presence of 
bulkier substituents in the phenyl ring at C4 position of the dihydropyridines 
positively contributes for the antitubercular activity. 
The electronic influence of the substituents at the carbamoyl phenyl ring present 
at 3 and 5 positions of dihydropyridines are important for antitubercular activity, in 
the order of σm>σp>σo. The presence of the electron withdrawing group at meta 
and Para position increase activity, while at ortho position decrease the activity. 
These electronic effects may influence the enzymatic hydrolysis of the amide 
bond present at 3 and 5 position if substituted dihydropyridines to corresponding 
acids inside the M. Tuberculosis. 
To explore further structural requirements of 1,4 dihydropyridines for 
antitubercular activity, 3D QSAR study has been carried out by Shah et al9. The 
two methods for 3D QSAR study were performed: 
1. Comparative molecular similarity indices analysis (CoMSIA)10 
2. Comparative molecular field analysis (CoMFA)10 
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According to the 3D QSAR study, a low electron density in the area of 3 and 4 
position of 3,5- disubstituted carbamoyl phenyl moiety, will have a positive effect 
on the biological activity. The compound containing electron withdrawing groups 
at these positions show more activity. The C4 position of dihydropyridines 
requires aryl group/phenyl group having electron density in the area of C4 
position. 
In continuation of work on dihydropyridine skeleton modification, this chapter 
reports synthesis of symmetrical 1,4-DHPs with naphthyl ring at C3 and C5 
positions of dihydropyridines and asymmetrical derivatives with naphthyl 
carbamoyl side chain.  
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2.3 REACTION SCHEMES  
 
2.3.1 Scheme 1 
 
 
 
 
 
 
 
 
 
2.3.2 Scheme 2   
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2.3.3 Scheme 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.4 Scheme 4  
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2.4 Experimental Observation 
 
In the preparation of acetoacetanilides, amount of caustic slurry is critical and 
reaction must be refluxed for 15 hrs unless the yield loss is observed. In the last 
stage of preparation of acetoacetanilide, toluene is to be distilled out, if the trace 
of toluene is not removed, then isolation of product becomes tricky and takes 
much time. During distillation, if excess heating done after complete distillation of 
toluene then product become charred and whole reaction mass become sticky 
and product can not be obtained. Temperature during distillation should be 
maintained and between 110-115 oC. During isolation of acetoacetanilide 
sufficient amount of ether wash is to be given to get non sticky and impurity free 
product. 
 
In the second step preparation of arylidine derivatives, the temperature is kept 
between 50-60 oC. The increase in temperature results in charring of products. 
Glacial acetic acid and piperidene is added only after dissolving the reactant. In 
final stage, mixture of acetoacetanilide and aldehyde heated at 80-90 oC. Only 
after complete dissolution, 1-2 ml of liq. ammonia is to be added. The resulting 
mass converted into solid after 7-9 hrs reflux time and cooling at room 
temperature and treated with chilled methanol to yield light yellow product. 
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2.5 EXPERIMENTAL 
 
2.5.1 N-(naphthalene-5-yl)-3-oxobutanaide (Scheme-1) 
A mixture of α-nephthayl amine and ethyl acetoacetate was refluxed at 1100 C in 
40 ml of toluene and catalytic amount of KOH/NaOH. The completion of the 
reaction was monitored by TLC. After completion of reaction, toluene was distilled 
out. The residue was cooled at room temperature and was treated with ether. 
The solid was filtered and dried. (Yield: 65 %)  
 
2.5.2 1,4-dihydro-4-(substituted phenyl)-2,6-dimethyl-N,N-di(naphthalene-1-
yl)pyridine-3,5-dicarboxamide (Scheme-2) 
[General method] 
A mixture of N-1-naphthyl-3-oxobutanamide (0.02 m) and substituted 
benzaldehyde (0.01 m) in 10 ml methanol was refluxed on steam bath for 5-10 
hrs. The reaction mixture was cooled and transferred to a beaker. On cooling, 
crystalline product separated out which was recrysatllized from hot methanol. 
Yield 45-62 %. 
 
Physical data of newly synthesized compounds are given in Table 2.6.1. 
 
2.5.3 Synthesis of substituted arylidene derivatives (Scheme-3) 
[General method]  
A mixture of substituted acetoacetanilide (0.01 m), substituted benzaldehyde 
(0.01 m) in 4-5 ml isopropyl alchohol (IPA) was mechanically stirred in presence 
of catalytic amount of glacial acetic acid and piperidene. The reaction time ranges 
from 20 min to 12 hrs for different aryl amines. White solid product isolated was 
filtered and washed with IPA to remove unreacted aldehyde. The compound was 
recrystallized from methanol. The yield of the compounds range from 50-70 %. 
 
2.5.4 Synthesis of substituted unsymmetrical carbamoyl DHP (Scheme-4) 
[General method]  
A mixture of substituted arylidene derivative (0.01 mole) and acetyl acetone (0.01 
mole) was added into 10 ml methanol in a 100 ml conical flask and then 1-2 ml of 
liq.  ammonia was added. The reaction mixture was refluxed with stirring for 3-10 
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hrs. Pale yellow product comes out, which was isolated and filtered when hot. It 
was further washed with methanol to remove the unreacted mass and other 
impurities. Recrystallization was carried out in methanol. The yield of title 
compounds range from 40-60 %. 
 
Physical data of newly synthesized compounds are given in Table 2.6.2. 
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2.6 PHYSICAL DATA TABLE 
 
2.6.1 Physical data of 1,4- dihydro-4-(substituted phenyl)-2,6-dimethyl-N3, 
N5- di(naphthalen-1-yl) pyridine-3,5-dicarboxamides (AKS 1-12) 
 
 
 
 
 
 
 
 
Code No. 
R MW MP in oC 
Yield 
in % 
Rf 
value  
AKS-1 4-OCH3 553.64 276-278 62 0.42 
AKS-2 3-NO2 566.62 189-191 69 0.46 
AKS-3 2-OCH3 552.64 256-258 54 0.36 
AKS-4 3,4-OCH3 583.67 156-148 52 0.31 
AKS-5 4-NO2 566.62 178-180 61 0.41 
AKS-6 2-Cl 558.06 146-148 52 0.51 
AKS-7 2,3-benzo 575.68 177-179 62 *0.42 
AKS-8 4-OH 539.62 156-158 54 0.38 
AKS-9 3,4,5-tri-OCH3 612.70 174-176 63 *0.51 
AKS-10 3-Cl 558.06 192-194 64 0.43 
AKS-11 H 523.62 187-189 60 0.37 
AKS-12 2-NO2 566.62 214-216 59 *0.42 
 
TLC solvent system:       Ethyl acetate   : Hexane            3.5 ml    : 1.5 ml 
                                        *Chloroform     : Methanol         9.5 ml    : 0.5 ml  
 
Visualization: UV light (long) 
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2.6.2 Physical data of Methyl-5-(naphthalen-1-yl-carbamoyl)-1,4-dihydro-4-  
(substituted phenyl)-2,6-dimethyl-4-phenylpyridine-3-carboxylate 
(AKS 13-20) 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TLC solvent system: Ethyl acetate  : Hexane       (2.5 ml)     :   (3.0 ml)  
 
Visualization: UV light (long) 
Code No. R MW MP in oC 
Yield 
in % 
Rf 
value   
AKS-13 H 412.48 256-258 61 0.49 
AKS-14 2-OCH3 444.52 196-198 47 0.53 
AKS-15 4-Cl 448.94 246-248 54 0.35 
AKS-16 4-F 432.48 286-288 58 0.41 
AKS-17 4-OCH3 444.52 242-244 61 0.46 
AKS-18 4-NO2 459.49 174-176 62 0.51 
AKS-19 3-NO2 459.49 212-214 59 0.43 
AKS-20 2-Cl 448.94 165-167 46 0.41 
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2.7 SPECTRAL DISCUSSION  
 
2.7.1 IR SPECTRAL ANALYSIS  
 
The infrared spectrum is significant range lies between 4000 and 610 cm-1. 
Absorption bands in the spectrum effect from energy changes arise as a 
consequence of molecular vibrations of the bond stretching and bending nature. 
The aromaticity of the compounds is determined from the significant absorption 
around 1600-1400 cm-1 and 850-660 C=C, C=O show considerable absorption 
between 2500-1600 cm-1. Similarly, assorted function groups demonstrate 
specific absorption in the finger print region which become the key point in their 
recognition. 
Spectral data of the only key transitional and final compounds are included. Using 
the instrument, SHIMADZU FT IR-8400, sample technique, KBr disc, frequency 
range, 400-4000 cm-1. 
Looking to the spectral learn of the newly synthesized DHPs molecules, the 
carbonyl (>C=O) of the amidic functionality stretching was observed at 1650-
1689 cm-1. The amide (>C-N stretching) is pragmatic at 1300-1400 cm-1. 
The stretching of the secondary amide (>NH) was observed between 3100-3400 
cm-1. In all the compounds two –NH- str vibration observed for two secondary 
amine groups. One of them illustrate absorption at inferior frequency due to 
carbonyl group attached to it. The stretching C-N appears at 1210-1420 cm-1 
which further adds up the evidence of the presence of secondary amine group. 
As far as the aromatic skeleton concerned, C-C multiple bonds stretching, C-H in 
plan bending and out of plan bending were observed at 1400-1600 cm-1 and 810-
730 cm-1 correspondingly. IR spectra of newly synthesized compounds are given 
on Pages 78-79. 
 
2.7.2 NMR SPECTRAL ANALYSIS 
 
Nuclear magnetic resonance (NMR) spectroscopy is dominant instrument for the 
organic chemist since instruments are now easily available ever since last 
decade. The technique is only relevant to those nuclei which possess a spin 
quantum number (I) greater then zero. The most significant of such nuclei as far 
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as the organic chemist is concerned are 1H and 13C both of which have spin 
quantum number of ½. The basis of the NMR experiment is to focus the nuclei to 
radiation which will result in transition from the lower energy state to higher one. 
The nuclei which are in the same environment have the same energy dissimilarity 
between spin orientations. So these energy differences are detected and 
interpreted to know the variety of location of the nuclei in the molecule. 
Instrument use for the NMR spectroscopy of the newly synthesized DHP was 
BRUKER AC 300 MHz FT-NMR, where TMS was used as the internal reference 
and CDCl3 or DMSO d6 were used as solvent. In case of AKS-2, two methyl 
groups were present at C2 and C5 position of pyridine ring, both methyl group 
have same environment therefore, these two methyl group revealed singlet at 
2.35 δ ppm. While chiral carbon of the pyridine nucleus at C4 show at 5.72 δ ppm 
with a singlet, thereby confirmed dihydropiridine nucleus. In the molecule, two 
protons of the amide linkage also show singlet at 9.24 δ ppm. Even as –NH 
protons of the pyridine nucleus also give singlet at 8.09 δ ppm, its give sound 
evidence of pyridine nucleus. While one protons of the phenyl ring provide triplet 
at 8.52 δ ppm with J value 2.06 Hz as a result of Meta coupling with one proton 
and it confirmed the meta substitution in phenyl ring. Even as this protons also 
give doublet at 7.94 δ ppm with   J=7.76 Hz cause of the ortho coupling with 
neighboring protons. Other protons also gave triplet- triplet splitting caused by 
ortho-meta coupling at 8.14 δ ppm with J=2.08, 7.44 Hz (please refer 1H NMR 
spectra of AKS-2). 
The NMR gives the promising evidence for the elucidation of the structure of the 
DHP molecules. 1HNMR spectra of newly synthesized compounds are given on 
Pages 80-82. 
 
2.7.3 MASS SPECTRAL ANALYSIS  
 
The MASS spectrometry is used for accurate determination of the molecular 
weight. It is also provide information concerning the structure of compound by an 
examination pattern. Once the organic molecule bombarded with the electrons 
under high vacuum, each molecule looses electron by various fission processes 
giving rise to ions and neutral fragments. The positive ions are expelled from the 
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ionization chamber and resolved by the means of magnetic field. When these 
ions arrive at the detector, they are recorded. The intense of the peak in the 
spectrum indicates the abundance of ions. The most intense peak is called base 
peak. When a single electron is removed from the molecule it gives rise to 
molecular ion peak and has uppermost molecular weight. 
For the entire newly synthesized compounds, molecular ion peak are in total 
agreement with their molecular weight. In case of AKS-2 and AKS-5 base peak 
were observed at 255 m/e value, caused by fragmentation at both carbonyl of 
dihydropiridine molecule, which was totally relevant to left behind pyridine 
nucleus. For AKS-3 molecular ion peak is observed at 552 m/e, which is also 
total agreement with its molecular weight. Base peak is observed at 432 due to 
subsequently loss of methyl group at C6 position and substituted phenyl ring from 
C4 position from dihydropiridine ring.  
Mass spectra of newly synthesized compounds are given on Page 83. 
 
2.7.4 Elemental Analysis 
 
Elemental analysis of the all the synthesized compounds was carried out on 
Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
(within the range of theoretical value) with the structures assigned. 
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Mass Fragmentation of 1,4- dihydro-4-(4-nitrophenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPECTRAL DATA  
 
 
1, 4 – Dihydro – 4 - (4-methoxy phenyl) – 2, 6 - dimethyl-N3, N5-di (napthalen-
1-yl)pyridine-3,5-dicarboxamide (AKS-1) 
IR (KBr, cm-1): 3284 (-NH), 3037-3011 (Ar-CH, str), 2924 (methyl,asym,str), 
2868 (methyl,sym,str), 1674 (>C=O,amide),1340 (C-N,str), 1637-1442 
(>C=C,ring skeletal vibration), 1516 (-NH Deformation)1219 (C-H, ipd), 813 (C-
H,opd),1089,1024 (C-O-C,sym,str). 
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C, H, N (in %):  Found: 78.10 (C), 5.64 (H), 7.59 (N) Cacld: 78.12 (C), 5.63 (H), 
7.61 (N) 
1,4- Dihydro-4-(3-nitrophenyl)-2,6-dimethyl-N3, N5-di(napthalen-1-yl)pyridine 
-3,5-dicarboxamide (AKS-2) 
IR (KBr, cm-1): 3273 (-NH), 3051 (Ar-CH, str), 2924 (methyl,asym,str), 2868,2759 
(methyl,sym,str), 1662 (>C=O,amide),1340 (C-N,str), 1637-1442 (>C=C,ring 
skeletal vibration), 1516 (-NH Deformation)1219 (C-H, ipd), 813 (C-
H,opd),1089,1024 (C-O-C,sym,str). 
1H NMR (In δ ppm): 2.35 (s, 6H, a), 5.72 (s, 1H, b), 7.34 (m, 2H, J=1.04), 7.44 
(m, 6H, f3, d3, d1 ), 7.60 (2H,d-d,  e4, f1,J=7.92, 9.08 ), 7.80 (2H, d, d2 J=8.16), 
7.94 (2H, d,e3, J=7.76 ), 8.09 (s, 1H,b3 ), 8.14-8.16 (t-t, 1H, e2, J=2.08, 7.44), 
8.52 (t, 1H, e1 J=2.08), 9.24 (s, 2H, b1, b2) 
Mass (m/e value):  566 (4), 424 (6), 418 (2), 397 (35), 367 (3), 281 (8), 255 
(100), 239 (3), 225 (18), 209 (33), 182 (13), 169 (74), 143 (53), 135 (39), 102 (5), 
89 (9), 77 (8), 63 (12), 44 (54) 
C, H, N (in %): Found: 73.93 (C), 4.96 (H), 9.58 (N) Cacld: 73.96 (C), 4.94 (H), 
9.60 (N) 
1, 4 – dihydro -4- (2-methoxy phenyl) -2,6- dimethyl -N3, N5-di (napthalen-1-
yl)pyridine-3,5-dicarboxamide (AKS-3) 
IR (KBr, cm-1):  3306(-NH), 3101-3068 (Ar-CH, str), 2918 (methyl,asym,str), 
2868 (methyl,sym,str), 1662 (>C=O,amide),1348 (C-N,str), 1591-1427 
(>C=C,ring skeletal vibration), 1591 (-NH Deformation)1247 (C-H, ipd), 773 (C-
H,opd),1069,1012 (C-O-C,sym,str). 
C, H, N (in %):  Found: 78.10 (C), 5.64 (H), 7.59 (N) Cacld: 78.12 (C), 5.65 (H), 
7.62 (N) 
1, 4- Dihydro -4- (3,4-dimethoxy phenyl) -2,6-dimethyl-N3, N5-di (napthalen-1-
yl)pyridine-3,5-dicarboxamide (AKS-4) 
IR (KBr, cm-1): 3325,3301 (-NH), 3057-3021 (Ar-CH, str), 2936 
(methyl,asym,str), 2868-2756 (methyl,sym,str), 1664 (>C=O,amide),1340 
(C-N,str), 1637-1442 (>C=C,ring skeletal vibration), 1516 (-NH Deformation)1219 
(C-H, ipd), 813 (C-H,opd),1089,1024 (C-O-C,sym,str). 
C, H, N (in %):  Found: 76.14 (C), 5.70 (H), 7.20 (N) Cacld:  76.12 (C), 5.72 (H), 
7.24 (N)   
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1, 4- Dihydro - 4-(4-nitro phenyl) - 2 , 6- dimethyl - N3, N5- di (napthalen – 1 - 
yl)pyridine-3,5-dicarboxamide (AKS-5) 
IR (KBr, cm-1): 3315,3273 (-NH), 3051,3010 (Ar-CH, str), 2956, 2930 
(methyl,asym,str), 2886,2725 (methyl,sym,str), 1672 (>C=O,amide),1352 (C-
N,str), 1650-1437 (>C=C,ring skeletal vibration), 1535 (-NH Deformation)1242 
(C-H, ipd), 756 (C-H,opd),1091,1014 (C-O-C,sym,str). 
1H NMR (In δ ppm): 2.36 (s, 6H), 5.65 (s, 1H), 7.33 (t, 2H, J= 8.12, 7.08 Hz), 
7.43 (t, 4H, J= 8.32, 7.48 Hz),  7.49 (m, 2H, J= 1.56, 4.36 Hz), 7.58 (t, 2H, J= 
10.68, 8.92, 1.48 Hz), 7.68 (d, 2H, J= 8.64 Hz), 7.82 (m, 2H, J= 7.56, 8.36, 8.68 
Hz), 8.13 (d, 2H, J= 7.52 Hz), 8.22 (t, 2H, J= 6.84, 1.92 Hz), 8.87 (s, 1H,  -NH), 
8.94 (s, 2H, -NH) 
Mass (m/e value): 566 (4), 424 (7), 397 (32), 382 (6), 367 (3), 312 (2), 281 (8), 
277 (2), 255 (100), 251 (4), 225 (18), 210 (5), 209 (15), 182 (9), 169 (75), 154 (4), 
143 (57), 139 (20), 115 (37), 102 (4), 89 (9), 70 (10), 63 (12), 44 (23) 
C, H, N (in %):  Found: 73.93 (C), 4.96 (H), 9.58 (N) Cacld:  73.95 (C), 4.99 (H), 
9.60 (N) 
1,4-Dihydro-4-(2-chlorophenyl)-2,6-dimethyl-N3,N-di(napthalen-1-yl)pyridine-
3,5-dicarboxamide (AKS-6) 
IR (KBr, cm-1): 3326,3275 (-NH), 3024 (Ar-CH, str), 2964,2910 (methyl,asym,str), 
2870, 2714 (methyl,sym,str), 1654 (>C=O,amide),1346 (C-N,str), 1610-1432 
(>C=C,ring skeletal vibration), 1541 (-NH Deformation)1242 (C-H, ipd), 786 (C-
H,opd),1095,1014 (C-O-C,sym,str). 
C, H, N (in %): Found: 75.32 (C), 5.06 (H), 7.53 (N) Cacld:   75.31 (C), 5.08 (H), 
7.56 (N) 
1,4- Dihydro -2,6- dimethyl-N3,N5,4-tri(napthalen-1-yl) pyridine-3,5-
dicarboxamide (AKS-7) 
IR (KBr, cm-1): 3336,3284 (-NH), 3045 (Ar-CH, str), 2965,2941 (methyl,asym,str), 
2878,2710 (methyl,sym,str), 1671 (>C=O,amide),1348 (C-N,str), 1621-1440 
(>C=C,ring skeletal vibration), 1518 (-NH Deformation)1235 (C-H, ipd), 801 (C-
H,opd),1090,1034 (C-O-C,sym,str). 
C, H, N (in %): Found: 81.65 (C), 5.45 (H), 7.32 (N) Cacld:   81.66 (C), 5.48 (H), 
7.34 (N) 
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1,4- Dihydro -4- (4-hydroxy phenyl) -2,6- dimethyl- N3, N5-di (napthalen-1-yl) 
pyridine -3,5- dicarboxamide (AKS-8) 
IR (KBr, cm-1): 3348,3273 (-NH), 3068,3014 (Ar-CH, str), 2945,2910 
(methyl,asym,str), 2878,2749 (methyl,sym,str), 1666 (>C=O,amide),1342 (C-
N,str), 1647-1440 (>C=C,ring skeletal vibration), 1526 (-NH Deformation)1220 
(C-H, ipd), 789 (C-H,opd),1099,1021 (C-O-C,sym,str). 
C, H, N (in %): Found: 77.90 (C), 5.42 (H), 7.79 (N) Cacld: 77.94 (C), 5.47 (H), 
7.84 (N) 
1,4- Dihydro-4-(3,4,5-trimethoxyphenyl)-2,6-dimethyl-N3, N5-di(napthalen-1-
yl)pyridine-3,5-dicarboxamide (AKS-9) 
IR (KBr, cm-1): 3317,3284 (-NH), 3050,3021 (Ar-CH, str), 2965,2924 
(methyl,asym,str), 2868,2724 (methyl,sym,str), 1670 (>C=O,amide),1344 (C-
N,str), 1638-1442 (>C=C,ring skeletal vibration), 1526 (-NH Deformation)1229 
(C-H, ipd), 765 (C-H,opd),1097,1010 (C-O-C,sym,str). 
C, H, N (in %): Found: 74.37 (C), 5.75 (H), 6.85 (N) Cacld:  74.34 (C), 5.78 (H), 
6.89 (N) 
1, 4- Dihydro -4- (3-chloro phenyl)- 2,6 –dimethyl -N3,N5-di (napthalen-1-
yl)pyridine-3,5-dicarboxamide (AKS-10) 
IR (KBr, cm-1): 3365,3252 (-NH), 3050 (Ar-CH, str), 2958,2924 (methyl,asym,str), 
2874,2740 (methyl,sym,str), 1665 (>C=O,amide),1342 (C-N,str), 1647-1435 
(>C=C,ring skeletal vibration), 1530 (-NH Deformation)1222 (C-H, ipd), 745 (C-
H,opd),1093,1013 (C-O-C,sym,str). 
C, H, N (in %): Found: 75.32 (C), 5.06 (H), 7.53 (N) Cacld:   75.30 (C), 5.10 (H), 
7.55 (N) 
1,4- Dihydro - 2,6 – dimethyl - N3,N5- di (napthalen-1-yl) -4- phenyl pyridine-
3,5-dicarboxamide (AKS-11) 
IR (KBr, cm-1): 3405,3387,3294 (-NH), 3084,3023 (Ar-CH, str), 2965,2924 
(methyl,asym,str), 2868,2745 (methyl,sym,str), 1671 (>C=O,amide),1352 (C-
N,str), 1631-1452 (>C=C,ring skeletal vibration), 1532 (-NH Deformation)1215 
(C-H, ipd), 744 (C-H,opd),1091,1021 (C-O-C,sym,str). 
C, H, N (in %): Found: 80.28 (C), 5.58 (H), 8.02 (N), Cacld: 80.26 (C), 5.59 (H), 
8.07 (N) 
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1,4- Dihydro – 4 - (2-nitro phenyl) - 2, 6 – dimethyl - N3, N5- di (napthalen - 1 -
yl)pyridine-3,5-dicarboxamide (AKS-12) 
IR (KBr, cm-1): 3412, 3374 (-NH), 3042,3014 (Ar-CH, str), 2962-2940- 
(methyl,asym,str), 1674 (>C=O,amide), 1721 (-C=O,ester)1352 (C-N,str), 1644-
1438 (>C=C,ring skeletal vibration), 1542 (-NH Deformation)1246 (C-H, ipd), 784 
(C-H,opd),1090,1008 (C-O-C,sym,str) 
1H NMR (In δ ppm): 2.32 (s, 6H), 5.66 (s, 1H), 7.32 (t, 2H, J= 7.60, 7.44), 7.42 (t,    
4H, J= 7.68, 5.64), 7.49 (d, 2H, J= 7.16 Hz), 7.56 (d, 2H, J= 8.44), 7.67 (d, 2H, J= 
8.04), 7.77 (m, 4H, J= 8.16, 8.84), 8.20 (d, 2H, J= 8.56), 9.17 (s, 2H) 
C, H, N (in %):  Found: 73.91 (C), 4.96 (H), 9.56 (N) Cacld:  73.95 (C), 4.99 (H), 
9.60 (N) 
Methyl –5-(naphthalene–1– yl - carbamoyl) - 1, 4 – dihydro -2,6-dimethyl-4-
phenylpyridine-3-carboxylate(AKS-13) 
IR (KBr, cm-1): 3367,3271 (-NH), 3065,3010 (Ar-CH, str), 2974-2946- 
(methyl,asym,str), 1671 (>C=O,amide), 1710 (-C=O,ester)1346 (C-N,str), 1640-
1440 (>C=C,ring skeletal vibration), 1556 (-NH Deformation)1240 (C-H, ipd), 796 
(C-H,opd),1099,1014 (C-O-C,sym,str) 
C, H, N (in %): Found: 75.71 (C), 5.86 (H), 6.79 (N), Cacld: 75.74 (C), 5.85 (H), 
6.82 (N)  
Methyl-5-(naphthalen-1-yl-carbamoyl)-1,4-dihydro-4-(2-methoxyphenyl)-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-14) 
IR (KBr, cm-1): 3345,3283 (-NH), 3070,3026 (Ar-CH, str), 2965-2924- 
(methyl,asym,str), 1669 (>C=O,amide), 1714 (-C=O,ester)1352 (C-N,str), 1650-
1436 (>C=C,ring skeletal vibration), 1543 (-NH Deformation)1232 (C-H, ipd), 774 
(C-H,opd),1089,1013 (C-O-C,sym,str). 
C, H, N (in %): Found: 73.28 (C), 5.92 (H), 6.33 (N), Cacld: 73.26 (C), 5.90 (H), 
6.34 (N) 
Methyl-5-(naphthalen-1-yl-carbamoyl)-1,4-dihydro-4-(4-chlorophenyl)-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-15) 
IR (KBr, cm-1): 3412,3301 (-NH), 3074,3026 (Ar-CH, str), 2965-2946- 
(methyl,asym,str), 1664 (>C=O,amide), 1717 (-C=O,ester)1342 (C-N,str), 1636-
1441 (>C=C,ring skeletal vibration), 1535 (-NH Deformation)1240 (C-H, ipd), 796 
(C-H,opd),1099,1014 (C-O-C,sym,str). 
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C, H, N (in %): Found: 69.87 (C), 5.19 (H), 6.27 (N), Cacld: 69.89 (C), 5.23 (H), 
6.30 (N) 
Methyl-5-(naphthalen-1-yl-carbamoyl)-1,4-dihydro-4-(4-flourophenyl)-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-16) 
IR (KBr, cm-1): 3367,3271 (-NH), 3065,3010 (Ar-CH, str), 2974-2946- 
(methyl,asym,str), 1671 (>C=O,amide), 1710 (-C=O,ester)1346 (C-N,str), 1640-
1440 (>C=C,ring skeletal vibration), 1556 (-NH Deformation)1240 (C-H, ipd), 796 
(C-H,opd),1099,1014 (C-O-C,sym,str). 
C, H, N (in %): Found: 72.54 (C), 5.39 (H), 4.44 (N), Cacld: 72.55 (C), 5.36 (H), 
4.48 (N) 
Methyl-5-(naphthalen-1-yl-carbamoyl)-1,4-dihydro-4-(4-methoxyphenyl)-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-17) 
IR (KBr, cm-1): 3357,3265 (-NH), 3024 (Ar-CH, str), 2968-2951- 
(methyl,asym,str), 1662 (>C=O,amide), 1718(-C=O,ester)1352 (C-N,str), 1645-
1442 (>C=C,ring skeletal vibration), 1531 (-NH Deformation)1219 (C-H, ipd), 889 
(C-H,opd),1093 (C-O-C,sym,str). 
C, H, N (in %): Found: 73.28 (C), 5.92 (H), 6.32 (N), Cacld: 73.26 (C), 5.97 (H), 
6.35 (N) 
Methyl -5- (naphthalene-1-yl-carbamoyl)- 1,4-dihydro -4- (4-nitro phenyl)-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-18) 
IR (KBr, cm-1): 3371,3302, (-NH), 3037 (Ar-CH, str),  1666 (>C=O,amide), 1718(-
C=O,ester)1334 (C-N,str), 1525-1440 (>C=C,ring skeletal vibration), 1525 (-NH 
Deformation)1236 (C-H, ipd), 790 (C-H,opd),1099-1039 (C-O-C,sym,str). 
C, H, N (in %): Cacld: 68.26 (C), 5.07 (H), 9.14 (N), Found: 68.24 (C), 5.10 (H), 
9.16 (N) 
Methyl-5- (naphthalene -1-yl-carbamoyl) -1,4-dihydro -4- (3-nitro phenyl)-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-19) 
IR (KBr, cm-1): 3324,3276 (-NH), 3051,3011 (Ar-CH, str), 2975-2930- 
(methyl,asym,str), 1666 (>C=O,amide), 1712 (-C=O,ester)1362 (C-N,str), 1640-
1433 (>C=C,ring skeletal vibration), 1534 (-NH Deformation)1240 (C-H, ipd), 786 
(C-H,opd),1099,1011 (C-O-C,sym,str). 
C, H, N (in %): Found: 68.26 (C), 5.07 (H), 9.14 (N), Cacld: 68.24 (C), 5.10 (H), 
9.16 (N) 
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Methyl-5- (naphthalen-1-yl-carbamoyl) -1,4-dihydro -4- (2-chloro phenyl)-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-20) 
IR (KBr, cm-1): 3410,3342 (-NH), 3074,3043 (Ar-CH, str), 2970-2945- 
(methyl,asym,str), 1668 (>C=O,amide), 1767 (-C=O,ester)1342 (C-N,str), 1644-
1442 (>C=C,ring skeletal vibration), 1550 (-NH Deformation)1251 (C-H, ipd), 801 
(C-H,opd),1089,1010 (C-O-C,sym,str). 
C, H, N (in %): Found: 69.87 (C), 5.19 (H), 6.27 (N), Cacld: 69.88 (C), 5.24 (H), 
6.229 (N) 
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IR spectrum of 1,4- dihydro-4-(4-methoxyphenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-1) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of 1,4- dihydro-4-(3-nitrophenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-2) 
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IR spectrum of 1,4- dihydro-4-(2-methoxyphenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of Methyl-5-(naphthalen-1-yl-carbamoyl)-1,4-dihydro-2,6-
dimethyl-4-phenylpyridine-3-carboxylate(AKS-13) 
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1H NMR spectrum of 1,4- dihydro-4-(4-nitrophenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-2) 
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1H NMR spectrum of 1,4- dihydro-4-(2-nitrophenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-12) 
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1H NMR spectrum of 1,4- dihydro-4-(4-nitrophenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-5) 
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Mass spectrum of 1,4- dihydro-4-(3-nitrophenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of 1,4- dihydro-4-(4-nitrophenyl)-2,6-dimethyl-N3, N5-
di(napthalen-1-yl)pyridine-3,5-dicarboxamide (AKS-5) 
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3.1 Biginelli Reaction 
P. Biginelli reported the synthesis of functionalized 3,4-dihydropyrimidin-(1H)-
ones (DHPMs) via three-component condensation reaction of an aromatic 
aldehyde, urea, and ethyl acetoacetate. In the past decade, this multicomponent 
reaction (MCR) has experienced a remarkable revival, mainly due to the 
interesting pharmacological properties associated with this dihydropyrimidine 
scaffold to generate small libraries of diverse structure1.  
 
 
 
 
  
 
 
 
 
3.1.1 Dihydropyrimidine Synthesis 
 
Generally the reaction was carried out by heating a mixture of the three 
components dissolved in ethanol with a catalytic amount of HCl at reflux 
temperature. The product of this one-pot, three-component synthesis that 
precipitated on cooling of the reaction mixture was identified correctly by Biginelli 
as 3,4-dihydropyrimidin-2(1H)-one. Apart from a series of publications by late 
Karl Folkers in the mid 1930s, the “Biginelli reaction” or “Biginelli condensation” 
as it was henceforth called was largely ignored in the early part of the 20th 
century. The synthetic potential of this new heterocycle synthesis therefore 
remained unexplored for quite some time. In the 1970s and 1980s, interest slowly 
increased, and the scope of the original cyclocondensation reaction was 
gradually extended by variation of all three building blocks, allowing access to a 
large number of multifunctionalized dihydropyrimidines.2-4  
 
3.1.2 Mechanistic Studies of Biginelli Reaction 5-9 
 
The mechanism of the Biginelli reaction has been the subject of some debate 
over the past decades. Early work by Folkers and Johnson3 suggested that 
bisureide, i.e. the primary bimolecular condensation product of benzaldehyde and 
O H
EtOOC
O
NH2
H2N
O NH
NH
O
EtOOC
EtOH
H+
 89
urea, is the first intermediate in this reaction. In 1973, Sweet and Fissekis5 
proposed a different pathway and suggested that carbonium ion,  
 
 
 
 
 
 
 
 
 
 
 
 
 
produced by an acid-catalyzed aldol reaction of benzaldehyde with ethyl 
acetoacetate, is formed in the first and limiting step of the Biginelli condensation. 
Kappe et al6 reinvestigated the mechanism in 1997 using 1H/13C NMR 
spectroscopy and trapping experiments and have established that the key step in 
this sequence involves the acid-catalyzed formation of an N-acyliminium ion 
intermediate [1] from the aldehyde and urea precursors. Interception of the 
iminium ion by ethyl acetoacetate [2], presumably through its enol tautomer [3], 
produces an open-chain ureide which subsequently cyclized to 
hexahydropyrimidine [4]. Acid-catalyzed elimination of water ultimately leads to 
the final DHPM product [5]. The reaction mechanism can therefore be classified 
as a α-amidoalkylation, or more specifically as a α-ureidoalkylation. The 
alternative “carbenium ion mechanism” does not constitute a major pathway; 
however, small amounts of enone are sometimes observed as byproduct. 
Although the highly reactive N-acyliminium ion species could not be isolated or 
directly observed, further evidence for the proposed mechanism was obtained by 
isolation of intermediates, employing sterically bulky or electron-deficient 
acetoacetates respectively. The relative stereochemistry in hexahydropyrimidine 
was established by an X-ray analysis. In fact, a number of hexahydropyrimidines 
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could be synthesized by using perfluorinated 1,3-dicarbonyl compounds or α-keto 
esters as building blocks in the Biginelli condensation. 
  3.2 Literature Survey  
 
Various modifications have been applied to Biginelli reaction to get better yield 
and to synthesize biologically active analogues. Different catalysts have been 
reported to increase the yield of the reaction. Microwave synthesis strategies are 
also applied to shorten the reaction time. Solid phase synthesis and 
combinatorial chemistry has made possible to generate library of DHPM 
analogues.  
3.2.1 Catalyst 
Essa H. Hu et al10 reported Biginelli reaction catalyzed with trifluoroborane 
etherate, transition metal salt, and proton source to yield 80-90% Biginelli 
product. They proposed a mechanism similar to that of Folkers and Johnson3 and 
to that of Kappe5 for the Biginelli reaction wherein formation of acyl imines 
intermediate  formed by reaction of the aldehyde with urea and stabilized by 
either trifluoroborane or the transition metal, is the key, rate limiting step. 
Subsequent addition of the α-keto ester enolate, followed by cyclization and 
dehydration, would afford the dihydropyrimidinone. Brindaban C. Ranu et 
al11reported Indium Chloride as an efficient catalyst for Biginelli reaction. A wide 
range of structurally varied α-dicarbonyl compound, aldehyde and urea were 
coupled together by this procedure to produce the corresponding 
dihydropyrimidinones. 
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A variety of substituted aromatic, aliphatic, and heterocyclic aldehydes have been 
subjected to this condensation very efficiently. Thiourea has been used with 
similar success to provide the corresponding dihydropyrimidin-2(1H)-thiones. 
 
 
 
 
 
 
 
 
Bose et al12used cerium (III) chloride as a catalyst and reported solvent free 
synthesis of Biginelli compounds using this new catalyst. This procedure provides 
higher yield, shorter reaction time and simple work up methods. Solvent free 
reactions using this catalyst gave about 70% yield and reaction time was about 
10 hrs. If ethanol is used as solvent, 90% yield was obtained with this catalyst. 25 
mol % amount of cerium (III) chloride heptahydrate was found to be sufficient to 
push the reaction forward. The increased amount did not build further advantage. 
 
 
 
 
 
 
 
 
 
 
Enantioselective one pot synthesis of Biginelli reaction is reported with use of 
lanthanide triflates/ytterbium triflates.  These catalyst leads to highly 
enantioselectivity and up to 99% enantioselective Biginelli reaction can be carried 
out.13 
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          Entry                Lewis acid                 Solvent               Yield, %   
     
         
             1                       La(OTf)3                     THF                    83 
             2                       Sm(OTf)3                    THF                    81 
             3                        Yb(OTf)3                              THF                    87      
             4                        Yb(OTf)3                            CH2Cl2                         80 
             5                        Yb(OTf)3                              CH3CN               86 
             6                        Yb(OTf)3                              CH3OH               88 
 
 
 
 
 
 
 
 
 
Very recently, chiral phosphoric acid is reported as highly enantioselective 
catalyst for Biginelli reaction. Reaction is reported in presence of 10 mol % of 
chiral phosphoric acid to produce desired enantioselective product. This is the 
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first organocatalytic asymmetric Biginelli reaction. The optimal chiral phosphoric 
acid afforded the reaction in high yields with excellent enantioselectivities of up to 
97%. A wide variety of substrates, including aldehydes and α-keto esters, could 
be tolerated. This reaction has an advantage of avoiding the contamination of 
transition metals in the manufacture of the medicinally relevant chiral 3,4-
dihydropyrimidin-2-(1H)-ones.14 
 
 
 
 
 
 
 
 
 
 
 
 
Recently Jiang and Chen15reported Yb (III)-Resin catalyzed Biginelli reaction 
under solvent-free conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heravi et al16 recently reported synthesis of dihydropyrimidones using 12-
molybdophosphoric acid in refluxing acetic acid to catalyze this three-component 
condensation reaction to afford the corresponding pyrimidinones in good yields. 
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An improved approach has been found to carry out the Biginelli reaction for the 
synthesis of 3,4- dihydropyrimidin- 2(1H)-one derivatives. This synthesis was 
performed in the presence of hydrochloric acid and β-cyclodextrin in ethanol 
solution. Compared with the classical Biginelli reaction conditions, this new 
approach has the advantage of excellent yields and short reaction time17. An 
efficient synthesis of 3,4-dihydropyrimidinones from the aldehyde, β-keto ester 
and urea in ethanol, using ferric chloride hexahydrate or nickel chloride 
hexahydrate as the catalyst, is described18. Compared with the classical Biginelli 
reaction conditions, this new method has the advantage of excellent yields (53-
97%) and short reaction time (4-5 hours). 5-Alkoxycarbonyl-4-aryl-3,4-
dihydropyrimidin-2-ones are synthesized by the one-pot reactions of aldehydes, 
β-ketoesters and urea using a catalytic amount of phosphotungstic acid (PTA) in 
ethanol. Thus modified Biginelli cyclocondensation not only shortens the reaction 
period and simplifies the operation, but also improves the yields.19 
Ruthenium (III) chloride efficiently catalyzes the three-component Biginelli 
reaction of an aldehyde, a β-keto ester, and urea or thiourea under solvent-free 
conditions to afford the corresponding 3,4-dihydropyrimidine-2-(1H)-ones in 
excellent yields20. The Biginelli reaction, a one-pot condensation of aldehydes, 
urea or thiourea, and -dicarbonyl compounds, is efficiently catalyzed by 
samarium diiodide.  
Scandium (III) triflate efficiently catalyzes the three-component condensation 
reaction of an aldehyde, a β-ketoester, and urea in refluxing acetonitrile to afford 
the corresponding 3,4-dihydropyrimidin-2(1H)-ones in excellent yields. The 
catalyst can be recovered and reused, making this method friendly and 
environmentally acceptable23. 
 
 
 
 
 
Shailaja et al24 have demonstrated experimentally a simple and straightforward 
protocol (combination system of SnCl2–LiCl) which provides dihydropyrimidin-2-
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one system in high yield and high purity while retaining the simplicity of the 
Biginelli concept. Magnesium bromide efficiently catalyzes the three-component 
condensation reaction of aldehyde, β-diketone and urea/thiourea under solvent 
free conditions to afford the corresponding dihydropyrimidinones in high yields 
and short reaction time.25 Bismuth nitrate pentahydrate catalyzes the three 
 
 
 
 
 
component condensation reaction of an aromatic aldehyde, urea and a β-
ketoester or a β-diketone under solvent-free conditions to afford the 
corresponding dihydropyrimidinones (DHPMs) in high yields. The method is also 
effective for the selective condensation of aryl aldehydes in the presence of 
aliphatic aldehydes26.  The biologically active dihydropyrimidinones are also easily 
synthesized in moderate to excellent yields under solvent-free conditions21. 
Hydroxyapatite doped with ZnCl2, CuCl2, NiCl2 and CoCl2 efficiently catalyses the 
three components Biginelli reaction between an aldehyde, ethyl acetoacetate and 
urea in refluxing toluene to afford the corresponding dihydropyrimidinones in high 
yields22.  
 
 
 
 
 
 
 
Sharma et al27 reported a simple, efficient, mild and green method has been 
developed for the synthesis of 3,4-dihydropyrimidin-2-ones employing dodecyl 
sulfonic acid as an excellent surfactant-type Bronsted acid catalyst in aqueous 
media at room temperature.  
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Yadav et al28 reported that Ceric ammonium nitrate efficiently catalyzes the three 
component Biginelli reaction in methanol to afford the corresponding 
dihydropyrimidinones in excellent yields. 
 
  
 
 
 
 
 
3.2.2 Ionic liquid  
Wang et al39 reported the Biginelli reaction between an aromatic aldehyde, ethyl 
acetoacetate, and urea - catalyzed by polymer-supported, re-usable, room-
temperature ionic liquids (RTIL) - was shown to efficiently proceed in glacial 
AcOH at 100° to afford the corresponding pyrimidine-5-carboxylates in yields up 
to 99% within 2 h. The catalyst(s) could be reused at least five times, basically 
without loss of activity, which makes this transformation not only straight-forward, 
but also considerably less expensive compared to methods involving classical 
RTIL catalysts. 
3.3 Biologically active dihydropyrimidones  
4-Aryl-1,4-dihydropyridines (DHPs, e.g nifedipine, ) are the most studied class of 
organic calcium channel modulators. More than 30 years after the introduction of 
nifedipine, many DHP analogs have now been synthesized and numerous 
second-generation commercial products have appeared on the market40, 41. In 
recent years, interest has also focused on aza-analogs such as 
dihydropyrimidines (DHPMs) which show a very similar pharmacological profile to 
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classical dihydropyridine calcium channel modulators42-49. Over the past few 
years several lead-compounds were developed that are superior in potency and 
duration of antihypertensive activity to classical DHP drugs, and compare 
favourable with second-generation drugs such as amlodipine and nicardipine50.   
 
 
. 
 
 
 
 
Barrow et al55 reported in vitro and in vivo evaluation of dihydropyrimidinone C-5 
amides as potent and selective α1a Receptor Antagonists for the treatment of 
benign prostatic hyperplasia. α1 adrenergic receptors mediate both vascular and 
lower urinary tract tone, and α1 receptor antagonists such as terazosin are used 
to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, 
three different subtypes of this receptor have been identified, with the α1a receptor 
being most prevalent in lower urinary tract tissue. 4-aryldihydropyrimidinones 
attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective α1a 
receptor subtype antagonists. In receptor binding assays, these types of 
compounds generally display Ki values for the α1A receptor subtype <1 nM while 
being greater than 100-fold selective versus the α1b and α1d receptor subtypes. 
Many of these compounds were also evaluated in vivo and found to be more 
potent than terazosin in both a rat model of prostate tone and a dog model of 
intra-urethral pressure without significantly affecting blood pressure. While many 
of the compounds tested displayed poor pharmacokinetics, one compound was 
found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and 
dogs. Due to its selectivity for the α1a over the α1b and α1d receptors as well as its 
favourable pharmacokinetic profile, it has the potential to relieve the symptoms of 
BPH without eliciting effects on the cardiovascular system.51-55 
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The 4-aryldihydropyrimidinone heterocycle attached to an aminopropyl-4-
arylpiperidine via a C-5 amide has proved to be an excellent template for 
selective α1a receptor subtype antagonists. These types of compounds are 
exceptionally potent in both cloned receptor binding studies as well as in in vivo 
pharmacodynamic models of prostatic tone. 
Compounds exhibited high binding affinity and subtype selectivity for the cloned 
human α1A receptor. Systematic modifications led to identification of highly potent 
and subtype-selective compounds with high binding affinity (Ki =0.2 nM) for α1a 
receptor and greater than 1500-fold selectivity over α1b and α1d adrenoceptors. 
The compounds were found to be functional antagonists in human, rat, and dog 
prostate tissues. They exhibited excellent selectively to inhibit intraurethral 
pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in 
mongrel dogs (Kb(DBP)/Kb(IUP))suggesting uroselectivity for α1a-selective 
compounds.56 
 
 
 
 
 
 
Cho et al57 reported 3-N-substituted-3,4-dihydropyrimidine and 3-N-substituted-
dihydropyrimidin-2(1H)-ones  as calcium channel antagonist. Compounds 
[especially  [R1=(CH2)2N(benzyl)(2-naphthylmethyl),R2=i-Pr,X=2-N02] and [R'= 
(CH2)2N(benzyl) (3,4-dichlorobenzyl),R2=i-Pr, X=2-NO2, Y=O/S] exhibited not 
only more potent and longer lasting vasodilative action but also a hypertensive 
activity with slow onset as compared with dihydropyridines. Moreover, some 
dihydropyrimidines[R'= (CH2)2N (benzyl) (3-phenylpropyl), R2=CH2 (cyclopropyl), 
X=2-NO2] were weaker in blocking atrioventricular conduction in anesthetized 
open-chest dogs and less toxic than the dihydropyridines. 
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Atwal et al58 examined a series of novel dihydropyrimidine calcium channel 
blockers that contain a basic group attached to either C5 or N3 of the heterocyclic 
ring. Structure-activity studies show that l-(phenyl methyl)-4-piperidinyl carbamate 
moiety at N3 and sulfur at C2 are optimal for vmrelaxant activity in vitro and impart 
potent and long-acting antihypertensive activity in vivo. One of the compounds 
was identified as a lead, and the individual enantiomers were synthesized. Two 
key steps of the synthesis were (1) the efficient separation of the diastereomeric 
ureido derivatives and (2) the high-yield transformation of 2-methoxy intermediate 
to the (p-methoxybenzyl) thio intermediates. Chirality was demonstrated to be a 
significant determinant of biological activity, with the dihydropyridine receptor 
recognizing the enamino ester moiety but not the carbamate moiety. 
Dihydropyrimidine is equipotent to nifidipine and amlodipine in vitro. In the 
spontaneously hypertensive rat, dihydropyrimidine is both more potent and longer 
acting than nifidipine and compares most favorably with the long-acting 
dihydropyridine derivative amlodipine. Dihydropyrimidine has the potential 
advantage of being a single enantiomer 
. 
 
 
 
 
 
In order to explain the potent antihypertensive activity of the modestly active (ICw 
= 3.2 pM) dihydropyrimidine calcium channel blocker, Atwal et al59 carried out 
drug metabolism studies in the rat and found it is metabolized. Two of the 
metabolites (ICw = 16 nM) and (ICw = 12 nM), were found to be responsible for 
the antihypertensive activity of compound. Potential metabolism in vivo precluded 
interest in pursuing compounds related to it. Structure-activity studies aimed at 
identifying additional aryl-substituted analogues led to comparable potential in 
vivo, though these compounds were less potent in vitro. To investigate the effects 
of absolute stereochemistry on potency, authors resolved via diastereomeric 
ureas, prepared by treatment with (R)-α-methylbenzylamine. The results 
demonstrate that the active R-(-)-enantiomer is both more potent and longer 
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acting than nifedipine as an antihypertensive agent in the SHR. The in vivo 
potency and duration is comparable to the long-acting dihydropyridine 
amlodipine. The superior oral antihypertensive activity compared to that of 
previously described carbamates could be explained by its improved oral 
bioavailability, possibly resulting from increased stability of the urea functionality. 
 
 
 
 
 
 
 
Atwal et al60 modified the structure of previously described dihydropyrimidine i.e. 
3-substituted 1,4-dihydropyrimidines. Structure- activity studies using potassium-
depolarized rabbit aorta show that ortho, meta-disubstituted aryl derivatives are 
more potent than either ortho- or meta-monosubstituted compounds. While 
vasorelaxant activity was critically dependent on the size of the C5 ester group, 
isopropyl ester being the best, a variety of substituents (carbamate, acyl, sulfonyl, 
and alkyl) were tolerated at N3. The results show dihydropyrimidines are 
significantly more potent than corresponding 2- heteroalkyl-l,4-dihydropyrimidines 
and only slightly less potent than similarly substituted 2-heteroalkyl-1-4-
dihydropyridines. Where as dihydropyridine enantiomer usually show 10-15-fold 
difference in activity, the enantiomers of dihydropyrimidine show more than a 
1000-fold difference in activity. These results strengthen the requirement of an 
enamino ester for binding to the dihydropyridine receptor and indicate a 
nonspecific role for the N3-substituent, 2-Heterosubstituted-4-aryl-l,4-dihydro-6-
methyl-pyrimidinecarbo- axcyildicesters, which lack the potential symmetry of 
dihydropyridine- calcium channel blockers, were prepared and evaluated for 
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biological activity. Biological assays using potassium-depolarized rabbit aorta and 
radio ligand binding techniques showed that some of these compounds are 
potent mimics of dihydropyridine calcium channel blockers. 
3.3.1 N3-Acylated dihydropyrimidines and their biological importance  
Kappe et al61-62 reported that N3-acylated DHPMs can be rapidly synthesized in a 
high throughput fashion by combining microwave-assisted acylations with 
microwave-assisted scavenging techniques. Scavenging experiments can be 
carried out employing either supported nucleophilic amine sequestration reagents 
or water. N-acylated DHPMs are pharmacologically important N-acylation of 
DHPM can be performed as shown below.  
 
 
 
 
 
 
 
N3-substituted DHPMs have been identified to possess potent pharmacological 
profiles, e.g. following compound exhibited high binding affinity and subtype 
selectivity for the cloned human α1a receptor63.  
 
 
 
 
 
 
 
 
Systematic modifications of above compounds led to identification of highly 
potent and subtype-selective compounds with high binding affinity (Ki = 0.2 nM) 
for α1a receptor and greater than 1500-fold selectivity over α1b and α1d 
adrenoceptors. The compounds were found to be functional antagonists in 
human, rat and dog prostate tissues. Modifications to the C5 position also play 
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Important role in potency of DHPM ring. 4-aryldihydropyrimidinones attached to 
an aminopropyl-4-arylpiperidine via a C-5 amide as selective α1a receptor subtype 
antagonists. In receptor binding assays, these types of compounds generally 
display Ki values for the α1a receptor subtype <1 nM while being greater than 
100-fold selective versus the α1b and α1d receptor subtypes. Many of these 
compounds were also evaluated in vivo and found to be more potent than 
terazosin in both a rat model of prostate tone and a dog model of intra-urethral 
pressure without significantly affecting blood pressure64.  
 
 
 
 
 
 
 
 
3.4 Heck cyclization of DHPMs 
The intramolecular Heck reaction can be observed in DHPM skeleton. The 
starting material for the intramolecular Heck reaction was prepared by selective 
N3-acylation of 4-(o-bromophenyl)-dihydropyrimidone with acryloyl chloride65 
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Applying intramolecular Heck reaction, tricyclic ring system can be obtained as 
shown below.66 
 
 
 
 
 
The computational experiments reveal that the formation of a tricyclic ring system 
did not flatten out the overall geometry. On the contrary, the aryl ring was still 
locked in a pseudo axial position, resembling other nonfused 4-aryl-
dihydropyrimidines.67-68 In fact, here; the intramolecular Heck strategy allows 
locking of the aryl ring in the proposed bioactive, that is, the pseudo axial 
orientation.69 
 
 
 
 
 
 
 
3.4.1 N3-Arylation DHPMs 
N3-arylated DHPM analogues cannot be obtained by classical Biginelli 
condensation strategies involving N-arylureas. Here, the corresponding N1-
substituted derivates will be formed exclusively70-71. Wannberg et al11 reported 
protocol using concentrated mixture of 20 mol % of cuprous iodide as catalyst, 
1.5 equiv of cesium carbonate as base, and 5 mol equiv of dimethylformamide as 
solvent. The reactions were conducted at 180 °C for 40 min with a set of eight 
differently substituted aryl iodides. 
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3.4.2 Fused bicyclic systems resulting from Dihydropyrimidines 
Many bicyclic fused systems can be synthesized from DHPM scaffold. Pyrazolo 
[4,3-d]pyrimidine derivatives synthesized by reacting sodium azide with N-Methyl, 
6-Bromomethyl DHPM. The possible mechanism of this transformation is shown 
below and involves decomposition of the diazide to vinyl diazo derivative, which 
undergoes spontaneous 1,5-electrocyclization to 3H-pyrazole. Subsequent 
migration of the ester substituent from the tetrahedral carbon to N2 (thermal van 
Alphen-Hüttel rearrangement) yields pyrazolo [4,3-d]pyrimidine. The structure 
confirming the position of the ester group at N2 was established by an X-ray 
analysis115. Use of the 4-chloroacetoacetate building 
 
 
 
 
 
 
 
 
 
 
block in a Biginelli-type condensation is very useful to get variety of bicyclic 
systems. The resulting functionalized DHPM appeared to be an ideal common 
chemical template for the generation of a variety of interesting bicyclic scaffolds 
such as furo[3,4-d]- pyrimidines, pyrrolo[3,4-d]pyrimidines, and pyrimido-[4,5-
d]pyridazines. Solid-phase and solution-phase protocols for the synthesis of 
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furo[3,4-d]pyrimidines, pyrrolo[3,4-d]-pyrimidines, and pyrimido[4,5-d]pyridazines 
are reported. The multistep solid-phase sequence involves the initial high-speed, 
microwave-promoted acetoacetylation of hydroxymethylpolystyrene resin with 
methyl 4-chloroacetoacetate. The immobilized 4-chloroacetoacetate precursor 
was subsequently subjected to three component Biginelli-type condensations 
employing urea and a variety of aromatic aldehydes. The resulting 6-
chloromethyl-functionalized resin-bound dihydropyrimidones served as common 
chemical platforms for the generation of the desired heterobicyclic scaffolds using 
three different traceless cyclative cleavage strategies. The corresponding 
furo[3,4-d]pyrimidines were obtained by microwave flash heating in a rapid, 
thermally triggered, cyclative release. Treatment of the chloromethyl 
dihydropyrimidone intermediates with a variety of primary amines followed by 
high-temperature microwave heating furnished the anticipated pyrrolo[3,4-
d]pyrimidine scaffolds via nucleophilic cyclative cleavage. In a similar way, 
reaction with monosubstituted hydrazines resulted in the formation of pyrimido 
[4,5-d]pyridazines. All compounds were obtained in moderate to good overall 
yields and purities116.  
 
 
 
 
 
 
 
 
 
 
3.5 Chemistry and biological importance of thaizolo[3,2-a]pyrimidine and 
pyrimido[2,1-b][1,3]thiazines scaffolds 
Preparation of thiazolo [3,2-a]pyrimidine derivatives is very well reported in 
literature. Two approaches is generally employed for synthesis. Literature survey 
on synthetic methodology for thiazolo [3,2-a]pyrimidine derivatives can be 
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summarized in Chart 1 & 2 where various methods are illustrated for synthesis of 
this class of compounds.  
Figure 1: Thiazolo [3,2-a] pyrimidine 2 was prepared in 30% yield by the reaction 
of 2-aminothiazole 1 with ethyl cyanoacetate  in a sodium ethoxide/ethanol 
mixture or using polyphosphoric acid or acetic acid. However, 
oxothiazolopyrimidine 3 was obtained upon treatment with phosphorous 
pentoxide and methanesulfonic acid. The reaction of 1 with ethyl acetoactate at 
140-150°C resulted in the formation of compound that was then converted to the 
Z-isomer upon heating at 250°C and cyclized to give 4. 2-Aminothiazole 5 
cyclized with acetylacetone at 100°C, in the presence of methanesulfonic acid-
phosphorus pentoxide or formic acid-phosphorus pentoxide, followed by 
treatment with 70% perchloric acid, to give the thiazolopyrimidin-4-ium salt 5. The 
ester 6 was obtained from 2-aminothiazole 1 with an excess of methyl 
methanetricarboxylate in 61 % yield. Cyclocondensation of 1 with diethyl 
ethoxymethylene malonate in acetic acid followed by hydrolysis of the ester gave 
7. Similarly, 2-aminothiazole 1 reacted with benzylidine in ethanol to give 8. 
Stanovink et al reported the synthesis of a series of thiazolopyrimidine derivatives 
upon reacting 2-aminothiazole with a variety of different reagents. Thus, 
dimethylaminobut- 2-enoate (or pentenoate), reacted with 1 to give 
thiazolopyrimidines.72-85 
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Figure 2: The reaction of 2-aminothiazole 1 with 2-hydropolyfluoroalk-2-enoate in 
basic medium gave two isomers, 7-oxo 2 and its isomeric 5-0x0 3. The structure 
of both 2 and 3 was established through 1H NMR, 19F NMR and mass spectra86. 
2-Aminothiazole derivatives, (R' = H, C02Et; R2 = Ph, aryl, Me), reacted with the 
acetylenic derivative and ester derivative in ethanol and polyphosphoric acid, 
respectively, to give the isomeric oxothiazolopyrimidine derivatives 4 and 5, in 5-
32% and 8-97 % yield, respectively87. Condensation of 2-aminothiazole 1 in 
absolute ethanol with the sodium salt of ethyl oximinocyanoacetate gave after 
acidification (pH 6) with diluted hydrochloric acid, the nitroso derivative 6 in 92% 
yield88. Treatment of the 2-aminothiazaole derivatives 5 with the hydrazone 
derivatives gave the oxothiazolo [3,2-a] pyrimidine derivatives 7.892-Amino-2-
thiazoline reacted with 2-acylamino-3- dimethylamino -propenoates in acetic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Figure-2 
           
to yield 6-acylamino-5-oxo-2,3-dihydro-5-thiazolo[3,2-a]pyrimidines in 73 and 
12% yields, respectively90.  
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Moreover, 2-amino-2-thiazoline reacted with an aromatic aldehyde and diethyl 
malonate, to give a mixture of thiazolidino[3,2-a]pyrimidines. Furthermore, 
malononitrile reacted to give following product91-92. 
 
 
 
 
 
 
 
2-Amino-thiazoline reacted with potassium 2-ethoxycarbonyl-2-fluorovinyl 
alcoholate in a sodium methoxide/methanol mixture to give 6-fluoro-2,3-dihydro-
5-oxothiazolo[3,2-a]pyrimidine93.  
 
 
 
 
 
2-(Methylthio)-24hiazoline reacted with /3-alanine to give a 5-oxothiazolo [3,2-a]-
pyrimidine derivative  in 23% yield94. 
 
 
 
 
 
Pyrmidinethione derivatives were alkylated with monochloroacetic acid or 
chloroacetyl chloride and then cyclized to give thiazolopyrimidine derivatives.95-105 
thus; pyrimidinethione reacted in dimethylformamide95 or in an acetic 
anhydride/pyridine mixture37 to give thiazolo-pyrimidines. Alkylation in the 
presence of an aromatic aldehyde gave the ylidene. Similarly, pyrimidinethione 
derivatives reacted with monochloroacetic acid in acetic acid/acetic 
anhydride/sodium acetate mixture or with chloroacetyl chloride in dry dioxane to 
give the corresponding thiazolopyrimidines99-100.  
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Treatment of mercaptopyrimidine derivative with 2-chloroethanol in 
dimethylformamide gave the asymmetrical thioether which underwent cyclization 
on refluxing with a mixture of acetic anhydride-pyridine, to give the 
oxothiazolopyrimidine109.  
 
 
 
 
 
1,3-Dibromopropan-2-ol reacted with mercaptopyrimidine derivative to give 
product through the non isolated intermediates. The same reaction product was 
obtained by reacting with I-bromomethyloxirane.110 
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Several derivatives of 4,5-disubstituted imidazole, 2,4,5-trisubstituted pyrimidine, 
2-substituted purine, thiazolo[3,2-a]purine, [1,3]thiazino[3,2-a]purine, thiazolo[2,3-
i]purine, [1,3]thiazino-[2,3-i]purine, and 6-substituted pyrazolo[3,4-d]pyrimidine 
were synthesized and tested as inhibitors of the xanthine oxidase enzyme111. 
Dihydropyrimidines are now known for calcium  
 
 
 
 
 
 
Channel blockers property. According to the literature, analogous derivatives are 
anti-inflammatory. Bo´szing and co-workers112 reported the synthesis of the 
pyrimidothiazines and assay these compounds for the same profile. Acute anti-
inflammatory activity was tested by inhibition of the carrageen an-induced paw 
edema in rats. 
Adam et al113 filed US patent for phenyl substituted thiazolo pyrimidine 
derivatives synthesized from DHPM. These compounds are novel and are 
distinguished by valuable therapeutic properties. Specifically, it has been found 
that the compounds of general formula given below are metabotropic glutamate 
receptor antagonists. These compounds are capable of high affinity binding to 
group II mGlu α receptors.  
 
 
 
 
 
 
 
 
Compounds displayed by general formulae given below exhibit excellent 
adenosine α3 receptor antagonism where A is an optionally substituted benzene 
ring. B may be substituted and R1 is optionally substituted cyclic group114.  
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3.6 Biginelli Reaction and problems associated with conventional   
methods  
The major limitations of Biginelli reaction are lower yield and longer reaction time. 
When thiourea is used for synthesis, yield obtained is very low and reaction 
completion takes longer time. Similar disadvantages are observed when different 
1,3-diketone and aldehyde other than aromatic are used for the synthesis of 
designed molecules. Moreover, product separation and work up also cause 
problem and needed special techniques. Thus, three main disadvantages are 
lower yield, longer reaction time and work up in Biginelli reaction when different 
building blocks are used to synthesize library of compound.  
3.7 Microwave assisted reaction  
The use of microwave as energy source in organic synthesis for better yield and 
shorter reaction time has been extensively investigated117-122. Most of the early 
pioneering experiments in MAOS were performed in domestic, sometimes 
modified, kitchen microwave ovens; the current trend is to use dedicated 
instruments which have only become available in the last few years for chemical 
synthesis. The number of publications related to MAOS has therefore increased 
dramatically since the late 1990s to a point where it might be assumed that, in a 
few years, most chemists will probably use microwave energy to heat chemical 
reactions on a laboratory scale. Not only is direct microwave heating able to 
reduce chemical reaction times from hours to minutes, but it is also known to 
reduce side reactions, increase yields, and improve reproducibility. Therefore, 
many academic and industrial research groups are already using MAOS as a 
forefront technology for rapid optimization of reactions, for the efficient synthesis 
of new chemical entities, and for discovering and probing new chemical reactivity. 
A large numbers of review articles provide extensive coverage of the subject123-
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128.Microwave-enhanced chemistry is based on the efficient heating of materials 
by “microwave dielectric heating” effects. This phenomenon is dependent on the 
ability of a specific material (solvent or reagent) to absorb microwave energy and 
convert it into heat. The electric component of an electromagnetic field causes 
heating by two main mechanisms: dipolar polarization and ionic conduction. 
Irradiation of the sample at microwave frequencies results in the dipoles or ions 
aligning in the applied electric field. As the applied field oscillates, the dipole or 
ion field attempts to realign itself with the alternating electric field and, in the 
process, energy is lost in the form of heat through molecular friction and dielectric 
loss. The amount of heat generated by this process is directly related to the 
ability of the matrix to align itself with the frequency of the applied field. If the 
dipole does not have enough time to realign, or reorients too quickly with the 
applied field, no heating occurs. The allocated frequency of 2.45 GHz used in all 
commercial systems lies between these two extremes and gives the molecular 
dipole time to align in the field, but not to follow the alternating field precisely129-
130. 
The heating characteristics of a particular material (for example, a solvent) under 
microwave irradiation conditions are dependent on its dielectric properties. The 
ability of a specific substance to convert electromagnetic energy into heat at a 
given frequency and temperature is determined by the so-called loss factor tanδ. 
This loss factor is expressed as the quotient tanδ=e’’/e’, where e’’ is the dielectric 
loss, which is indicative of the efficiency with which electromagnetic radiation is 
converted into heat, and e’ is the dielectric constant describing the ability of 
molecules to be polarized by the electric field. A reaction medium with a high tanδ 
value is required for efficient absorption and, consequently, for rapid heating131. 
 
Solvent tanδ Solvent tanδ 
Toluene 0.040 Dichlorobenzene 0.280 
Acetone 0.054 Nitrobenzene 0.589 
Chloroform 0.091 Formic acid 0.722 
Water 0.123 DMSO 0.825 
Dichloroethane 0.127 Ethanol 0.941 
DMf 0.161 Ethylene glycol 1.350 
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3.7.1 Name reactions  
Following scheme shows an example of a standard Heck reaction involving aryl 
bromides and acrylic acid to furnish the corresponding cinnamic acids. 
Optimization of the reaction conditions under small-scale (2 mmol) single-mode 
microwave conditions led to a protocol that employed acetonitrile as the solvent, 
1 mol% palladium acetae/p-tolyl phosphine as the catalyst system, and 
triethylamine as the base. The reaction time was 15 minutes at a reaction 
temperature of 180ºC. 
 
 
 
 
 
The Suzuki reaction (the palladium-catalyzed cross-coupling of aryl halides with 
boronic acids) is arguably one of the most versatile and at the same time also 
one of the most often used cross-coupling reactions in modern organic synthesis. 
Carrying out high-speed Suzuki reactions under controlled microwave conditions 
can be considered almost a routine synthetic procedure today, given the 
enormous literature precedent for this transformation. Recent examples include 
the use of the Suzuki protocol for the high-speed modification of various 
heterocyclic scaffolds of pharmacological interest132-140. A significant advance in 
Suzuki chemistry has been the observation that Suzuki couplings can be readily 
carried out using water as the solvent in conjunction with microwave heating141-
144.  
 
 
 
 
General protocols for microwave-assisted Sonogashira reactions under controlled 
conditions were first reported in 2001 by ErdMlyi and Gogoll151-152. Many more 
examples can be cited for different name reaction.  
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3.7.2 Some additional chemistry on Biginelli reaction  
Kappe et al32 recently described a high yielding and rapid microwave-assisted 
protocol that allows the synthesis of gram quantities of DHPMs utilizing controlled 
single-mode microwave irradiation. As the first model reaction for scale-up 
experiments, they selected the standard Biginelli cyclocondensation, where in a 
one-pot process equimolar amounts of benzaldehyde, ethyl acetoacetate, and 
urea react under Lewis acid (FeCl3) catalysis to the corresponding 
dihydropyrimidine. Utilizing single-mode microwave irradiation, the reaction can 
be carried out on a 4.0 mmol scale in AcOH/EtOH 3:1 at 120 oC within 10 min, 
compared to 3-4 h using conventional thermal heating, providing DHPM in 88% 
isolated yield and high purity (>98%).  
 
 
 
 
 
 
 
 
Dihydropyrimidines were synthesised in high yields by one-pot cyclocondensation 
reaction of aldehydes, acetoacetates and urea using various acid catalysts like 
Amberlyst-15, Nafion-H, KSF clay and dry acetic acid under microwave 
irradiation.33 
The antimony (III) chloride impregnated on alumina efficiently catalyses a one-
pot, three-component condensation reaction among an aldehyde, a β-ketoester, 
I
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X
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and urea or thiourea to afford the corresponding dihydropyrimidinones in good to 
excellent yields. The reactions are probed in microwave (MW), ultrasonic, and 
thermal conditions and the best results are found using MW under solvent-free 
conditions34. Cupric chloride dihydrate catalyzes the three-component Biginelli 
condensation between an aldehyde, a β-ketoester and urea or thiourea under 
microwave irradiation in the absence of solvent to yield various substituted 3,4-
dihydropyrimidin-2(1H)-ones. The reaction is also effective when performed at 
room temperature in acetonitrile or at 100 °C in a solvent free approach, without 
any side reactions as observed by Biginelli and others.35  
The publications by Gupta36 and Dandia37 describe 26 examples of microwave-
enhanced solution-phase Biginelli reactions employing ethyl acetoacetate, (thio) 
ureas, and a wide variety of aromatic aldehydes as building blocks. Upon 
irradiation of the individual reaction mixtures (ethanol, catalytic HCl) in an open 
glass beaker inside the cavity of a domestic microwave oven the reaction times 
were reduced from 2–24 hours of conventional heating (80 ºC, reflux) to 3–11 
minutes under microwave activation (ca. 200–300 W). At the same time, the 
yields of DHPM obtained by the authors were markedly improved compared to 
those reported earlier using conventional conditions.  
Kappe38 reinvestigated above reactions using a purpose-built commercial 
microwave reactor with on-line temperature, pressure, and microwave power 
control. Transformations carried out under microwave heating at atmospheric 
pressure in ethanol solution show no rate or yield increase when the temperature 
is identical to conventional thermal heating. In the case of superheating by 
microwave irradiation at atmospheric pressure the observed yield and rate 
increase phenomenon are rationalized as a consequence of a thermal (kinetic) 
effect. Under sealed vessel conditions (20 bar, 180 ºC) the yield of products is 
decreased and formation of various byproducts observed. The only significant 
rate and yield enhancements are found when the reaction is performed under 
“open system” conditions where the solvent is allowed to rapidly evaporate during 
microwave irradiation. However, the observed rate and yield enhancements in 
these experiments are a consequence of the solvent-free conditions rather than 
caused specifically by microwave irradiation. This was confirmed by control 
experiments of the solvent less Biginelli reaction under microwave and thermal 
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heating. Various heterocyclic systems can be synthesized in short time with high 
yield. Heterocyclic systems like dihydroquinolone, triazine, dihydropyridines and 
other bicyclic systems are reported in literature synthesized using microwave145-
149. Few examples are shown below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.8 Rearrangements  
Ley and co-workers150 have described the microwave assisted Claisen 
rearrangement of allyl ether in their synthesis of the natural product carpanone. A 
97% yield of the rearranged product could be obtained by three successive 15-
minute irradiations at 220 ºC. This is an example of microwave assisted reaction 
clubbed with ionic liquid.  
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3.8.1  Cycloaddition reaction 
Reaction scheme display microwave assisted Diels Alder reaction in neat 
condition without using any solvent. First process gave 97% yield in 20 min. In 
second process, diastereomers were obtained.153-154 
 
 
 
 
 
 
 
 
 
 
 
 
3.8.2 Oxidation  
The osmium-catalyzed dihydroxylation reaction, the addition of osmium tetroxide 
to olefins to produce a vicinal diol, is one of the most selective and reliable 
organic transformations. Recent work by Sharpless, Fokin, and coworkers155 has 
uncovered that electron-deficient olefins can be converted into the corresponding 
diols much more efficiently when the reaction medium is kept acidic. 
 
 
 
 
 
 
3.8.3 Multicomponent Reaction (MCR)  
The Mannich reaction has been known since the early 1900s and has since then 
been one of the most important transformations to produce β-amino ketones. 
Although the reaction is powerful, it suffers from some disadvantages, such as 
the need for drastic reaction conditions, long reaction times, and sometimes low 
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yields of products. Luthman and coworkers156 have reported microwave-assisted 
Mannich reactions as MCR that employed paraformaldehyde as a source of 
formaldehyde, a secondary amine in the form of its hydrochloride salt, and a 
substituted acetophenone.  
 
 
 
 
 
 
 
 
 
 
3.8.4 Nucleophilic Aromatic Substitution 
A number of publications report efficient nucleophilic aromatic substitutions driven 
by microwave heating involving either halogen substituted aromatic or 
heteroaromatic systems. Scheme given below summarizes some heteroaromatic 
systems and nucleophiles along with the reaction conditions that have been 
developed by Cherng for microwave-assisted nucleophilic substitution reactions. 
In general, the microwave-driven processes provide significantly higher yields of 
the desired products in much shorter reaction times157-161.  
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3.8.5 Solid Phase Organic Synthesis  
Solid-phase organic synthesis (SPOS) exhibits several advantages compared 
with classical protocols in solution. Reactions can be accelerated and driven to 
completion by using a large excess of reagents, as these can easily be removed 
by filtration and subsequent washing of the solid support. In addition, SPOS can 
easily be automated by using appropriate robotics and applied to “split-and-mix” 
strategies, useful for the synthesis of large combinatorial libraries162-163 
A study published in 2001 demonstrated that high temperature microwave 
heating (200 8C) can be effectively employed to attach aromatic carboxylic acids 
to chloromethylated polystyrene resins (Merrifield and Wang) by the cesium 
carbonate method. Significant rate accelerations and higher loadings were 
observed when the microwave-assisted protocol was compared to the 
conventional thermal method. Reaction times were reduced from 12–48 hours 
with conventional heating at 80 ºC to 3–15 minutes with microwave heating at 
200 ºC in NMP in open glass vessels164-165. 
 
 
 
 
 
Kappe et al166 have reported microwave assisted synthesis of bicyclic systems 
derived from Biginelli DHPM derivatives.  
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In recent years, various methods have been examined for the synthesis of DHPM 
on solid phase. Li and Lam29 describe a convenient traceless solid-phase 
approach to synthesize3,4-dihydropyrimidine-2-ones. Key steps in the synthesis 
are (i) sulfinate acidification, (ii) condensation of urea or thiourea with aldehydes 
and sulfinic acid, and (iii) traceless product release by a one-pot cyclization-
dehydration process. Since a variety of reagents can be used in steps (ii) and (iii), 
the overall strategy appears to be applicable to library generation. 
 
 
 
 
 
 
 
 
 
 
 
Very recently, Gross et al30 developed a protocol based on immobilized α-
ketoamides to increase the diversity of DHPM. The resulting synthetic protocol 
proved to be suitable for the preparation of a small library using different building 
blocks. They found that the expected DHPM derivatives were formed in high 
purity and yield if aromatic aldehyde- and α-ketoamide building blocks were used. 
The usage of an aliphatic aldehyde leads to an isomeric DHPM mixture. Purities 
and yields were not affected if thiourea was used instead of urea. 
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Lusch and Tallarico31 reported a direct, Lewis acid-catalyzed Biginelli synthesis of 
3,4-dihydropyrimidinones on high-capacity polystyrene macrobeads with a 
polymer O-silyl-attached N-(3-hydroxypropyl)urea.  
 
  
 
 
 
 
 
 
 
 
 
 
Resin-urea was first reacted separately with either 4-bromo- or 4-
chlorobenzaldehyde or lithium trifluoromethanesulfonate in acetonitrile at 80 °C. 
After washing, the beads were pooled and reacted with ethyl acetoacetate and 
lithium trifluoromethanesulfonate in acetonitrile at 80 °C. Formation of only one 
kind of Biginelli product per bead demonstrated the feasibility of a solid-phase 
non-Atwal two-step split-and-pool synthesis of 3,4-dihydropyrimidinones.  
 
3.9 Synthetic Aspects. 
Scheme- 4 
Thiazolo pyrimidine and pyrimido thiazine are very important bicyclic system in 
medicinal chemistry. Various synthetic routes have been reported in literature to 
synthesize these bicyclic systems. Utility of dihydropyrimidine ring to synthesize 
such bicyclic system can be used to obtain derivatives with phenyl carbamoyl as 
side chain on pyrimidine ring of bicyclic system. 
Dihydropyrimidine ring, substituted with phenyl carbamoyl side chain at C5 
position, was synthesized by reacting acetoacetanilide, thiourea and aldehyde. 
This dihydropyrimidine ring was reacted with dihalo alkane to get fused bicyclic 
systems. In synthesis of thiazolo pyrimidine system, 1,2-dibromo ethane was 
reacted with 2-thiodihydropyrimidine derivatives. Pyrimido-thiazine systems can 
be synthesized using 1,3-dibromo propane in place of 1,2-dibromo ethane with 
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shorter reaction time and better yields as compared with synthesis of thiazolo 
pyrimidine systems.  
Scheme -5 
N-substitution in dihydropyrimidine ring is reported to enhance activity profile. 
Similarly, substitutions at C5 position also plays key role in activity profile. N-
phenyl substituted dihydropyridines were also synthesized by our group and it 
also showed interesting biological profile. Results obtained in dihydropyridine 
modification, inspired to introduce phenyl carbamoyl moiety at C-5 position of 
dihydropyrimidine skeleton. This modification to dihydropyrimidine skeleton 
exhibited moderate biological profile. Moderate anti tubercular activity was 
observed for these derivatives against Mycobacterium H37Rv. 
Our laboratory is involved in the synthesis of modified 1,4-dihydropyridine and 
dihydropyrimidine skeleton derivatives for last few years. Introduction of phenyl 
carbamoyl moiety at C-3 and/or C-5 position in dihydropyridine skeleton has 
showed diverse activity profile. Very promising results obtained with these 
modifications to dihydropyridine skeleton. For the synthesis of N-phenyl 
dihydropyrimidines we used different N-phenyl ureas with methyl substitution (-
Phenyl, -3-methylphenyl, 2,4-dimethylphenyl) were synthesized.  
Acetoacetanilides were synthesized with different halogen substitutions (4-chloro, 
4-flouro, 3-chloro-4-flouro). Scheme 3 is synthesis of N-phenyl substituted DHPM 
derivatives by reacting N-(phenyl/3-methylphenyl/ 2,4-dimethyl) urea, (4-chloro, 
4-flouro, 3-chloro-4-flouro) acetoacetanilide and aromatic aldehyde. The reaction 
time was observed 8-12 hours depending on the substitution on substitutions on 
4-phenyl and N-phenyl ring. The synthesized compounds are characterized by 
IR, NMR and Mass spectral analysis and are under screening against 
Mycobacterium H37Rv for anti tubercular activity.  
 
Scheme 6 
Work done earlier in our lab on 1,4-dihydropyridine and interesting results 
obtained for this structural class inspire to modify aza analogs of 1,4-
dihydropyridine i.e. dihydropyrimidine. Earlier library of compounds was 
generated of dihydropyrimidine derivatives with phenyl carbamoyl moiety at C5 
position. Moderate pharmacological profile obtained for this library. In 
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continuation of this work, it was planned to develop various modified compounds 
associated with aliphatic chain at C4 position of dihydropyrimidines. Phenyl ring 
at C4 position of classical dihydropyrimidine is replaced with aliphatic chain. Work 
deals with an aliphatic aldehyde (butyraldehyde) as a substrate to obtain a 
dihydropyrimidine skeleton without phenyl or heteroaryl ring at C4. The aim of this 
work was to develop small library of novel DHPM compounds which give diversity 
from earlier ones. When the reactions carried out by conventional methods, long 
reaction time (10-12 hours) was observed.  To overcome these problems, 
microwave irradiation technique was utilized reduce reaction time (10-15 minutes. 
Different solvent were used (methanol, ethanol, THF, acetonitrile, DMF) but 
methanol was found to be most suitable.  
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INTRODUCTION  
 
 
A general introduction of Chemistry of Pyrimidines and their biological activities 
and related structure modifications are already mentioned as a separate Chapter 
3 earlier.  
 
The current chapter deals with the synthesis of N-(substituted phenyl)-7-methyl- 2, 
3- dihydro - 5H -[1,3] thiazolo [3,2-a] pyrimidines and 3, 4- dihydro -2H, 6H-
pyrimido[2,1-b][1,3]thiazine-7-carboxamides. 
 
The title compounds are prepared by (i) Preparation of respective 
acetoacetanelides [AA] (ii) Multicomponent reaction of AA with aromatic aldehyde 
and thiourea leading to thiopyrimidines (iii) Cyclization of thipyrimidines into final 
fused pyrimidine derivatives. 
 
The chemistry, reaction mechanism, experimental protocols, spectral and 
physical data and interpretation are given in subsequent pages. 
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4.1 REACTION SCHEMES  
 
4.1.1   Scheme-1 
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4.1.2 Scheme-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3 Scheme-3 
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4.1.4 Reaction Mechanism  
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4.1.5 Reaction Mechanism  
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4.2 Experimental Observations 
The mixture of aldehyde, thiourea, and acetoacetanilide refluxed at 65-70 oC for 5 
hours to give crystalline product directly. 
During reaction, the quantity of Con. HCl is very significant. The permanent 
monitoring of reaction is necessary, if not, an arylidene product is isolated and 
cyclocondensation leftovers incomplete. The colours of crystalline products are 
light yellow to orange. 
 
Thin layer chromatography 
It was approved on silica Gel-G as a stationary phase. The slurry was primed by 
adding up 20 ml distilled water to 10 gm Silica Gel in 250 ml beaker with constant 
stirring and the slurry was poured over glass plate and unvarying thin layer was 
prepared. The plate was held in reserve dried at 105 oC in an oven and activated 
before used.  
The reactions of all newly synthesized compounds and intermediate were 
supervised and the purity was checked by TLC. 
 
Mobile phase: 1. Ethyl acetate  : Hexane 
                        2. Chloroform    : Methanol 
 
Melting point 
All the melting points were taken in open end capillary by  means of paraffin bath 
with standard Zeal thermometer and they were uncorrected. 
 
4.3 Experimental  
 
4.3.1 4-Chloro/flouro acetoacetanilide  
4-chloro/flouro aniline (0.1M) and ethyl acetoacetate (0.1 M) was refluxed at 110° 
C in 40 ml of toluene and catalytic amount of KOH/NaOH. The completion of 
reaction was monitored with TLC. After completion of reaction, toluene was 
distilled out. The residue was cooled at room temperature and was treated with 
ether. The solid was filtrated and dried. (Yield: 4-chloroacetoacetanilide – 62%, 4-
flouroacetoacetanilide – 56%. M.P.; 4-chloroacetoacetanilide - 114° C 
(Reported*-115 0C.), 4-fluoroacetoacetanilide - 129° C (Reported* – 128 oC).  
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4.3.2 N - (Substituted phenyl)- 1, 2, 3, 4 - tetrahydro-6-methyl-4-(substituted 
phenyl)-2-thioxopyrimidine-5-carboxamides (Scheme-1) 
[General method] 
Acetoacetanilide (0.01M), aldehyde (0.01M) and thiourea (0.015M) were 
dissolved in minimum quantity of methanol. It was heated for 5-10 minutes to get 
the clear solution. Few drops of Con. HCl were added to the reaction mixture as a 
catalyst. The reaction mixture was then refluxed in water bath for 6-10 hrs. The 
progress of reaction was monitored by TLC. The reaction mixture was allowed to 
cool at room temperature. The solid separated was filtered, washed with hot 
methanol and dried. (2a-p) (Yield: 45-60%).  
 
Physical data of newly synthesized compounds are given in Table 4.1.1. 
 
4.3.3 N - (4-Chloro phenyl) – 3, 5, 8, 8a - tetrahydro-7-methyl-5-phenyl-2H-
thiazolo [3, 2-a] pyrimidine-6-carboxamide (Scheme-2 & 3) 
[General method]  
N-(substituted phenyl)-1,2,3,4-tetrahydro-6-methyl-4-(substituted phenyl)-2-
thioxopyrimidine-5-carboxamide (0.01M) and dibromo ethane (or dibromo 
propane) were dissolved in DMF and heated at 140° C for 2-2.5 hrs. The reaction 
mixture was poured on crushed ice and was extracted with chloroform. The 
chloroform was removed under vacuum. (Yield: 55-65%).  
 
Physical data of newly synthesized compounds are given in Table 4.1.2 and 4.1.3. 
 
 
* Naliapara, Y. T.; Ph.D. Thesis., Saurashtra University, Rajkot (1998)  
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4.4 PHYSICAL DATA 
 
4.4.1 Physical data of N-(substituted phenyl)-6-methyl-4-(substituted 
phenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine -5-carboxamides (AKS 
551-567) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. Code  R1 R2 MW Yield 
in % 
Rf   
value 
1. AKS- 551 4-Cl 4-OH 373.85 63 0.38 
2. AKS- 552 4-Cl 4-N(CH3)2 400.92 51 0.51 
3. AKS- 553 4-Cl 4-CL 392.303 68 0.45 
4. AKS- 554 4-Cl 2-OCH3 387.88 49 0.53 
5. AKS- 554 4-Cl 2,3,5,6-  
dibenzo 
457.97 56 035 
6. AKS- 555 4-Cl 2,3 benzo 407.91 53 0.46 
7. AKS- 556 4-Cl 3-NO2 402.89 58 0.54 
8. AKS- 557 4-Cl 4-NO2 402.89 61 0..36 
9. AKS- 558 4-F 3-NO2 386.40 55 *0.52 
10. AKS- 559 4-F 2-OH 357.40 59 *0.40 
11. AKS- 560 4-F 4-Cl 375.88 61 *0.38 
12. AKS- 561 4-F 2-OCH3 371.47 48 *0.45 
NH NH
N
H
CH3 S
O
R1
R2
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13. AKS- 562 4-F 2,3,5,6-   
dibenzo 
441.51 62 *0.39 
14. AKS- 563 4-F H 341.40 52 *0.41 
15. AKS- 564 2,3-benzo 4-Cl 407.95 44 *0.35 
16. AKS-565 2,3-benzo 4-OH 389.51 48 *0.54 
17. AKS-566 2,3-benzo 4-NO2     418.46 62 *0.51 
18. AKS-567 2,3-benzo 2-NO2  418.46 56 *0..37 
 
 
TLC solvent system:     Ethyl acetate : Hexane  3.5 ml : 6.5 ml 
                *CH2Cl2               : MeOH            9.5 ml : 0.5 ml 
 
 
Visualization: UV light (long) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
133
               4.4.2 Physical data of N-(substituted phenyl)-7-methyl-5-(substituted 
phenyl)-2,3-dihydro-5H-1,3]thiazolo[3,2-a]pyrimidine-6-carboxamides 
(AKS 570-587) 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. Code R1 R2 MW MP° C Yield 
in % 
Rf value 
1 AKS-570 4-Cl 2-OH 399.89 140-142 57 0.41 
2 AKS-571 4-Cl 4-N(CH3)2 426.95 210-212 69 0.49 
3 AKS-572 4-Cl 3,4-Di OH 415.89 174-176 77 0.36 
4 AKS-573 4-Cl 4-Cl 418.33 210-212 65 0.42 
5 AKS-574 4-Cl 2-OCH3 413.92 160-162 66 0.62 
6 AKS-575 4-Cl 2-Cl 418.34 177-178 60 0.56 
7 AKS-576 4-Cl 3-NO2 428.89 214-17 59 0.58 
8 AKS-577 4-F H 367.43 220-224 65 0.45 
9 AKS-578 4-F 2-OCH3 397.46 246-248 61 0.54 
10 AKS-579 4-F 3-NO2 412.43 198-200 71 *0.46 
11 AKS-580 4-F 3-Cl 401.88 146-148 56 *0.39 
12 AKS-581 4-F 4-Cl 401.88 174-176 75 0.41 
13 AKS-582 4-F 2-NO2 412.43 222-224 62 0.51 
NH N
N
O
CH3 S
R1
R2
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14 AKS-583 4-F 3-OCH3 397.46 165-167 74 *0.35 
15 AKS-584 4-F 4-OCH3 397.46 212-214 53 *0.48 
16 AKS-585 4-F 2-Cl 401.88 189-191 62 *0.53 
17 AKS-586 2,3-Benzo 4-OCH3 431.54 234-236 56 *0.51 
18 AKS-587 2,3 -Benzo 2-Cl 433.95 184-186 53 *0.46 
 
       TLC solvent system:          EA: Hexane          4 ml : 6 ml       
                                                 * CH2Cl2: MeOH    9 ml : 1 ml    
 
 
       Visualization: UV light (long) 
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4.4.3 Physical data of compounds N-(4-chlorophenyl)-6-(substituted 
phenyl)-8-methyl-3,4-dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazine-7-
carboxamide (AKS-588-593) 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. Code R MW MP° C Yield 
in % 
Rf value 
19 AKS-588 4-Cl 432.36 189-193 68 0.42 
20 AKS-589 2-OCH3 427.94 222-224 74 0.51 
21 AKS-590 2- OH 413.92 174-176 56 0.36 
22 AKS-591 4-NO2 442.91 256-257 63 0.48 
23 AKS-592 3-NO2 442.91 185-187 71 0.41 
24 AKS-593 2-Cl 432.36 212-214 47 0.35 
 
       TLC solvent system:     CH2Cl2 : MeOH        9 ml : 1 ml  
 
        Visualization: UV light (long) 
NH N
NCH3 S
Cl
O
R
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4.5 SPECTRAL ANALYSIS  
 
Spectral data of only key intermediate and final compounds are included. 
Elemental analysis of the compounds was in agreements (within 0.4% of the 
theoretical value) with the structures assigned. The constitution of newly 
synthesized compounds was supported by IR, NMR, and MASS spectral study. 
The details are as under. 
 
4.5.1 MASS SPECTRAL ANALYSIS 
 
Systematic fragmentation pattern was observed in mass spectral investigation. 
Peaks for specific fragments were recognized in each mass spectrum. Molecular 
ion peaks observed were in harmony with molecular weight of compounds.  
Molecular ion peak (M+) of the compounds were in total conformity with its 
molecular weight. In presence of halogen respective M+1 peak was observed. M/e 
value were obtained at 442, 431, 431, 401, and 433 in mass spectrum of 
compounds AKS-592, AKS-588, AKS- 593, AKS-585 ASK-587 correspondingly.  
A base peak in each spectrum was obtained as a consequence of specific 
fragmentation in each molecule. Fragment obtained caused by cleavage of bond 
adjacent to carbonyl double bond in the phenyl carbamoyl side chain at C5 
location gave base peak in each spectrum. Base peak obtained at 316, 305, 305, 
255 and 291 m/e values in mass spectrum of compound AKS-592, AKS-588, 
AKS-593, AKS-585 and AKS-587 respectively were due to precise fragmentation 
pattern observed in this series. 
The second characteristic peak observed in each spectrum as a result of cleave 
adjacent bond to carbonyl double bond at the additional elevation. Peaks were 
pragmatic at 288, 277, 277, 264 and 264 m/e values in relevant spectrum for 
these fragments. Mass spectra of the synthesized compounds are given on 
Pages 153-155. 
 
4.5.2 IR SPECTRAL ANALYSIS  
IR spectral study of newly synthesized compounds reveals following details. 
Amide Carbonyl was observed at 1680-1645 cm-1.The stretching of secondary 
amine (>NH) appeared in the region of ~3119-3300cm-1, its bending and C-N 
stretching appears at 1345 cm-1 to 1370 cm-1  respectively. The aromatic moiety 
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show distinctive absorptions in several region of the spectrum. Absorption owing 
to the C-H stretching vibration of aromatic compounds occurs near 3030 cm-1. 
There are four absorption bands in the (1667-1429 cm-1) region that are 
particularly diagnostic of aromatic structure. These happens near ~1600, 1580, 
1500, 1440 cm-1 and are caused by C=C skeletal in plan vibrations. The other 
frequencies were due to aromatic moieties o.o.p. appears around at ~1085 cm-1. 
The C-H stretching of methyl group observed at 2850 cm-1(sym.) and ~2900 
(asym.) and its bending observed at ~1384 cm-1. The numbers of absorption 
bands of variable intensity appear in the 1000-670 cm-1 region that is caused by 
C-H bending vibrations. This absorption depends on the number of adjacent free 
hydrogen atoms aromatic nucleus contains. An aromatic compound containing 
five closest hydrogen atoms absorbs in both the 750-700 cm-1 regions. If the 
compound contains four hydrogen atoms, its absorbs robustly only near 750 cm-
1. Superior degrees of substitution on the aromatic focus are usually weak and 
not easily assigned.  Representative IR Spectra are given Pages 145-146. The IR 
data of all synthesized compounds are specified for individual compounds 
separately.  
 
4.5.3 1H NMR SPECTRAL ANALYSIS 
 
Following representative signals were observed in all the NMR spectra of this 
series. 
Looking to NMR spectra of the title compounds, methyl (CH3) protons were 
observed as a singlet at 2.2 -2.8 δ ppm. In most of derivatives –NH proton were 
observed 7.0 -9.2 δ ppm. The aromatic protons are pragmatic between around 
6.60- 8.30 δ ppm.  For splitting patterns of meta phenyl functionality, two triplets 
are observed in the aromatic region due to ortho/Meta dicoupling of phenyl 
protons. For ortho substituted phenyl ring, three doublets are observed due to di-
ortho/meta coupling of phenyl protons. In NMR spectrum, we observed four to six 
multiplet splitting pattern in aliphatic region as a result of the presence of 1,3 -
thiazolidine and 1,3- thiazine nucleus, where all of the protons are chemically 
equivalent but magnetically nonequivalent, therefore all of these protons show 
multiplet splitting pattern instead of triplet. In case of, 1, 3- thiazine nucleus, at C5 
position, two protons were shown in highly defensive region, thereby both protons 
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gave multiplet signal at similar region. 1H NMR spectra of the representative 
compounds are given on Pages 147-152. 
 
4.5.3 ELEMENTAL ANALYSIS 
 
Elemental analysis of the all the synthesized compounds was carried out on 
Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
(within the range of theoretical value) with the structures assigned. 
 
Mass fragmentation of N-(4-chlorophenyl)-8-methyl-6-(3-nitrophenyl)-3,4-
dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazine-7-carboxamide(AKS-592) 
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SPECTRAL DATA 
N - (4-Chloro phenyl) – 5 - (2-hydroxy phenyl) – 7- methyl – 2 , 3 – dihydro - 
5H - [1,3] thiazolo [3,2-a] pyrimidine – 6 - carboxamide (AKS-570). 
IR(KBr) cm-1   : 3243 (-NH, str), 3019 (-CH=CH), 2928 (Ar-CH,asym), 2858 (Ar-
CH,sym),1679 (-C=O),1526 (-C-C skeletal vibration),1282 (C-S, str),1190(C-H 
IPD),1089(C-O-C),758(C-H, OPD). 
C, H, N (In %): Found: 60.07 (C), 4.54 (H), 10.51 (N), Cacld: 60.10 (C), 4.52 (H), 
10.54 (N) 
N - (4-Chlorophenyl) – 5 - (4,N,N-dimethyl) – 7 – methyl – 2 , 3 – dihydro - 5H 
-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide (AKS-571). 
IR(KBr) cm-1   : 3189 (-NH, str), 3040 (-CH=CH), 2949 (Ar-CH,asym), 2869 Ar-
CH,sym),1646 (-C=O),1563 (-C-C skeletal vibration),1245 (C-S, str),1176 (C-H 
IPD),1070 (C-O-C),768 (C-H, OPD) 
C, H, N (In %): Found: 61.89 (C), 5.43 (H), 13.12 (N), Cacld: 61.85 (C), 5.41 (H), 
13.14 (N) 
N - (4-Chloro phenyl) – 5 - (3,4-dihydroxy phenyl) – 7 – methyl – 2, 3 - 
dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide (AKS-572). 
IR(KBr)cm-1: 3562 (-OH),3213 (-NH, str), 3023 (-CH=CH), 2910 (Ar-
CH,asym),2846 (Ar-CH,sym),1668 (-C=O),1523 (-C-C skeletal vibration),1274 (C-
S, str),1174 (C-H IPD),1083 (C-O-C),768 (C-H, OPD). 
C, H, N (In %): Found: 57.76 (C), 4.36 (H), 10.10 (N), Cacld: 57.77 (C), 4.34 (H), 
10.14 (N) 
N , 5 – bis (4-Chloro phenyl) – 7 – methyl – 2 , 3 – dihydro - 5H -[1,3] thiazolo 
[3,2-a ] pyrimidine -6 - carboxamide (AKS-573). 
IR(KBR)cm-1: 3273 (-NH, str), 3051 (-CH=CH), 2924 (Ar-CH,asym), 2868,2769 
(Ar-CH,sym),1662 (-C=O),1442,1456 (-C-C skeletal vibration),1240,1269 (C-S, 
str),1190 (C-H IPD),1016,1107 (C-O-C),707 (C-H, OPD). 
C, H, N (In %): Found: 57.42 (C), 4.10 (H), 10.04 (N), Cacld: 57.43 (C), 4.12 (H), 
10.09 (N) 
N - (4-Chloro phenyl) – 5 - (2-methoxy phenyl) – 7 – methyl – 2 ,3 – dihydro -
5H - [1,3]thiazolo[ 3 , 2 – a ]pyrimidine – 6 - c arboxamide (AKS-574). 
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IR(KBr)cm-1:3192 (-NH,str),3142 (-CH=CH),2937 (Ar-CH,asym), 2881,2835 (Ar-
CH,sym),1681 (-C=O),1460,1417 (-C-Cskeletal vibration),1240,1285 (C-S, 
str),1188 (C-H IPD),1049,1026 (C-O-C),794 (C-H, OPD). 
C, H, N (In %): Found: 60.94 (C), 4.87 (H), 10.15 (N), Cacld: 60.98 (C), 4.84 (H), 
10.20 (N) 
5 - (2-Chloro phenyl) – N - (4-chloro phenyl) – 7 – methyl - 2,3 – dihydro - 5H 
- [1,3] thiazolo [3,2-a] pyrimidine – 6 – carboxamide (AKS-575). 
IR(KBr) cm-1   : 3221 (-NH, str), 3036 (-CH=CH), 2925 (Ar-CH,asym), 2834 (Ar-
CH,sym),1674 (-C=O),1552 (-C-C skeletal vibration),1289 (C-S, str),1158 (C-H 
IPD),1065 (C-O-C),759 (C-H, OPD). 
C, H, N (In %): Found: 57.42 (C), 4.10 (H), 10.04 (N), Cacld: 57.44 (C), 4.12 (H), 
10.07 (N) 
N - (4-Chloro phenyl) – 7 – methyl – 5 - (3-nitro phenyl)-2,3-dihydro-5H-
1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide (AKS-576). 
IR(KBr) cm-1   : 3174 (-NH, str), 3021 (-CH=CH), 2926 (Ar-CH,asym), 2845 (Ar-
CH,sym),1675 (-C=O),1532 (-C-C skeletal vibration),1270 (C-S, str),1175 (C-H 
IPD),1083 (C-O-C),781 (C-H, OPD). 
1HNMR (CDCl3, δ ppm): 2.17 (3H,s,1), 3.20 (2H,m,4,5), 3.39 (1H,m,3), 3.68 
(1H,2), 5.71 (1H,s,6), 7.19 (2H,m,13,14, J= 2.84, 2.92 Hz), 7.42 (2H,m,11,12, J= 
2.00, 2.96 Hz), 7.53 (1H,t,8, J= 7.92, 7.88 Hz), 7.72 (1H,d,9, J= 7.64 Hz), 8.15 
(1H,m,7, J= 0.64, 0.84 Hz), 8.24 (1H,t,10, J= 1.84 Hz), 8.64 (1H,s,15) 
C, H, N (In %): Found: 56.01 (C), 4.00 (H), 13.06 (N), Cacld: 56.05 (C), 4.04 (H), 
13.07 (N), 
N-(4-Fluoro phenyl) -7-methyl- 5-phenyl- 2,3-dihydro- 5H-[1,3] thiazolo [3,2-
a]pyrimidine -6-carboxamide (AKS-577). 
IR(KBr) cm-1   : 3186 (-NH, str), 3010 (-CH=CH), 2915 (Ar-CH,asym), 2834 (Ar-
CH,sym),1676 (-C=O),1526 (-C-C skeletal vibration),1276 (C-S, str),1191 (C-H 
IPD),1078 (C-O-C),774 (C-H, OPD). 
C, H, N (In %): Found: 65.38 (C), 4.94 (H), 11.44 (N), Cacld: 65.40 (C), 4.89 (H), 
11.47 (N) 
N - (4-Fluorophenyl) – 5 - (2-methoxyphenyl) – 7 - methyl - 2,3 – dihydro - 5H 
-[1,3] thiazolo [3,2-a] pyrimidine – 6 - carboxamide (AKS-578). 
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IR(KBr) cm-1   : 3224 (-NH, str), 3023 (-CH=CH), 2915 (Ar-CH,asym), 2842 (Ar-
CH,sym),1663 (-C=O),1522 (-C-C skeletal vibration),1276 (C-S, str),1184 (C-H 
IPD),1090 (C-O-C),765 (C-H, OPD). 
C, H, N (In %): Found: 63.46 (C), 5.07 (H), 10.57 (N), Cacld: 63.48 (C), 5.08 (H), 
10.60 (N) 
N - (4-Fluoro phenyl) – 7 - methyl – 5 - (3-nitro phenyl)- 2,3 – dihydro - 5H - 
[1,3] thiazolo [3,2-a] pyrimidine - 6- carboxamide (AKS-579). 
IR(KBr) cm-1   : 3210 (-NH, str), 3036 (-CH=CH), 2916 (Ar-CH,asym), 2845 (Ar-
CH,sym),1674 (-C=O),1556 (-C-C skeletal vibration),1280 (C-S, str),1145 (C-H 
IPD),1069 (C-O-C),774 (C-H, OPD). 
C, H, N (In %): Found: 58.24 (C), 4.15 (H), 13.58 (N), Cacld: 58.21 (C), 4.17 (H), 
13.60 (N) 
5 - (3-Chloro phenyl) – N - (4-fluorophenyl) – 7 – methyl - 2,3 – dihydro - 5H - 
[1,3] thiazolo [3,2-a] pyrimidine –6- carboxamide (AKS-580). 
IR(KBr) cm-1   : 3174 (-NH, str), 3021 (-CH=CH), 2926 (Ar-CH,asym), 2845 (Ar-
CH,sym),1675 (-C=O),1532 (-C-C skeletal vibration),1270 (C-S, str),1175 (C-H 
IPD),1083 (C-O-C),781 (C-H, OPD). 
C, H, N (In %): Found: 59.77 (C), 4.26 (H), 10.46 (N), Cacld: 59.74 (C), 4.224 
(H), 10.49 (N) 
5 - (4-Chloro phenyl) – N - (4-fluorophenyl) – 7 – methyl - 2,3 – dihydro - 5H - 
[1,3] thiazolo [3,2-a] pyrimidine -6- carboxamide (AKS-581). 
IR(KBr) cm-1   : 3216 (-NH, str), 3010 (-CH=CH), 2915 (Ar-CH,asym), 2852 (Ar-
CH,sym),1668 (-C=O),1540 (-C-C skeletal vibration),1263 (C-S, str),1163 (C-H 
IPD),1075 (C-O-C),768 (C-H, OPD). 
C, H, N (In %): Found: 59.77 (C), 4.26 (H), 10.46 (N), Cacld: 59.79 (C), 4.29 (H), 
10.47 (N) 
N - (4-Fluoro phenyl) -7- methyl -5- (3-nitro phenyl) -2,3- dihydro -5H- [1,3] 
thiazolo [3,2-a] pyrimidine -6- carboxamide (AKS-582). 
IR(KBr) cm-1   : 3213 (-NH, str), 3023 (-CH=CH), 2923 (Ar-CH,asym), 2842 (Ar-
CH,sym),1662 (-C=O),1522 (-C-C skeletal vibration),1276 (C-S, str),1184 (C-H 
IPD),1090 (C-O-C),752 (C-H, OPD). 
C, H, N (In %): Found:  58.24 (C), 4.15 (H), 13.58 (N), Cacld: 58.21 (C), 4.17 
(H), 13.61 (N) 
         
 
142
N - (4-Fluoro phenyl) -5- (3-methoxy phenyl) -7- methyl -2,3- dihydro -5H-[1,3] 
thiazolo [3,2-a] pyrimidine -6- carboxamide (AKS-583). 
IR(KBr) cm-1   : 3145 (-NH, str), 3021 (-CH=CH), 2918 (Ar-CH,asym), 2834 (Ar-
CH,sym),1665 (-C=O),1526 (-C-C skeletal vibration),1276 (C-S, str),1191 (C-H 
IPD),1078 (C-O-C),771 (C-H, OPD). 
C, H, N (In %): Found: 63.46 (C), 5.07 (H), 10.57 (N), Cacld: 63.44 (C), 5.10 (H), 
10.60 (N) 
N - (4-Fluoro phenyl) -5- (4-methoxyphenyl) -7- methyl -2,3- dihydro -5H- [1,3] 
thiazolo [3,2-a] pyrimidine -6- carboxamide (AKS-584). 
IR(KBr) cm-1   : 3223 (-NH, str), 3025 (-CH=CH), 2932 (Ar-CH,asym), 2842 (Ar-
CH,sym),1673 (-C=O),1540 (-C-C skeletal vibration),1263 (C-S, str),1163 (C-H 
IPD),1080 (C-O-C),753 (C-H, OPD). 
C, H, N (In %): Found: 63.46 (C), 5.07 (H), 10.57 (N), Cacld: 63.44 (C), 5.10 (H), 
10.60 (N) 
5 - (2-Chloro phenyl) -N- (4-fluoro phenyl) -7- methyl -2,3- dihydro -5H-[1,3] 
thiazolo [3,2-a] pyrimidine -6- carboxamide (AKS-585). 
IR(KBr) cm-1   : 3214 (-NH, str), 3010 (-CH=CH), 2915 (Ar-CH,asym), 2852 (Ar-
CH,sym),1662 (-C=O),1546 (-C-C skeletal vibration),1274 (C-S, str),1168 (C-H 
IPD),1075 (C-O-C),768 (C-H, OPD). 
1HNMR (CDCl3, δ ppm): 2.17 (s,3H,1), 3.11 (m,1H,4), 3.25 (m,1H,5), 3.35 
(m,1H,3) 3.74 (m,1H,2), 6.11 (s,1H,6), 6.92 (t-t,2H,7,9, J= 3.32, 2.04 Hz ), 7.25 (t-
t,1H,8, J= 1.64, 2.04 Hz), 7.33 (qt-qt ,2H,13,14, J= 1.04, 3.04 Hz),  7.46 
(m,2H,11,12, J= 2.04, 3.24, 4.92 Hz), 9.01 (s,1H,15), 7.60 (t,1H,10, J= 0.92, 7.00 
Hz). 
Mass (m/z value) : 401 (12), 386 (10), 366 (5), 295 (3), 291 (100), 255 (2), 228 
(22), 213 (4), 197 (4), 187 (8), 179 (12), 163 (4), 151 (10), 127 (23), 115 (4), 110 
(11), 86 (24), 83 (14), 67 (17), 42 (8), 41 (3). 
C, H, N (in %): Found: 59.77 (C), 4.26 (H), 10.46 (N), Cacld: 59.74 (C), 4.224 
(H), 10.49 (N) 
5 - (4-Methoxy phenyl) -7- methyl - N- 1-naphthyl -2,3- dihydro -5H-[1,3] 
thiazolo [3,2-a] pyrimidine -6- carboxamide (AKS-586). 
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IR(KBr) cm-1   : 3186 (-NH, str), 3025 (-CH=CH), 2916 (Ar-CH,asym), 2834 (Ar-
CH,sym),1670 (-C=O),1526 (-C-C skeletal vibration),1276 (C-S, str),1191 (C-H 
IPD),1069 (C-O-C), 768 (C-H, OPD). 
1HNMR(CDCl3,δppm):  2.31(s,3H,1),3.10(m,1H,3),3.20(m,1H,2),3.44 
(m,1H,5),3.56 (m,1H,4),3.82 (s,1H,11),5.44 (s,1H,6),7.77 ,2H,16,18,J=9.2,9.2 Hz), 
7.38 (d,1H,17,J=8.2 Hz), 6.91-7.29 (m,4H,7,8,9,10,J=8.76,7.02 Hz),7.34-7.43  
(m,5H,12,13,14,15,19) 
13CNMR(δppm):14.73 (C1), 22.34 (C2), 25.75 (C3), 51.12 (C4), 57.10 (C5), 107.73 
(C6), 120.54 (C7), 121.16 (C8), 125.71 (C9), 125.91 (C10), 126.19 (C11),   127.34 (C12), 
128.50 (C13), 128.68 (C14), 130.08 (C15), 130.31 (C16), 130.96 (C17), 132.17 (C18), 
133.03 (C19), 134.08 (C20), 137.34 (C21), 146.95 (C22), 157.02 (C23), 164.95 (C24), 
166.70 (C25). 
C, H, N (In %): Found: 66.43 (C), 4.65 (H), 9.68 (N), Cacld: 66.44 (C), 4.67 (H), 
9.70 (N) 
5 - (2-Chloro phenyl) -7- methyl -N- 1-naphthyl- 2,3- dihydro -5H- [1,3] 
thiazolo [3,2-a] pyrimidine -6- carboxamide (AKS-587). 
IR(KBr) cm-1   : 3186 (-NH, str), 3018 (-CH=CH), 2926 (Ar-CH,asym), 2823 (Ar-
CH,sym),1671 (-C=O),1522 (-C-C skeletal vibration),1272 (C-S, str),1195 (C-H 
IPD),1072 (C-O-C),765 (C-H, OPD). 
Mass (m/z value) : 435 (5), 433 (10), 322 (2), 295 (3), 291 (100), 255 (85), 228 
(18), 213 (4), 196 (5), 187 (5), 170 (5), 161 (4), 153 (7), 127 (17), 115 (22), 101 
(4), 86 (18), 77 (4), 67 (11), 42 (5), 41 (1). 
C, H, N (In %): Found: 69.91 (C), 5.40 (H), 9.78 (N), Cacld: 69.87 (C), 5.44 (H), 
9.80 (N), 
N- 6- Bis (4-chloro phenyl) -8- methyl -3,4- dihydro -2H ,6H- pyrimido [2,1-b] 
[1,3] thiazine -7- carboxamide (AKS-588). 
IR(KBr) cm-1   : 3284 (-NH, str), 3012 (-CH=CH), 2924 (Ar-CH,asym), 2868 (Ar-
CH,sym),1674 (-C=O),1516 (-C-C skeletal vibration),1263 (C-S, str),1190 (C-H 
IPD),1089 (C-O-C),813 (C-H, OPD). 
1HNMR (CDCl3, δ ppm): 2.15 (m,1H,17), 2.23 (m,1H,16), 2.23 (m,3H,1), 2.90 
(m,1H,5), 2.98 (m,1H,4), 3.21 (m,1H,3), 3.33 (m,1H,2), 5.21 (s,1H,6), 7.07 
(s,1H,15),7.21-7.24(t-t,2H,13,14,J=2.04,2.88HZ),7.29-7.37 (m,6H,7,8,910,11,12) 
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Mass: 435 (2), 431 (10), 416 (3), 329 (10), 323 (2), 305 (100), 290 (4), 277 (18), 
263 (2), 250 (3), 237 (2), 214 (3), 204 (2), 189 (10), 167 (18), 143 (14), 127 (17), 
125 (13), 100 (38), 90 (4), 72 (24), 67 (18), 42 (7), 41 (44). 
C, H, N (In %): Found: 58.34 (C), 4.43 (H), 9.72 (N), Cacld: 58.31 (C), 4.41 (H), 
9.74 (N), 
N - (4-Chloro phenyl) -8- methyl -6- (2-methoxyphenyl) -3,4- dihydro -2H, 6H- 
pyrimido [2,1-b] [1,3] thiazine -7- carboxamide (AKS-589). 
IR(KBr) cm-1   : 3256 (-NH, str), 3018 (-CH=CH), 2965 (Ar-CH,asym), 2829 (Ar-
CH,sym),1668 (-C=O),1570 (-C-C skeletal vibration),1253 (C-S, str),1168 (C-H 
IPD),1072 (C-O-C),786 (C-H, OPD). 
1HNMR (CDCl3, δ ppm): 2.07-2.13 (m,1H,5), 2.16-2.29 (m,1H,4), 2.29 (s,1H,1), 
2.82-2.95 (m,2H,6,7), 3.17-3.24 (m,1H,3), 3.41-3.45 (m,1H,2), 3.47 (s,3H,17), 
5.80 (s,1H,12), 7.66 (d-d,1H,9,J=1.72,7.68 Hz), 7.26-7.37 (m,5H,8,10,11,13,14), 
7.18-7.22 (t-t,2H,15,16, J=2.92 Hz), 7.04 (s,1H,18). 
C, H, N (In %): Found: 61.74 (C), 5.18 (H), 9.82 (N), Cacld: 61.77 (C), 5.14 (H), 
9.86 (N), 
N - (4-Chloro phenyl) -6- (2-hydroxy phenyl) -8- methyl -3,4- dihydro -2H, 6H-
pyrimido [2,1-b] [1,3] thiazine -7- carboxamide (AKS-590). 
IR(KBr) cm-1   : 3196 (-NH, str), 3034 (-CH=CH), 2945 (Ar-CH,asym), 2852 (Ar-
CH,sym),1662 (-C=O),1546 (-C-C skeletal vibration),1270 (C-S, str),1190 (C-H 
IPD),1062 (C-O-C),765 (C-H, OPD). 
C, H, N (In %): Found: 60.94 (C), 4.87 (H), 10.15 (N), Cacld: 60.96 (C), 4.88 (H), 
10.20 (N) 
N - (4-Chloro phenyl) -8- methyl -6- (4-nitro phenyl) -3,4- dihydro -2H, 6H- 
pyrimido [2,1-b] [1,3] thiazine -7- carboxamide (AKS-591). 
IR(KBr) cm-1   : 3292 (-NH, str), 3026 (-CH=CH), 2941,2942 (Ar-CH,asym), 
2847,2866 (Ar-CH,sym),1689 (-C=O),1498,1462 (-C-C skeletal vibration),1247 
(C-S, str),1188 (C-H IPD),1091 (C-O-C),775 (C-H, OPD). 
C, H, N (In %): Found: 56.95 (C), 4.32 (H), 12.65 (N), Cacld: 56.92 (C), 4.36 (H), 
12.67 (N), 
N - (4-Chloro phenyl) -8- methyl -6- (3-nitro phenyl) -3,4- dihydro -2H, 6H- 
pyrimido [2,1-b] [1,3] thiazine -7- carboxamide (AKS-592). 
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IR(KBr) cm-1   : 3216 (-NH, str), 3015 (-CH=CH), 2968 (Ar-CH,asym), 2842 (Ar-
CH,sym),1677 (-C=O),1570 (-C-C skeletal vibration),1290 (C-S, str),1182 (C-H 
IPD),1075 (C-O-C),771 (C-H, OPD). 
1HNMR (CDCl3, δ ppm): 2.25 (m,3H,1), 2.19 (m,1H,16), 2.25 (m,1H,17), 2.93 
(m,1H,4), 3.02 (m,1H,15), 3.2 (m,1H,3), 3.42 (m,1H,2), 5.39 (s,1H,6), 7.23 (t-t, 
2H,13,14, J= 2.92, 1.96 Hz), 7.37 (m,3H,11,12,15), 7.53 (t,1H,8, J= 7.88, 7.96 
Hz), 7.76 (t,1H,9, J=1.32, 6.44 Hz), 8.15 (qt-qt,1H,10,J=1.86,1.86 Hz), 8.20 
(t,1H,7, J= 1.92 Hz ) 
Mass:  442 (9), 425 (14), 316 (100), 288 (7), 270 (20), 242 (6), 223 (1), 200 (2), 
193 (7), 168 (3), 167 (20), 153 (9), 127 (14), 115 (8), 100 (27), 90 (9), 72 (22), 67 
(15), 44 (12). 
C, H, N (In %): Found: 56.95 (C), 4.32 (N), 12.65 (N), Cacld: 56.98 (C), 4.34 (N), 
12.67 (N) 
6 - (2-Chlorophenyl) -N- (4-chloro phenyl) -8- methyl -3,4- dihydro -2H, 6H-
pyrimido [2,1-b] [1,3] thiazine -7- carboxamide (AKS-593). 
IR(KBr) cm-1   : 3189 (-NH, str), 3046 (-CH=CH), 2972 (Ar-CH,asym), 2874 (Ar-
CH,sym),1686 (-C=O),1562 (-C-C skeletal vibration),1274 (C-S, str),1189 (C-H 
IPD),1092 (C-O-C),768 (C-H, OPD). 
Mass: 431 (8), 416 (3), 305 (100), 269 (76), 242 (5), 193 (8), 170 (5), 167 (8), 
153 (4), 128 (14), 125 (7), 100 (14), 90 (4), 72 (18), 67 (16), 42 (7). 
C, H, N (In %): Found: 58.34 (C), 4.43 (H), 9.72 (N), Cacld: 58.33 (C), 4.46 (H), 
9.75 (N), 
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IR spectrum of N,6-Bis(4-chlorophenyl)-8-methyl-3,4-dihydro-2H,6H-
pyrimido[2,1-b][1,3]thiazine-7-carboxamide(AKS-588). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum of N-(4-Chlorophenyl)-8-methyl-6-(4-nitrophenyl)-3,4-dihydro-
2H,6H-pyrimido[2,1-b][1,3]thiazine-7-carboxamide(AKS-591). 
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IR Spectrum of N,5-Bis(4-chlorophenyl)-7-methyl-2,3-dihydro-5H-
[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide(AKS-573). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of N-(4-Chlorophenyl)-5-(2-methoxyphenyl)-7-methyl-2,3-
dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide(AKS-574). 
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1H NMR Spectrum of 5-(2-Chlorophenyl)-N-(4-chlorophenyl)-7-methyl-2,3-
dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide(AKS-585) 
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1H NMR Spectrum of N-(4-Chlorophenyl)-7-methyl-5-(3-nitrophenyl)-2,3-
dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide(AKS-576). 
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1H NMR Spectrum of N-(4-Chlorophenyl)-8-methyl-6-(3-nitrophenyl)-3,4-
dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazine-7-carboxamide(AKS-592) 
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1H NMR Spectrum of N,6-Bis(4-chlorophenyl)-8-methyl-3,4-dihydro-2H,6H-
pyrimido[2,1-b][1,3]thiazine-7-carboxamide(AKS-588). 
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1H NMR Spectrum of N,6-Bis(1-naphthyl)-8-methyl-3,4-dihydro-2H,6H-
pyrimido[2,1-b][1,3]thiazine-7-carboxamide(AKS-586). 
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1H NMR Spectrum of N-(4-Chlorophenyl)-7-methyl-5-(3-methoxy phenyl)-2,3-
dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide(AKS-589). 
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Mass Spectrum of N-(4-Chlorophenyl)-8-methyl-6-(3-nitrophenyl)-3,4-
dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazine-7-carboxamide (AKS-592) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of N,6-Bis(4-chlorophenyl)-8-methyl-3,4-dihydro-2H,6H-
pyrimido[2,1-b][1,3]thiazine-7-carboxamide (AKS-588) 
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Mass Spectrum of 6-(2-Chlorophenyl)-N-(4-chlorophenyl)-8-methyl-3,4-
dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazine-7-carboxamide (AKS-593) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of 5-(2-Chlorophenyl)-N-(4-fluorophenyl)-7-methyl-2,3-
dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide (AKS-585). 
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Mass Spectrum of 5-(2-Chlorophenyl)-7-methyl-N-1-naphthyl-2,3-dihydro-
5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide (AKS-587). 
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13C Spectra of 5-(4-methoxyphenyl)-7-methyl-N-1-naphthyl-2,3-dihydro-5H-
[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide(AKS-586) 
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INTRODUCTION  
 
 
In earlier Chapter, a synthesis of thazolo fused pyrimidine system was developed. 
Though Biginelli is well explored as multicomponent rection (MCR), very few work 
is reported to use this facile reaction for N-substituted Biginelli products. 
 
On basis of previous work on N-substituted 1,4-dihydropyridines, the current 
approach was to use same approach to synthesize practically N-substituted 
carbamoyl bearing compounds. 
 
The current Chapter deals with reaction scheme, plausible mechanism, physical 
data, spectral data and interpretation of this newly synthesized compounds.  
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5.1 REACTOIN SCHEMES  
 
5.1.1 Scheme-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.2 Scheme-2 
 
 
 
 
 
 
 
 
 
 
 
5.1.3 Scheme-3 
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5.1.4 REACTION MECHANISM  
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5.2 Experimental  
 
5.2.1 N-Substituted phenylureaA (Scheme-1)  
 
The base used are aniline, meta toluidine and 2,4 dimethyl aniline, they were first                
converted into respective hydrochloride salts form. 
Aniline (3-methyl/2,4-dimethylaniline) hydrochloride (0.2M) and urea (0.2M) were 
dissolved in 100 ml of water. 2 ml of glacial acetic acid and 2 ml of conc. HCl was 
added to this solution. The reaction mixture was refluxed and white crystals 
appeared after 30-40 minutes. The reflux was continued for another 30 minutes. 
The reaction mixture was cooled and filtered. The solid product was taken into 
300 ml of water and boiled. It was filtered, and the filtrate was concentrated and 
allowed to cool. The crystal of phenyl urea was filtered and dried. (Mp: 1-
phenylurea – 146-47° (Reported 147 oC) C; 1-(3-methylphenyl)-urea - 159° C 
(Reported 161 oC); 1-(2,4-dimethylphenyl)-urea – 168-69° C) (Reported 166 oC).  
 
Physical data of the synthesized compounds are specified in Table 5.3.1 
 
5.2.2 4-Chloro/Flouro acetoacetanilideB (scheme-2) 
 
4-chloro/flouro aniline (0.1M) and ethyl acetoacetate was refluxed at 110° C in 40 
ml of toluene and catalytic amount of KOH/NaOH. The completion of reaction 
was monitored with TLC. After completion of reaction, toluene was distilled out. 
The residue was cooled at room temperature and was treated with ether. The 
solid was filtrated and dried. (Yield: 4-chloroacetoacetanilide – 62%, 4-
flouroacetoacetanilide – 56%. Mp: 4-chloroacetoacetanilide - 114° C 
(Reported115 oC), 4-fluoroacetoacetanilide - 129° C (Reported 128 oC).  
 
Physical data of the synthesized compounds are specified in Table 5.3.2 
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5.2.3 4-(Substituted phenyl)-N-(substitutedphenyl) - 1, 2, 3, 4- tetrahydro- 6-
methyl-2-oxo-1-(substitutedphenyl) pyrimidine-5-carboxamides (Scheme-3) 
[General method] 
 
Acetoacetanilide (0.01M), aldehyde (0.01M) and N-phenyl urea (0.015M) were 
dissolved in methanol and refluxed until clear solution is obtained. Few drops of 
Con. HCl was added to reaction mixture and was refluxed for 8-12 hrs. The 
reaction was monitored with TLC and after completion; the reaction mixture was 
allowed to cool. The solid separated was filtered, washed with hot methanol and 
dried. (Yield – 45-60%).  
Similarly other compounds were prepared by adopting this process. 
 
Physical data of newly synthesized compounds are specified in Table 5.3.3 
 
 
A Vogel’s text book of practical organic chemistry, 5th Edition, Page no. 965 
BNaliapara, Y. T.; Ph.D. Thesis., Saurashtra University, 1998 
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5.3 PHYSICAL DATA 
 
5.3.1 Physical data of N-(substituted phenyl)-3-oxobutanamide (1a-1b) 
 
 
 
 
 
 
 
 
 
No.  R1 MW Yield in 
% 
MP in oC Rf value  
1a 4-Cl 211.64 58 184-186 0.64 
1b 4-F 195.19 52 165-167 0.69 
 
 
5.3.2 Physical data of 1-(substituted phenyl) urea (2a-2c) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TLC solvent system       :  Ethyl acetate   : Hexane      3.0 ml : 7.0 ml 
 
         :    *CH2Cl2               : MeOH  9.4 ml :0.6 ml 
 
Visualization: UV light (long) 
 
 
No.  R1 MW Yield in 
% 
MP in oC Rf value  
2a H 136.15 55 146-148 0.41* 
2b 3-CH3 150.18  65 186-188 0.37 
2c 2,4-di-CH3 164.20  60 212-214 0.30* 
H
N
O O
R1
N
H
NH2
O
R
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5.3.3 Physical data of N-(substituted phenyl)-N-(substituted phenyl)-6-
methyl-2-oxo-4(substituted phenyl)-1, 2, 3, 4-tetrahydropyrimidine-5-
carboxamides (AKS 901-920) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code 
No. 
R R1 R2 MW Melting 
Point 
In oC 
Yield 
in % 
Rf 
Value 
AKS-901 H 4-Cl H 417.88 256-258 59 0.36 
AKS-902 H 4-Cl 3-NO2 462.88 241-243 53 0.42 
AKS-903 H 4-Cl 2-NO2 462.88 196-198 48 0.39 
AKS-904 H 4-CL 2-Cl 452.33 214-216 58 0.50 
AKS-905 H 4-CL 4-F 435.87 174-176 53 0.43 
AKS-906 H 4-Cl 2,3- benzo 467.94 245-246 48 0.48 
AKS-907 H 4-Cl 2-OH 433.88 194-196 47 0.52 
AKS-908 H 4-F 2,3-benzo 451.49 176-178 58 0.47 
AKS-909 3-CH3 4-Cl 3-Cl 466.35 189-191 51 0.39 
AKS-910 3 -CH3 4-Cl 2,3- benzo 481.97 165-167 55 0.41 
AKS-911 3- CH3 4-Cl 4-OCH3 461.94 185-187 57 0.43* 
AKS-912 3 -CH3 4-Cl 2,3.5,6-
dibenzo 
532.03 244-246 48 0.36* 
AKS-913 3- CH3 4-Cl 3-NO2 476.91 221-223 59 0.33* 
AKS-914 2,4diCH3 4-Cl H 445.94 274-276 57 0.46 
AKS-915 2,4diCH3 4-Cl 3-NO2 490.93 256-258 46 0.42* 
NH NH
N O
O
CH3
R1
R2
R
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AKS-916 2,4diCH3 4-Cl 3,4,5-tri 
OCH2 
536.01 246-248 49 0.46 
 
 
AKS-917 2,4diCH3 4-Cl 3-Cl 480.38 185-187 61 0.52 
AKS-918 H 4-F 4-OH 417.43 249-251 53 0.35* 
AKS-919 H 4-F H 401.43 286-288 46 0.41 
AKS-920 H 4-F 3-NO2 446.43 196-198 56 0.52 
 
 
 
TLC solvent system       :  Ethyl acetate         : Hexane     3.0 ml : 7.0 ml 
         :    *CH2Cl2                         : MeOH       9.4 ml : 0.6 ml 
 
Visualization: UV light (long) 
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5.4 SPECTRAL ANALYSIS  
 
5.4.1 MASS SPECTRAL ANALYSIS  
 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct 
Injection Probe technique. The molecular ion peak was found in concordance 
with molecular weight of the individual compound. Characteristic M+2 ion peaks 
with one-third intensity of molecular ion peak were observed in case of 
compounds having chlorine atom. The DHPMs made of 4-chloro acetoacetanilide 
showed this characteristic peak. Various fragmentation details are obtained for 
each compound in this series which are as under. 
Cleavage of α-bond to double bond is predictable to give peak in mass spectrum. 
Cleave of C-N bond (α-bond to >C=O bond at carbomoyl side chain at C5 
position) gave intense peak in each one spectrum. Cleavage of second α-bond to 
>C=O bond of carbamoyl moiety gives an additional characteristic peak which is 
observed in every mass spectra.  Cleavage of methyl (-CH3) group at C6 site from 
above fragment gave distinguishing peak at m/e value less than 15.Cleavage to 
both α-bonds to C=O bond of DHPM ring, gives another distinctive peak for this 
progression of compounds. Thus, molecular ion peak, one-third strength M+2 
peak for chloro derivatives and further than characteristic peaks observed for this 
series were in support to assigned structure to these compounds. Mass spectra 
of the recently synthesized compounds are given on Pages 182-183. 
 
5.4.2 IR SPECTRAL ANALYSIS  
 
As per spectral data of newly synthesized dihydropyrimidine molecules, 
mainstream of the carbonyl (>C=O) stretching observed at ~1640-1700cm-1 due 
to amide carbonyl functionality. The additional conformation of the amide group is 
revealed by >C-N stretching in range of 1501-1592. The stretching of secondary 
amine (>NH) come forward around ~3428-3432 cm-1, its bending and C-N 
stretching come out at 1501-1592 cm-1 correspondingly. The C-H stretching of 
aromatic moiety was observed at ~3030 cm-1. 
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The supplementary characterization owing to aromatics moiety C-C multiple bond 
stretching, C-H in plane bending and out of plane bending emerge around at 
~1501-1592 cm-1, ~1080 cm-1 and ~680-790 cm-1. The C-H stretching of methyl 
group observed at ~2920-2923 cm-1(asym) and ~2831-2851(sym) and its bending 
was observed at ~1383 cm-1. IR spectra of the newly synthesized compounds are 
given on Pages 175-177. 
 
 
5.4.3 1H NMR SPECTRAL ANALYSIS 
 
It was observed during study of 1H NMR spectra of the title compounds that 
methyl protons are observed as singlet at 2.10-2.16 δ ppm. Asymmetric carbon 
protons (>CH) in all compounds were observed between 5.0-5.9 δ ppm. The 
amide (>NH) protons gave singlet between 7.0-9.8 δ ppm. The aromatic protons 
were observed at close to 6.60-8.30 δ ppm. 
Two triplets are evidently observed in the aromatic region as a result of ortho/di-
meta coupling of meta nitro phenyl protons. For the ortho substituted phenyl ring, 
three doublets is observed due to di-ortho/meta coupling of phenyl protons and 
for para substitution, doublet of doublet was observed in the spectrum. In case of  
N-(4-chlorophenyl)-4-(4-fluorophenyl)-6-methyl-2-oxo-1-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide spectrum owing to ortho di coupling,  triplet 
–triplet splitting pattern in place of doublet- doublet,  caused by the attendance of 
neighboring  fluorine atom. 1HNMR spectra of the recently synthesized 
compounds are given on Pages 178-181. 
 
5.4.4 ELEMENTAL ANALYSIS 
 
Elemental analysis of the all the synthesized compounds was carried out on 
Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
(within the range of theoretical value) with the structures assigned. 
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Mass fragmentation of mass spectrum of N-(3-methylphenyl)-N-(4-
chlorophenyl)-6-methyl-2-oxo-4(4-methoxyphenyl)-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-911). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPECTRAL DATA 
 
4-(Phenyl) N-(4-chloro phenyl) -6- methyl -2 -oxo- 1, 4 –diphenyl - 1, 2, 3, 4 - 
tetrahydropyrimidine-5-carboxamide (AKS-901). 
IR(KBr,cm-1): 3363-3286 (-NH),3049 (Ar-CH,str), 2916 (methyl,asym,str), 2870 
(methyl, sym,str), 1720(>C=O, cyclic), 1685 (>C=O,amide),1523 (C-N,str), 1597-
1491 (>C=C,ring skeletal vibration), 1170 (C-H, ipd), 798-771 (C-H,opd),1087-
1058 (C-O-C,sym,str),1242(C-O-C, asym,str). 667 (-C=C-,opd,bend). 
C, H, N (in %): Found: 68.98 (C), 4.82 (H), 10.06 (N), Cacld: 68.94 (C), 4.80 (H), 
10.07 (N) 
4-(3-Nitro phenyl) -N- (4-chloro phenyl) -6- methyl -2-oxo- 1-phenyl -1, 2, 3,4-
tetrahydropyrimidine-5-carboxamide (AKS-902). 
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IR(KBr,cm-1): 3292-3228 (-NH), 3101 (Ar-CH, str), 2924, (methyl,asym,str), 
2870(methyl, sym,str), 1701 (>C=O, cyclic), 1685 (>C=O,amide),1525 (C-N,str), 
1591-1492 (>C=C,ring skeletal vibration), 1176(C-H, ipd), 775 (C-H,opd),1010-
1089 (C-O-C,sym,str),1244 (C-O-C, asym,str). 682 (-C=C-,opd,bend). 
1H NMR(δ ppm): 1.85 (s, 3H, a), 5.57 (d, 1H, b), 7.21 (m, 4H, c1, c2, b3, b4), 7.39 
(t, 1H, b5, J=1.16, 7.24 Hz), 7.46 (d-d, 2H, b1, b2, J=7.88, 1.08 Hz), 7.57 (m, 3H, 
c3, c4, a4), 8.07 (d, 1H, a3, J=3.24 Hz), 8.13 (t-t, 1H, a2, J=2.20 Hz), 8.39 (t, 1H, 
a1, J=1.92 Hz), 9.90 (s, 1H, e1) 
C, H, N (in %): Found: 62.27 (C), 4.14 (H), 12.10 (N), Cacld: 62.24 (C), 4.10 (H), 
12.13 (N) 
4-(2-Nitro phenyl) -N- (4-chloro phenyl) -6- methyl -2-oxo- 1-phenyl -1, 2, 3,4-
tetrahydropyrimidine-5-carboxamide (AKS-903). 
IR(KBr,cm-1): 3315-3227 (-NH), 3093-3070 (Ar-CH, str), 2924 (methyl,asym,str), 
1701 (>C=O, cyclic), 1662 (>C=O,amide),1529 (C-N,str), 1529-1475 (>C=C,ring 
skeletal vibration), 1174-1130 (C-H, ipd), 790 (C-H,opd),1010-1080 (C-O-
C,sym,str),1244 (C-O-C, asym,str). 624 (-C=C-,opd,bend). 
C, H, N (in %): Found: 62.27 (C), 4.14 (H), 12.10 (N), Cacld: 62.27 (C), 4.14 (H), 
1.10 (N) 
4-(2-Chloro phenyl) -N- (4-chloro phenyl) -6- methyl-2-oxo-1-phenyl-1, 2, 3, 4 
-tetrahydropyrimidine-5-carboxamide (AKS-904). 
IR(KBr,cm-1): 3377-3286 (-NH), 3055 (Ar-CH, str), 2949 (methyl,asym,str), 
1716(>C=O, cyclic), 1666 (>C=O,amide),1548 (C-N,str), 1593-1467 (>C=C,ring 
skeletal vibration), 1176-1122(C-H, ipd), 775 (C-H,opd),1093 (C-O-
C,sym,str),1253 (C-O-C, asym,str). 501 (-C=C-,opd,bend). 
C, H, N (in %): Found: 63.72 (C), 4.42 (H), 9.25 (N), Cacld: 63.74 (C), 4.39 (H), 
9.29 (N) 
4-(4-Fluoro phenyl) -N- (4-chloro phenyl) -6-methyl-2-oxo- 1-phenyl-1, 2, 3, 4 
-tetrahydropyrimidine-5-carboxamide (AKS-905). 
IR(KBr,cm-1): 3319-3290 (-NH), 3037-3011 (Ar-CH, str), 2953-2916 
(methyl,asym,str), 2854-2779 (methyl,sym,str) 1724 (>C=O, cyclic), 1654 
(>C=O,amide),1531 (C-N,str), 1593-1491 (>C=C,ring skeletal vibration), 1159 (C-
H, ipd), 767 (C-H,opd),1095 (C-O-C,sym,str),1259 (C-O-C, asym,str). 505(-C=C-
,opd,bend). 
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1H NMR(δ ppm): 1.81 (3H,s), 5.48 (1H,s), 7.21 (4H,m), 7.34 (2H,d-
d,J=8.52Hz,1.96Hz), 7.38 (1H,d,J=7.20Hz), 7.43 (4H,m,), 7.57 (2H,d,J=8.88Hz 
,2.08Hz)  
C, H, N (in %): Found: 66.11 (C), 4.34 (H), 9.61 (N), Cacld: 66.13 (C), 4.39 (H), 
9.64 (N) 
4- (Naphthyl) - N - (4-chloro phenyl) -6- methyl -2- oxo- 1-phenyl-1, 2, 3, 4 -
tetrahydropyrimidine-5-carboxamide (AKS-906). 
IR(KBr,cm-1): 3325-3236 (-NH), 3176-3039 (Ar-CH, str), 2951-2920, 
(methyl,asym,str), 2854-2783 (methyl,sym,str) 1724 (>C=O, cyclic), 1637 
(>C=O,amide),1518 (C-N,str), 1637-2000(overtone combination region) 1593-
1491 (>C=C,ring skeletal vibration), 1136 (C-H, ipd), 794-773(C-H,opd),1078 (C-
O-C,sym,str),1282-1242 (C-O-C, asym,str). 509-435 (-C=C-,opd,bend). 
Mass (m/z value): 468 (2), 392 (1), 376 (1), 305 (1), 265 (1), 249 (10, 232 (52), 
218 (2), 203 (4), 188 (28), 174 (8), 161 (100), 146 (4), 133 (90), 118 (10), 104 
(31), 89 (14), 77 (54), 63 (14), 51 (37) 
C, H, N (in %): Found: 71.84 (C), 4.78 (H), 8.94 (N), Cacld: 71.87 (C), 4.74 (H), 
8.98 (N) 
4-(2-Hydroxy phenyl)-N-(4-chloro phenyl)-6-methyl-2-oxo-1-phenyl-1, 2, 3, 4-
tetrahydropyrimidine-5-carboxamide (AKS-907). 
IR(KBr,cm-1): 3524-3612 (OH,str) 3343-3256 (-NH), 3089-3020 (Ar-CH, str), 
2978-2948, (methyl,asym,str), 2866-2754 (methyl,sym,str) 1721 (>C=O, cyclic), 
1686 (>C=O,amide),1545 (C-N,str), 1589-1486 (>C=C,ring skeletal vibration), 
1168(C-H, ipd), 778 (C-H,opd),1082 (C-O-C,sym,str),1252 (C-O-C, asym,str). 
602 (-C=C-,opd,bend). 
Mass (m/z value): 434 (6), 432 (100), 415 (4), 401 (1), 388 (1), 371 (1), 355 (2), 
342 (2), 326 (16), 313 (5), 298 (3), 285 (5), 270 (5), 253 (2), 242 (5), 227 (2), 214 
(3), 200 (1), 188 (11), 164 (1), 151 (1), 127 (1), 114 (1), 100 (1), 91 (100), 77 (1), 
65 (20), 44 (4). 
C, H, N (in %): Found: 66.46 (C), 4.66 (H), 9.68 (N), Cacld: 66.41 (C), 4.65 (H), 
9.68 (N) 
4- (Napthyl) – N - (4-fluoro phenyl) -6- methyl -2 -oxo -1-phenyl -1, 2, 3, 4 -
tetrahydropyrimidine-5-carboxamide (AKS-908). 
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IR(KBr,cm-1): 3312-3215 (-NH), 3171-3026 (Ar-CH, str), 2954-2932, 
(methyl,asym,str), 2858-2778 (methyl,sym,str) 1724 (>C=O, cyclic), 1645 
(>C=O,amide),1519 (C-N,str), 1632-2000 (overtone combination region)1585-
1495 (>C=C,ring skeletal vibration), 1139 (C-H, ipd), 798-775(C-H,opd),1074 (C-
O-C,sym,str),1287-1249 (C-O-C, asym,str). 515-431 (-C=C-,opd,bend). 
C, H, N (in %): Found: 74.47 (C), 4.94 (H), 9.30 (N), Cacld: 74.49 (C), 4.91 (H), 
9.31 (N) 
1-(3-Methyl phenyl) -N- (4-chloro phenyl) -6- methyl -2-oxo-4(3-clorophenyl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-909). 
IR(KBr,cm-1): 3325-3218 (-NH), 3085-3070 (Ar-CH, str), 2956, (methyl,asym,str), 
1710 (>C=O, cyclic), 1665 (>C=O,amide),1522C-N,str), 1529-1474 (>C=C,ring 
skeletal vibration), 1174-1130 (C-H, ipd), 795 (C-H,opd),1080-1012 (C-O-
C,sym,str),1254(C-O-C, asym,str). 633 (-C=C-,opd,bend). 
C, H, N (in %): Found: 64.41 (C), 4.52 (H), 9.00 (N), Cacld: 64.39 (C), 4.54 (H), 
9.01 (N) 
N-(3-Methyl phenyl)-N-(4-chloro phenyl)-6-methyl-2-oxo-4(nepthyl)-1, 2, 3, 4 
-tetrahydropyrimidine-5-carboxamide (AKS-910). 
IR(KBr,cm-1): 3323-3217 (-NH), 3185-3020 (Ar-CH, str), 2966-2941, 
(methyl,asym,str), 2846-2765 (methyl,sym,str) 1712(>C=O, cyclic), 1668 
(>C=O,amide),1520 (C-N,str), 2000-1637 (overtone combination region) 1584-
1491 (>C=C,ring skeletal vibration), 1145 (C-H, ipd), 775 (C- H,opd),1077 (C-O-
C,sym,str),1283-1242 (C-O-C, asym,str). 431 (-C=C-,opd,bend). 
C, H, N (in %): Found: 72.24 (C), 5.01 (H), 8.69 (N), Cacld: 72.27 (C), 5.02 (H), 
8.72 (N) 
N-(3-Methyl phenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-4(4-methoxyphenyl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-911). 
IR(KBr,cm-1): 3320-3214 (-NH), 3077-3062 (Ar-CH, str), 2956 ,(methyl,asym,str), 
1711 (>C=O, cyclic), 1670 (>C=O,amide),1536 (C-N,str), 1529-1477 (>C=C,ring 
skeletal vibration), 1188-1110 (C-H, ipd), 786 (C-H,opd),1085-1023 (C-O-
C,sym,str),1242(C-O-C, asym,str). 602 (-C=C-,opd,bend). 
Mass (m/e): 462 (5), 448 (1), 445 (10), 411 (1), 336 (78), 334 (10), 308 (3), 294 
(4), 293 (8), 265 (2), 245 (1), 213 (3), 204 (2), 187 (4), 177 (4), 153 (7), 155 (1), 
127 (22), 118 (100), 103 (4), 91 (4), 77 (67), 67 (10), 44 (74). 
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C, H, N (in %): Found: 67.62 (C), 5.26 (H), 9.08 (N), Cacld: 67.60 (C), 5.24 (H), 
9.10 (N) 
N-(3-Methyl phenyl)-N-(4-chloro phenyl)-6-methyl-2-oxo-4(4-anthryl)-1, 2,3,4-
tetrahydropyrimidine-5-carboxamide(AKS-912). 
IR(KBr,cm-1): 3336-3221 (-NH), 3166-3042 (Ar-CH, str), 2965-2910, 
(methyl,asym,str), 2862-2784 (methyl,sym,str) 1701 (>C=O, cyclic), 1674 
(>C=O,amide),1523 (C-N,str), 1630-2000 (overtone combination region) 1594-
1494 (>C=C,ring skeletal vibration), 1133(C-H, ipd), 794-763 (C-H,opd), 1078-
1025 (C-O-C,sym,str),1286-1241 (C-O-C, asym,str). 525-447 (-C=C-,opd,bend). 
C, H, N (in %): Found: 74.53 (C), 4.91 (H), 7.87 (N), Cacld: 74.50 (C), 4.93 (H), 
7.90 (N) 
N-(3-Methyl phenyl)-N-(4-chloro phenyl) -6- methyl -2- oxo-4 (4-nitro phenyl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamide(AKS-913). 
IR(KBr,cm-1): 3324-3217 (-NH), 3110(Ar-CH, str), 2924-2865, (methyl,asym,str), 
2876-2789 (methyl, sym,str), 1701 (>C=O, cyclic), 1680 (>C=O,amide),1522 (C-
N,str), 1590-1498 (>C=C,ring skeletal vibration), 1169 (C-H, ipd), 762 (C-
H,opd),1089-1025 (C-O-C,sym,str),1254 (C-O-C, asym,str). 677 (-C=C-
,opd,bend). 
1H NMR(δ ppm):  1.88 (s, 3H, a), 2.38 (s, 1H, b4), 5.60 (d, 1H, b), 7.05 (d,1H, b3 
J=11.76 Hz), 7.19 (m, 3H, a4, c3, c4), 7.33 (t, 1H, a3, J=7.72, 7.76 Hz),  7.54 (m, 
3H, c1, c2, b1), 7.75 (d, 1H, b2, J=3.04 Hz), 7.83 (t, 1H, b5, J=7.66, 1.20 Hz), 8.14 
(t-t, 1H, a2, J=2.20 Hz), 8.43 (t, 1H, a1, J= 1.96 Hz), 9.67 (s, 1H, e1) 
C, H, N (in %): Found: 62.98 (C), 4.41 (H), 11.72 (N), Cacld: 62.96 (C), 4.44 (H), 
11.75 (N) 
N-(2, 4-Di-methyl phenyl)-N-(4-chloro phenyl)-6-methyl-2-oxo-4-(phenyl)-1, 2, 
3, 4-tetrahydropyrimidine-5-carboxamide (AKS-914). 
IR(KBr,cm-1): 3320-3211 (-NH), 3110-3025 (Ar-CH, str), 2922-2889, 
(methyl,asym,str), 2865-2781 (methyl, sym,str), 1711 (>C=O, cyclic), 1675 
(>C=O,amide),1544 (C-N,str), 1592-1485 (>C=C,ring skeletal vibration), 1165 (C-
H, ipd), 752 (C-H,opd),1094-1021 (C-O-C,sym,str),1265 (C-O-C, asym,str). 656 (-
C=C-,opd,bend). 
C, H, N (in %): Found: 70.06 (C), 5.40 (H), 9.40 (N), Cacld: 70.03 (C), 5.42 (H), 
9.42(N) 
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N-(2,4-Di-methylphenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-4(3-nitrophenyl)-
1, 2, 3, 4-tetrahydropyrimidine-5-carboxamide(AKS-915). 
IR(KBr,cm-1): 3296-3210 (-NH), 3101(Ar-CH, str), 2924, (methyl,asym,str), 2870 
(methyl, sym,str), 1701 (>C=O, cyclic), 1680 (>C=O,amide),1525 (C-N,str), 1492-
1591 (>C=C,ring skeletal vibration), 1176 (C-H, ipd), 775 (C-H,opd),1010-1089 
(C-O-C,sym,str),1244 (C-O-C, asym,str). 676 (-C=C-,opd,bend). 
C, H, N (in %): Found: 63.63 (C), 4.74 (H), 7.19 (N), Cacld: 63.61 (C), 4.72 (H), 
7.22 (N) 
N- (2,4-Di-methylphenyl) -N- (4-chlorophenyl) -6- methyl -2- oxo -4 (3,4,5-tri-
methoxyphenyl)-1, 2, 3, 4- tetrahydropyrimidine -5- carboxamide (AKS-916). 
IR(KBr,cm-1): 3322-3225 (-NH), 3088-3062 (Ar-CH, str), 2956-2932, 
(methyl,asym,str),2868-2755 (methyl,str,sym) 1711 (>C=O, cyclic), 1675 
(>C=O,amide),1531C-N,str), 1529-1457 (>C=C,ring skeletal vibration), 1190-
1120 (C-H, ipd), 776 (C-H,opd),1085-1023 (C-O-C,sym,str),1232 (C-O-C, 
asym,str). 665 (-C=C-,opd,bend). 
C, H, N (in %): Found: 64.96 (C), 5.60 (H), 7.82 (N), Cacld: 64.98 (C), 5.64 (H), 
7.84 (N), 
N- (2,4-Di-methylphenyl) -N- (4-chlorophenyl) -6- methyl- 2- oxo- 4 (3-
clorophenyl) -1, 2, 3, 4- tetrahydropyrimidine - 5- carboxamide (AKS-917). 
IR(KBr,cm-1): 3322-3214 (-NH), 3075-3010 (Ar-CH, str), 2966 ,(methyl,asym,str), 
1712 (>C=O, cyclic), 1662 (>C=O,amide),1533 (C-N,str), 1533-1484 (>C=C,ring 
skeletal vibration), 1175-1122 (C-H, ipd), 789(C-H,opd),1090-1033 (C-O-
C,sym,str),1244 (C-O-C, asym,str). 656 (-C=C-,opd,bend). 
C, H, N (in %): Found: 65.04 (C), 4.85 (H), 8.72 (N), Calcd: 65.01 (C), 4.83 (H), 
8.75 (N), 
4-(4-Hydroxy phenyl)-N-(4-fluoro phenyl)-6-methyl-2-oxo-1-phenyl-1, 2, 3, 4 -
tetrahydropyrimidine-5-carboxamide (AKS-918). 
IR(KBr,cm-1): 3565-3622 (OH,str) 3310-3244 (-NH), 3101-3020 (Ar-CH, str), 
2965-2928, (methyl,asym,str), 2877-2744 (methyl,sym,str) 1718 (>C=O, cyclic), 
1680 (>C=O,amide),1542 (C-N,str), 1592-1475 (>C=C,ring skeletal vibration), 
1162 (C-H, ipd), 770 (C-H,opd),1080 (C-O-C,sym,str),1256 (C-O-C, asym,str). 
601 (-C=C-,opd,bend). 
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1H NMR (δ ppm): 1.68 (3H,s), 5.48 (1H,s), 6.53 (1H,d,J=8.8), 6.87 (3H,m), 7.18 
(5H,m), 7.32 (3H,t,J=8.32Hz, 9.87Hz), 7.64 (2H,d,J=8.80), 8.35 (1H,s) 9.59 
(1H,s) 
C,H,N(in %) : Found: 69.07 (C), 4.81 (H), 10.05 (N), Cacld: 69.05 (C), 4.83 (H), 
10.07 (N 
N - (4-Fluoro phenyl) - 6- methyl -2- oxo- 1, 4- diphenyl -1, 2, 3, 4  
tetrahydropyrimidine -5- carboxamide (AKS-919). 
IR(KBr,cm-1): 3356-3276(-NH),3044-2986(Ar-CH, str), 2924,(methyl,asym,str), 
2856(methyl, sym,str), 17210(>C=O, cyclic), 1678(>C=O,amide),1521(C-N,str), 
1593-1496(>C=C,ring skeletal vibration), 1174( C-H, ipd), 796-774 (C-
H,opd),1084-1057 (C-O-C,sym,str),1252 (C-O-C, asym,str). 645 (-C=C-
,opd,bend) 
C, H, N (in %): Found: 71.84 (C), 5.06 (H), 10.44 (N), Cacld: 71.81 (C), 5.02 (H), 
10.47 (N), 
4-(3-Nitro phenyl)-N- (4-fluoro phenyl)- 6-methyl -2- oxo -1- phenyl-1, 2, 3, 4 -
tetrahydropyrimidine-5-carboxamide(AKS-920). 
IR(KBr,cm-1): 3292-3210 (-NH), 3115-2986 (Ar-CH, str), 2924, (methyl,asym,str), 
2877-2796 (methyl, sym,str), 1701 (>C=O, cyclic), 1680 (>C=O,amide),1525 (C-
N,str), 1593-1496 (>C=C,ring skeletal vibration), 1180 (C-H, ipd), 765 (C-
H,opd),1089-1020 (C-O-C,sym,str),1258 (C-O-C, asym,str). 680 (-C=C-
,opd,bend). 
Mass (m/e): 447 (25), 321 (100), 293 (10), 278 (20), 265 (2), 250 (28), 187 (4), 
177 (4), 153 (8), 127 (44), 91 (4), 77 (27), 67 (5), 44 (17). 
C, H, N (in %): Found: 64.60 (C), 4.25 (H), 12.53 (N), Cacld: 64.57 (C), 4.29 (H), 
12.55 (N), 
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IR spectrum of 4-(phenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-1-phenyl-
1,2,3,4-tetrahydropyrimidine-5-carboxamide(AKS-901) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IR spectrum of 4-(3-nitro phenyl)-N-(4-chloro phenyl)- 6- methyl- 2- oxo -1-
phenyl-1, 2, 3, 4- tetrahydropyrimidine-5-carboxamide (AKS-902) 
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IR spectrum of 4-(2-nitrophenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-1-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-903) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of 4-(2-chlorophenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-1-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-904) 
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IR spectrum of 4-(4-flourophenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-1-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-905) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of 4-(2,3-benzophenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-1-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 
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1H NMR spectrum of N-(4-chlorophenyl)-4-(4-fluorophenyl)-6-methyl-2-oxo-
1-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-905). 
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1H NMR spectrum of 4-(4-hydroxyphenyl)-N-(4-fluorophenyl)-6-methyl-2-
oxo-1-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-918). 
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1H NMR spectrum of 4-(3-nitrophenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-1-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-902) 
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1H NMR spectrum of N-(3-methylphenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-
4(4-nitroyphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-913). 
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Mass spectrum of N-(3-methylphenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-
4(4-methoxyphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-911). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of 4-(3-nitrophenyl)-N-(4-fluorophenyl)-6-methyl-2-oxo-1-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-920) 
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Mass spectrum of 4-(2,3-benzophenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-1-
phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide(AKS-906). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of 4-(2-hydroxyphenyl)-N-(4-chlorophenyl)-6-methyl-2-oxo-
1-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-907). 
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INTRODUCTION 
 
 
The current chapter is in a sequential study of multicomponent reaction mentioned in 
earlier two chapters. The introductory chapter reveals the importance of Microwave 
assisted organic synthesis explored recently various scientist world over. The 
current chapter is an add on study of such synthetic efforts to obtain successfully the 
title compounds.  
 
In this chapter, C4 aromatic or heteroaromatic skeleton is removed to obtain novel 
alkylated dihydropyrimidines as final products.  
 185
 
6.1 REACTION SCHEMES  
 
6.1.1 Scheme-1 
 
 
 
 
 
 
 
 
 
 
 
6.1.2 Scheme-2 
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6.1.3 Scheme-3 
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6.1.4 REACTION MECHANISM 
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6.2 EXPERIMENTAL 
 
N- (Substitutedphenyl)–6–methyl - 2-oxo–4 -1,2 3, 4–tetrahydro pyrimidine- 5 - 
carboxamides (Scheme-2) 
[General method] 
 
Substituted acetanilide, butyraldehyde and urea were dissolved in methanol and few 
drops of Con.HCl was added. The reaction mixture was irradiated under microwave 
(200W) power at 90 oC for 10-12 minutes. Completion of reaction was monitored by 
TLC. The reaction mixture was allowed to stand at room temprature. The solid 
separated was filtered and recrystallized from dimethyl formamide (Yield 45-65 %).  
 
Physical data of newly synthesized compounds are given in Table  6.3.1 
 
N- (Substituted phenyl) – 6 – propyl – 2 – thioxo - 1,2,3,4 – tetrahyropyrimidine 
- 5 - carboxamides (Scheme-3) 
[General method] 
 
Substituted acetanilide, butyraldehyde and thiourea were dissolved in methanol and 
few drops of con. HCl added. The reaction mixture was irradiated with microwave 
(200W) at 90 oC for 10-12 minutes. Completion of reaction was monitored by TLC. 
The reaction mixture was allowed to stand at room temprature. The solid separated 
was filtered and recrystallized from dimtheyl formamide (Yield 40-68 %).  
 
Physical data of newly synthesized compounds are given in Table 6.3.2 
 
Microwave apparatus used was QPRo-M Microwave synthesizer. 
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6.3 PHYSICAL DATA 
 
6.3.1 Physical data of N-(2-methylphenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamides (AKS 921-931) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TLC solvent system         Ethyl acetate    : Hexane     3.0 ml : 7.0 ml 
 
            *CH2Cl2                     : MeOH       9.5 ml : 0.5 ml 
  
Visualization: UV light (long)
Code No. R MW MP in oC Yield 
in % 
RF 
Value   
AKS-921 H 273.33 165-167 68 0.32 
AKS-922 4-Cl 307.77 184-186 66 0.51* 
AKS-923 4-F 291.32 154-156 67 0.52 
AKS-924 4-CH3 287.35 198-200 63 0.48 
AKS-925 2-CH3 287.35 274-276 48 0.39 
AKS-926 3-CH3 287.35 178-180 56 0.47* 
AKS-927 2,3-di-CH3 302.38 168-170 51 0.36 
AKS-928 3-NO2 319.32 224-226 61 0.42* 
AKS-929 2,4-di-CH3 302.38 147-149 49 0.41 
AKS-930 2-Cl 307.77 186-188 53 0.39 
AKS-931 3,4-di benzo 323.38 245-247 61 0.42 
NH NH
N
H
O
CH3 O
CH3
R
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6.3.2   Physical data of 6-methyl-N-(substituted phenyl)-4-propyl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamides (AKS 912-920) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
    
 
TLC solvent system        Ethyl acetate     : Hexane      3.0 ml   : 7.0 ml 
  
                       *CH2Cl2                      : MeOH     9.4 ml  : 0.6 ml 
 
           Visualization UV light (long) 
Code No. R MW MP in oC Yield 
in % 
Rf 
Value  
AKS-932 H 289.39 286-288 69 0.37 
AKS-933 2-CH3 303.42 245-247 58 0.41 
AKS-934 3-CH3 303.42 189-191 64 0.42 
AKS-935 4-Cl 323.84 246-248 68 0.36 
AKS-936 4-F 307.38 174-176 56 0.43* 
AKS-937 2,3-di-CH3 317.44 197-199 63 0.33* 
AKS-938 2,4-di-CH3 317.44 165-167 65 0.42 
AKS-939 2,3 -di- bezo 339.45 186-188 68 0.51 
AKS-940 3,4-di-benzo 339.45 145-146 70 0.53* 
NH NH
N
H
CH3
O
S
CH3
R
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6.3 SPECTRAL ANALYSIS 
 
6.3.1 IR SPECTRAL ANALYSIS  
 
Spectral data of key intermediate and compounds are included. Instrument used; 
SHIMADZU FT IR-8400, sample technique, KBr disc, frequency assortment, 400-
4000 cm-1. Looking to the spectral data of recently synthesized 
(dihydropyrimidines) molecules, the carbonyl (>C=O) of the amidic functionality 
stretching was observed at 1655-1695 cm-1 and an extra ketonic group (-NH-CO-
NH) was observed at in the area of at 1700 cm-1-1720 cm-1 owing to amidic 
functionality.  The conformation of the amide group (>C-N, str) was establish in 
range of 1495-1525 cm-1. The stretching of amine (-NH) come out approximately 
close to 3150-3400 cm-1. The stretching of C-N emerge at 1501-1596 cm-1.The 
C-O-C str (symmetric vibration) was established between 1001-1090 cm-1.C-S str 
and bending vibration at 1275-1030 cm-1, and 650-700 cm-1 correspondingly. The 
C-H str of aromatic moiety was observed at just about 2900-3040 cm-1C-H in 
plane bending and, out of plane bending was pragmatic at 1400-1630 cm-1 and 
710-860 cm-1. 
IR spectra of the newly synthesized compounds are given on Pages 199-201. 
 
6.3.2 1H NMR SPECTRAL ANALYSIS  
 
1H NMR Spectrum of the N-(substituted phenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide demonstrate signals relevant to the number 
of protons and their electronic location known as chemical shift. Chemical shift 
progress to either up field (shielding) or down field (dishelding), according to the 
electronic locality of the consequent proton. In addition to this, each one 1H NMR 
signal supporting splitted into number of associate peaks according to the 
number of neighbouring protons nearby in the skeleton of molecule. The splitting 
of the NMR signal promoted significant information concerning to the degree of 
interface between neighboring protons by way of spin- spin coupling constant.  
1H NMR spectra of AKS-903, shows a singlet because of the existence of three 
amino groups. Both –NH proton of the dihyropirimidine ring illustrate singlet at 
9.57 and 10.44 δ ppm. Even though other proton of the –NH-C=O linkage make 
clear singlet at 6.87 δ ppm. Two protons of phenyl residue (d2, d2) show a doublet 
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at 7.59 δ ppm with J value 8.81 Hz. Other two protons of the phenyl residue (d1, 
d1) gave triplet-triplet at 7.19-7.23 with J value 9.84, 8.84 (Ortho coupling with d2 
protons) in place of doublet of doublet because of the being there fluorine atom at 
ortho position. Hc proton of the dihyropyrimidine sphere show singlet at 4.98 δ 
ppm. In this molecule, alkyl chain is close to C4 carbon of dihyropyrimidine ring 
and have seven protons, even as methyl protons (3H) which is extremely 
shielded show triplet at 0.95 δ ppm. Left behind four protons are chemically 
correspondent but magnetically dissimilar, hence each and every one of the four 
protons show diverse δ ppm. Methyl protons of dihyropyrimidine ring at C6 should 
be give singlet, but the existence of methylenic protons of an alkyl side a singlet 
will join together with Hc2 signal, consequently it shows multiplet at 1.43 δ ppm. 
From the alkyl side chain, Hc1, Hc2, Hb1, Hb2 demonstrate multiplet at 2.33, 1.52, 
3.31 and 2.58 δ ppm correspondingly. 
1H NMR spectra of newly synthesized compounds are given on Page 202. 
 
6.3.3 MASS SPECTRAL ANALYSIS 
  
As EI-MS spectrum of the N-(substituted phenyl)-6-methyl-2-oxo-4-propyl-
1,2,3,4-tetrahydropyrimidine-5-carboxamide exhibited special feature like 
molecular ion peak and fragmentation pattern relevant to the nature of molecule, 
it become one of the most important tool for characterization of the structure of 
molecule. 
In the EI-MS spectrum of 6-methyl-2-oxo-N-phenyl-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide, the appearance of an intense molecular ion 
peak at m/z at 273. A fragmentation at 259 relevant to tetrahydropyrimidine 
suggests that loss of methyl from the pyrimidine ring at C5 position. Loss of two –
CH3 and CH2 from the alkyl chain, mass peaks observed at 245 and 231 
respectively. Then cleavage from the carbonyl carbon, peak is observed at 127 
due to loss of aromatic amine radical. For AKS- 917 loss of methyl group 
subsequently from the pyrimide ring, alkyl side chain, and phenyl ring peak will 
observed at 303, 289, 275 respectively. A peak at 231, is relevant to loss of sulfur 
atom from the pyrimidine ring. Moreover, m/z 215 suggests that loss of two 
hydrogen from C2 and relevant nitrogen of pyrimidine ring. For AKS-908, a peak 
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is observed at 291 due to loss of two methyl group from pyrimidine ring at C6 and 
alkyl side chain at C4. For AKS-906, a peak at 259 (m/z) relevant to loss of two 
methyl from the pyrimidine rings at C6 position and second methyl from the 
phenyl residue. Similarly other compounds can be interpreted for their mass 
fragmentation pattern. 
Mass spectra of newly synthesized compounds are given on Pages 203-205. 
 
6.3.4 ELEMENTAL ANALYSIS 
 
Elemental analysis of the all the synthesized compounds was carried out on 
Elemental Vario EL III Carlo Erba 1108 model and the results are in agreements 
(within the range of theoretical value) with the structures assigned. 
 
SPECTRAL DATA 
6- Methyl -2-oxo – N - phenyl -4- propyl -1, 2, 3, 4 – tetrahydropyrimidine - 5 -
carboxamide (AKS-921) 
IR (KBr, cm-1): 3440 (-NH), 2923 (methyl,asym,str), 2852 (methyl,sym,str), 1676 
(>C=O,amide), 1739 (-NH-CO-NH) 1350 (C-N,str), 1614-1444 (>C=C,ring 
skeletone vibration), 1550 (-NH Deformation)1244 (C-H, ipd), 765 (C-
H,opd),1091,1018 (C-O-C,sym,str). 
MASS (m/e value): 273 (100), 258 (8), 245 (49), 231 (13), 213 (8), 203 (3), 185 
(7), 171 (23), 155 (8), 153 (39), 127 (42), 115 (12), 99 (8), 86 (32), 77 (6), 67 
(22), 44 (18) 
C, H, N (in %): Found: 70.33 (C), 8.48 (H), 15.37 (N), Cacld: 70.35 (C), 8.46 (H), 
15.40 (N) 
N-(4-Chlorophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-922) 
IR (KBr, cm-1): 3440 (-NH), 2908 (methyl,asym,str), 2887  (methyl,sym,str), 
1706(>C=O,amide), 1731 (-NH-CO-NH) 1368 (C-N,str), 1610-1466 (>C=C,ring 
skeletone vibration), 1522 (-NH Deformation)1242 (C-H, ipd), 757 (C-
H,opd),1087,1010 (C-O-C,sym,str). 
C, H, N (in %): Found: 62.43 (C), 7.20 (H), 13.66 (N), Cacld: 62.40 (C), 7.23 (H), 
13.68 (N) 
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N-(4-Flourophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-923) 
IR (KBr, cm-1): 3423,3224 (-NH), 3062(Ar-CH,str) 2929 (methyl,asym,str), 2854 
(methyl,sym,str), 1652 (>C=O,amide), 1718 (-NH-CO-NH) 1331 (C-N,str), 1604-
1425 (>C=C,ring skeletone vibration), 1535 (-NH Deformation)1222 (C-H, ipd), 
759 (C-H,opd),1022 (C-O-C,sym,str). 
1H NMR (δ ppm):  0.95 (t, 3Hb), 1.43 (m, 3Ha), 1.52(m, Hc1), 2.33 (m,Hc2), 2.58 
(m,Hd1), 3.31 (m,Hd2), 4.95 (s,He), 6.87 (s, Hf1),  9.57 (s, Hf2), 10.44 (s,Hf3), 7.59 
(d, Hg2), 7.19-7.23 (t-t, Hg1). 
C, H, N (in %): Found: 65.96 (C), 7.61 (H), 14.42 (N), Cacld:  65.93 (C), 7.58 
(H), 14.44 (N) 
N-(4-Methylphenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-924) 
IR (KBr, cm-1): 3423, 3353 (-NH), 2929 (methyl,asym,str), 2871,2736 
(methyl,sym,str), 1654 (>C=O,amide), 1735 (-NH-CO-NH) 1334,1375 (C-N,str), 
1625-1461 (>C=C,ring skeletone vibration), 1571 (-NH Deformation)1242 (C-H, 
ipd), 734 (C-H,opd),1101,1024 (C-O-C,sym,str). 
C, H, N (in %): Found:  71.04 (C), 8.77 (H), 14.62 (N), Cacld: 71.01 (C), 8.79 
(H), 14.66 (N) 
N-(2-Methylphenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-925) 
IR (KBr, cm-1): 3414, 3314 (-NH), 3040(Ar-CH, str) 2968, 2910 (methyl,asym,str), 
2864,2745 (methyl,sym,str), 1666 (>C=O,amide), 1718 (-NH-CO-NH) ,1365 (C-
N,str), 1640-1442 (>C=C,ring skeletone vibration), 1561 (-NH Deformation)1246 
(C-H, ipd), 778 (C-H,opd),1096,1011 (C-O-C,sym,str). 
C, H, N (in %): Found:  71.01 (C), 8.75 (H), 14.61 (N), Cacld: 71.01 (C), 8.79 
(H), 14.66 (N) 
N-(3-Methylphenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-926) 
IR (KBr, cm-1):  3368 (-NH), 3064, 3012(Ar-CH, str) 2975, 2924    
(methyl,asym,str), 2854,2776 (methyl,sym,str), 1680 (>C=O,amide), 1710 (-NH-
CO-NH) ,1354 (C-N,str), 1656-1443 (>C=C,ring skeletone vibration), 1555 (-NH 
Deformation)1261 (C-H, ipd), 801 (C-H,opd),1099,1010 (C-O-C,sym,str). 
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C, H, N (in %): Found: 71.02 (C), 8.74 (H), 14.61 (N), Cacld: 71.01 (C), 8.79 (H), 
14.66 (N) 
MASS (m/e): 287 (100), 270 (18), 259 (83), 240 (18), 230 (16), 215 (23), 202 
(15), 189 (15), 176 (3), 156 (5), 144 (5), 128 (14), 115 (14), 102 (17), 89 (8), 77 
(19), 63 (9), 44 (32) 
 
N - (2,3-Dimethyl phenyl) -6- methyl -2 -oxo-  4 - propyl -1, 2, 3, 4- tetrahydro-
pyrimidine-5-carboxamide (AKS-927) 
IR (KBr, cm-1): 3424, 3362 (-NH), 3026 (Ar-CH, str) 2989, 2956 
(methyl,asym,str), 2888,2744 (methyl,sym,str), 1674 (>C=O,amide), 1720 (-NH-
CO-NH) ,1363 (C-N,str), 1641-1448 (>C=C,ring skeletone vibration), 1551 (-NH 
Deformation)1247 (C-H, ipd), 762 (C-H,opd),1078,1020 (C-O-C,sym,str). 
MASS (m/e):  302 (100), 274 (1), 256 (23), 243 (1), 228 (19), 200 (17), 179 (4), 
153 (23), 127 (47), 115 (12), 110 (31), 86 (65), 83 (49), 60 (52), 44 (63) 
C, H, N (in %): Found:  71.72 (C), 9.03 (H), 13.94 (N), Cacld: 71.70 (C), 9.09 
(H), 13.96 (N) 
N-(3-Nitro phenyl) -6-methyl -2- oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (AKS-928) 
IR (KBr, cm-1): 3456, 3314 (-NH), 3040, 3012 (Ar-CH, str) 2974, 2932 
(methyl,asym,str), 2856,2755 (methyl,sym,str), 1682 (>C=O,amide), 1712 (-NH-
CO-NH) ,1362 (C-N,str), 1640-1442 (>C=C,ring skeletone vibration), 1561 (-NH 
Deformation)1259 (C-H, ipd), 778 (C-H,opd),1096,1018 (C-O-C,sym,str). 
MASS (m/e): 319 (57), 291 (40) 248 (13), 214 (6), 208 (4), 183 (5), 170 (18), 165 
(1), 141 (13), 130 (4), 116 (7), 104 (7), 91 (100), 77 (22), 65 (39), 46 (40) 
C, H, N (in %):Found:  60.36 (C), 6.97 (H), 17.60 (N), Cacld: :  60.40 (C), 6.93 
(H), 17.64 (N) 
N - (2,4-Dimethyl phenyl) -6- methyl -2- oxo -4- propyl - 1, 2, 3, 4-tetrahydro- 
pyrimidine-5-carboxamide (AKS-929) 
IR (KBr, cm-1): 3414, 3314 (-NH), 3040(Ar-CH, str) 2968, 2910 (methyl,asym,str), 
2864,2745 (methyl,sym,str), 1666 (>C=O,amide), 1718 (-NH-CO-NH) ,1365 (C-
N,str), 1640-1442 (>C=C,ring skeletone vibration), 1561 (-NH Deformation)1246 
(C-H, ipd), 778 (C-H,opd),1096,1011 (C-O-C,sym,str). 
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C, H, N (in %): Found: 71.72 (C), 9.03 (H), 13.94 (N), Cacld: 71.74 (C), 9.01 (H), 
13.96 (N) 
N-(2-Chlorophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-tetrahydropyrimidine-5-
carboxamide(AKS-930) 
IR (KBr, cm-1): 3424, 3310 (-NH), 3042, 3010(Ar-CH, str) 2989, 2926 
(methyl,asym,str), 2874,2754 (methyl,sym,str), 1676 (>C=O,amide), 1728 (-NH-
CO-NH) ,1356 (C-N,str), 1624-1450 (>C=C,ring skeletone vibration), 1552 (-NH 
Deformation)1258 (C-H, ipd), 786 (C-H,opd),1098,1022 (C-O-C,sym,str). 
C, H, N (in %): Found:  62.43 (C), 7.20 (H), 13.65 (N), Cacld: 62.46 (C), 7.24 
(H), 13.69 (N) 
6-Methyl- N -1- naphthyl -2- oxo -4- propyl-1, 2, 3, 4 -tetrahydro pyrimidine-5-
carboxamide (AKS-931) 
IR (KBr, cm-1): 3423, 3354 (-NH), 3024(Ar-CH, str) 2968, 2910 (methyl,asym,str), 
2864,2745 (methyl,sym,str), 1666 (>C=O,amide), 1718 (-NH-CO-NH) ,1365 (C-
N,str), 1640-1442 (>C=C,ring skeletone vibration), 1540 (-NH Deformation)1254 
(C-H, ipd), 788 (C-H,opd),1088,1014 (C-O-C,sym,str). 
C, H, N (in %): Found: 74.27 (C), 7.79 (H), 12.99 (N), Cacld: 74.24 (C), 7.81 (H), 
12.99 (N) 
6 - Methyl -N- phenyl -4- propyl -2- thioxo- 1, 2, 3, 4- tetrahydropyrimidine -5-
carboxamide (AKS-932) 
IR (KBr, cm-1): 3456, 3324 (-NH), 3010(Ar-CH, str) 2958, 2910 (methyl,asym,str), 
2874 (methyl,sym,str), 1674 (>C=O,amide), 1710 (-NH-CO-NH) ,1346 (C-N,str), 
1644-1432 (>C=C,ring skeletone vibration), 1554 (-NH Deformation)1262 (C-H, 
ipd), 803 (C-H,opd),1094,1010 (C-O-C,sym,str). 
C, H, N (in %): Found:  66.39 (C), 8.01 (H), 14.52 (N), Cacld: 66.42 (C), 8.00 
(H), 14.56 (N), 
6-Methyl-N-(2-methylphenyl)-4-propyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (AKS-933) 
IR (KBr, cm-1): 3417 (-NH), 2864, 1660 (>C=O,amide),  ,1321 (C-N,str), 1598-
1469 (>C=C,ring skeletone vibration), 1055, 1205(C=S, str) 1598 (-NH 
Deformation)1299 (C-H, ipd), 781 (C-H,opd),1020,1055 (C-O-C,sym,str). 
C, H, N (in %): Found: 67.28 (C), 8.30 (H), 13.85 (N), Cacld: 67.30 (C), 8.34 (H), 
13.88 (N) 
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6-Methyl-N-(3-methylphenyl)-4-propyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (AKS-934) 
IR (KBr, cm-1): 3414, 3354 (-NH), 3054 (Ar-CH, str) 2986, 2924 
(methyl,asym,str), 2870,2765 (methyl,sym,str), 1671 (>C=O,amide) ,1374 (C-
N,str), 1650-1441 (>C=C,ring skeletone vibration), 1551 (-NH Deformation)1244 
(C-H, ipd), 778 (C-H,opd),1094,1020 (C-O-C,sym,str). 
C, H, N (in %): Found:  67.28 (C), 8.30 (H), 13.85 (N), Cacld: 67.30 (C), 8.34 
(H), 13.88 (N) 
6-Methyl-N-(4-chlorophenyl)-4-propyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (AKS-935) 
IR (KBr, cm-1): 3378 (-NH), 3065, 3014 (Ar-CH, str) 2954,  (methyl,asym,str), 
2877,2774 (methyl,sym,str), 1668 (>C=O,amide) ,1365 (C-N,str), 1640-1452 
(>C=C,ring skeletone vibration), 1548 (-NH Deformation)1264 (C-H, ipd), 768 (C-
H,opd),1084,1011 (C-O-C,sym,str). 
C, H, N (in %): Found: 59.33 (C), 6.85 (H), 12.97 (N), Cacld: 59.36 (C), 6.82 (H), 
12.99 (N) 
6-Methyl-N-(4-flourophenyl)-4-propyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-
5-carboxamide (AKS-936) 
IR (KBr, cm-1): 3425, 3378 (-NH), 3054 (Ar-CH, str) 2954, 2910 
(methyl,asym,str), 2868,2743 (methyl,sym,str), 1678 (>C=O,amide) ,1361 (C-
N,str), 1641-1440 (>C=C,ring skeletone vibration), 1555 (-NH Deformation)1244 
(C-H, ipd), 789 (C-H,opd),1098,1014 (C-O-C,sym,str). 
C, H, N (in %): Found: 62.51 (C), 7.21 (H), 13.67 (N),Cacld: 62.49 (C), 7.24 (H), 
13.69 (N) 
6- Methyl -N- (2,3-dimethyl phenyl) -4- propyl -2- thioxo- 1, 2, 3, 4 -tetrahydro 
pyrimidine-5-carboxamide (AKS-937) 
IR (KBr, cm-1): 3425, 3378 (-NH), 3054 (Ar-CH, str) 2954, 2910 
(methyl,asym,str), 2868,2743 (methyl,sym,str), 1678 (>C=O,amide) ,1361 (C-
N,str), 1641-1440 (>C=C,ring skeletone vibration), 1555 (-NH Deformation)1244 
(C-H, ipd), 789 (C-H,opd),1098,1014 (C-O-C,sym,str). 
MASS (m/e): 317 (100), 303 (30), 289 (39), 273 (17), 257 (18), 245 (7), 230 (16), 
215 (23), 202 (15), 189 (15), 176 (3), 156 (5), 144 (5), 128 (14), 115 (14), 102 
(17), 89 (8), 77 (19), 63 (9), 44 (32) 
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C, H, N (in %): Found:  68.09 (C), 8.57 (H), 13.24 (N), Cacld:  68.12 (C), 8.55 
(H), 13.28 (N) 
6- Methyl -N- (2,4-dimethyl phenyl) -4- propyl -2- thioxo- 1, 2, 3, 4-tetrahydro 
pyrimidine-5-carboxamide (AKS-938) 
IR (KBr, cm-1): 3464, 3314 (-NH), 3054, 3012 (Ar-CH, str) 2978, 2920 
(methyl,asym,str), 2878,2784 (methyl,sym,str), 1680 (>C=O,amide) ,1350 (C-
N,str), 1638-1438 (>C=C,ring skeletone vibration), 1535 (-NH Deformation)1258 
(C-H, ipd), 789 (C-H,opd),1078,1011 (C-O-C,sym,str). 
C, H, N (in %): Found:  68.08 (C), 8.55 (H), 13.22 (N), Cacld: 68.12 (C), 8.55 
(H), 13.28 (N) 
6-Methyl-N-1- naphthyl -4- propyl- 2- hioxo-1, 2, 3, 4 -tetrahydropyrimidine-5-
carboxamide (AKS-939) 
IR (KBr, cm-1): 3451 (-NH), 3064, 3010 (Ar-CH, str) 2968, 2924 
(methyl,asym,str), 2864,2780 (methyl,sym,str), 1671 (>C=O,amide) ,1354 (C-
N,str), 1640-1454 (>C=C,ring skeletone vibration), 1551 (-NH Deformation)1242 
(C-H, ipd), 794 (C-H,opd),1084,1010 (C-O-C,sym,str). 
C, H, N (in %): Found:  70.76 (C), 7.42 (H), 12.38 (N), Cacld:  70.72 (C), 7.40 
(H), 12.46 (N) 
6-Methyl-N-2-naphthyl-4-propyl -2- thioxo- 1, 2 ,3, 4 -tetrahydropyrimidine-5-
carboxamide (AKS-940) 
IR (KBr, cm-1): 3389 (-NH), 3068, 3024 (Ar-CH, str) 2974, 2910 
(methyl,asym,str), 2874,2756 (methyl,sym,str), 1668 (>C=O,amide) ,1348 (C-
N,str), 1651-1442 (>C=C,ring skeletone vibration), 1546 (-NH Deformation)1252 
(C-H, ipd), 782 (C-H,opd),1080,1015 (C-O-C,sym,str). 
C, H, N (in %): Found: 70.76 (C), 7.42 H), 12.38 (N), Cacld: 70.77 (C), 7.46 H), 
12.40 (N) 
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IR spectrum of 6- Methyl -2-oxo- N- phenyl-4-propyl-1, 2, 3, 4-tetrahydro-
pyrimidine-5-carboxamide (AKS-921) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of N-(4-Chloro phenyl) -6- methyl -2- oxo- 4- propyl-1, 2 3, 4-
tetrahydropyrimidine-5-carboxamide (AKS-922) 
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IR spectrum of N-( 4-Flouro phenyl)- 6- methyl - 2-oxo -4- propyl-1, 2, 3, 4-
tetrahydropyrimidine-5-carboxamide (AKS-923) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
IR spectrum of N-(4-Methylphenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-924) 
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IR spectrum of 6-Methyl-N-(2-methylphenyl)-4-propyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-933) 
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1H NMR spectrum of N-(4-Fluorophenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-923) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH
N
H
CH3
O
NH
F
CH3 O
H
H
H
H
a
b
 c1
c2
 d1
d2
e
f1
f2
 f3
g1
g1 g2
g2
 203
Mass spectrum of 6-Methyl-N-(3-nitrophenyl)-2-oxo-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-928) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of 6-Methyl-N-(3-methylphenyl)-2-oxo-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-926) 
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Mass spectrum of N-(2,3-Dimethylphenyl)-6-methyl-4-propyl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (AKS-937) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of - 6- Methyl -2- oxo- N- phenyl -4- propyl- 1,2,3,4 -
tetrahydropyrimidine-5-carboxamide (AKS-921) 
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Mass spectrum of N-(2,3-Dimethylphenyl)-6-methyl-2-oxo-4-propyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (AKS-927) 
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Biological Activity Study 
The present work deals with the antimicrobial screening of the compounds (AKS 
and VGM series) synthesized in earlier Chapters. 
The minimum inhibition concentration (MIC) values were determined in the 
present study. 
 
Protocol 
Determination of MIC by Agar-dilution method was carried out as per the NCCLS 
guidelines M7-A5 
 
Preparation of plates containing the antimicrobial agent 
To Mueller-Hinton agar (19 ml) medium (Hi Media), cooled to approximately 
500C, 1 ml of antimicrobial agent, dissolved in DMSO is added.  The 
antimicrobial agent is mixed thoroughly into the medium and poured into Borosil 
glass petriplates of 9 cm diameter and allowed to solidify.  The 7 test cultures 
selected for the determination of MIC are spot-inoculated  
(2 ml/spot) on a single plate prepared.  
Preparation of solutions of antimicrobial agents to be incorporated into the agar-
based medium 
10mg of the antimicrobial agent is dissolved in 5ml of DMSO to prepare the main 
stock of the compound to be tested.  1ml of this main stock is added to 19 ml of 
Mueller Hinton agar medium to make the final concentration of 100 mg/ml in the 
agar medium. The main stock solution is further diluted in DMSO by two-fold 
dilution procedure to obtain the desired concentration in the agar medium. 
 
Preparation of inoculum of the test cultures 
For all cultures other than M.smegmatis strains 
One loopful of culture from slant is inoculated into 5mL Muellar Hinton broth 
(HiMedia) in a test tube.  The tube is incubated at 37 0C till the absorbance at 
625nm equals that of 0.5 Mc. Farland standard (Section 5). The absorbance 
readings are taken against a sterile Mueller Hinton broth blank. The cultures are 
then transferred to 2-8oC temperature and maintained this temperature till the 
time of inoculating the plates.  Appropriate dilutions of the cultures (either 10 or 
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100 fold, depending on the culture) are made based on the viable count of the 
cultures, previously done to establish the relationship between absorbance at 
625mn and viable count, before inoculating the plates containing the antimicrobial 
test agents. 2ml of this diluted culture is used to spot-inoculate the plates with 
antimicrobial test agents. 
 
For M.smegmatis strains 
One loopful of the culture from slant is used to inoculate 25 ml Mycoseed brotha 
with 2-3 glass beads.  The broth is incubated at 35 0C for 5 days on 250rpm 
shaker.  2 ml of undiluted, 1:10 and 1:100 fold diluted culture is spot-inoculated 
on a Mueller Hinton agar control plate (section 6) and the spots are observed for 
confluent growth. The maximum dilution of the culture that gives a confluent 
growth of the spot on the Mueller Hinton agar control plates is selected for spot 
inoculation of the plates containing the antimicrobial test agents. 
 
Preparation of 0.5 Mc. Farland standard 
The 0.5 Mc. Farland standard solution as a reference for turbidity measurement 
is prepared as per the NCCLS guidelines M7-A5. 
Briefly, 0.5mL of 1.175% w/v BaCl2 solution is added to 99.5 ml of 1% v/v H2SO4 
solution with constant stirring.  The absorbance of the solution is measured at 
625nm against a D.M.water blank by a uv-visible spectrophotometer. The 
absorbance lies in the range of 0.08 to 0.1. The Mc. Farland standard solution is 
stored in dark at room temperature and vortexed vigorously prior to use. 
 
Controls 
Two control plates (i.e.plates without any antimicrobial agent incorporated into 
the agar medium) with 1ml DMSO in 19mL Mueller Hinton agar medium are kept 
with each MIC experiment to check the growth of the cultures inoculated on the 
plates and the effect of the solvent (DMSO) on the cultures.  2 ml of all the test 
cultures are spot-inoculated onto these two plates. 
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Incubation time and temperature 
The plates are incubated at 35oC for 48 hours for M.smegmatis and 24 hours for 
all other cultures before taking the results of MIC. 
 
Evaluation of the results 
The antimicrobial test compounds that show the growth of all the cultures at a 
concentration of 100 mg/ml are not tested further for the determination of the MIC. 
The compounds that show no growth of any of the culture at 100 mg/ml 
concentration are further tested with lower doses of the test compounds for the 
determination of the MIC values. 
If the test culture that show 1-5 colonies per spot instead of the confluent growth 
as in the control plate, it is considered to be inhibited by the test compound. 
 
 
1. F. Simoncini et al.; Farmaco, 23, 559 (1968); C. A.  69, 109851 (1968). 
2. Bhatt, S., Deo, K., Kundu, P., Chavda, M. & Shah, A.; Indian J. Chem., Sect 42B, 1502  (2003). 
3. Chavda, M., Shah, A., Bhatt, S., Deo, K. & Kundu, P.; Arzneim-Forsch, Drug,  
     Res., 53, 196   (2003). 
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7.1 Antimicrobial Activity  (as per protocol) 
Microorganism (MIC, µg/ml) 
Sr. No 
 
Code 
S.coccus 
Pypgens 
A77 
S.aureus 
SG511 
S.aureus 
E710 
E.coccus 
Faecalis 
M.smegmatis 
(MY-1) 
M.smegmatis 
(MY-1) 
1. VGM-1 2.5 5.0 5.0 10.0 5.0 5.0 
2. VGM-2 2.5 5.0 5.0 10.0 5.0 5.0 
3. VGM-3 1.25 5.0 5.0 - 5.0 5.0 
4. VGM-4 100 - - - - 50 
5. VGM-5 100 - - - - 100 
6. VGM-6 2.5 - - - 12.5 10 
7. VGM-7 5.0 - - - 12.5 12.5 
8. VGM-8 1.25 2.5 2.5 5.0 5.0 5.0 
9. VGM-9 25 - 50 - 100 50 
10. AKS-921 2.5 - - - 12.5 10 
11. AKS-922 12.5 - - - 100 12.5 
12. AKS-923 -- - - - - - 
13. AKS-924 2.5 -- - - - 50 
14. AKS-925 - - - - - - 
15. AKS-926 - - - - 100 100 
16. AKS-575 - - - - 50 - 
17. AKS-576 - - - - - - 
18. AKS-577 - - - - 100 100 
19. AKS-578 - - - - - - 
20. AKS-579 - - - - - - 
21. AKS-580 - - - - - - 
22. AKS-581 - - - - - - 
23. AKS-582 - - - - - - 
24. AKS-583 25.0 - - - 100 - 
25. AKS-584 5.0 - - - 12.5 12.5 
26. AKS-585 5.0 - - - 100 100 
27. AKS-586 2.5 - - - 50 - 
28. AKS-587 12.5 - - - - - 
29. AKS-589 2.5 - -- - - - 
30. AKS-590 --- -  - - - 
31. AKS-901 5.0 - - - - 12.5 
32. AKS-902 -- - - - - - 
33. AKS-903 100 - - - - - 
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7.2 Antimicrobial Activity data  
    
Compound 
1 mg/100ml 
Gram Positive 
S. aureus 
Gram Negative 
E. coli 
VGM-12 15 - 
VGM-13 14 - 
VGM-14 29 - 
VGM-15 25 - 
AKS-910 16 - 
AKS-912 - - 
AKS-913 26 - 
AKS-914 11 - 
AKS-915 - - 
  
* Diameter zones of growth of inhibition in mm.       
 
 
 
 
 
 
 
 
34. AKS-904 -- - - - 100 100 
35. AKS-905 100 - - - 100 - 
36. AKS-906 -- - - - - - 
37. AKS-907 100 - - - - - 
38. AKS-908 100 - - - - - 
39. AKS-909 -- - - - 100 - 
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Conclusion 
Three types of antimicrobial studies were carried out. 
In the first study, Protocol was followed and the minimum inhibition concentration 
were determined of 40 compounds against Streptococcus pyogens A77, 
S.aureus SG511, S.aureus E710, Enterococcus Faecalis,M. Smegmatis MY-1 
and M. Smegmatis MY-2. 
Many compounds have shown very proming MIC at 1.25 mg/ml, 2.5 mg/ml, 5 
mg/ml and 10 mg/ml against some of the species discussed above. 
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SUMMARY OF WORK 
 
The work presented in the thesis entitled “Synthesis, Characterization and 
Pharmacological Study of some Bioactive Molecules” can be summarized below.  
 
Chapter 1 covers synthesis of pyrazolo derivatives. Initially, 2, 4 dimethyl 3-acetyl 
pyrrole are synthesized by Knorr Pyrrole synthesis. Further Chalcone derivatives 
are synthesized from 3-acetyl pyrrole and substituted aromatic aldehyde. Target 
molecules were synthesized from chalcone and hydrazine hydrate using KOH as 
catalyst. In prologue part, various methods for synthesis of pyrrole and biological 
profile were described. The synthesized molecules are well characterized by IR, 
1H NMR and Mass analysis. 
 
In Chapter 2, extension of work on dihydropyridine skeleton modification, carried 
out by synthesis of symmetrical 1, 4-DHPs with naphthyl ring at C3 and C5 site of 
dihydropyridines and asymmetrical derivatives with naphthyl carbamoyl side 
chain. Symmetrical dihydropyridines have been synthesized using 
acetoacetanilide of α-naphthayl amine and substituted aromatic aldehyde with liq. 
ammonia. Total twenty compounds (AKS 1-20) were synthesized and well 
characterized by IR, 1H NMR and Mass technique.  
 
In Chapter 3, a mini review of pyrimidines derivatives containing thiazolo and 
thiazine ring is given. Literature survey included for microwave assisted synthesis 
of 2-oxo and thioxo tetrahydropyrimide derivatives. Biginelli dihydropyrimidine 
synthesis and Intramolecular Heck cyclization in DHPMs skeleton were 
documented. Many bicyclic fused systems synthesized from dihydropyrimidines 
scaffold are discussed. Chemistry and biological importance of thiazolo 
pyrimidine and thiazine pyrimidine scaffold are included in this Chapter.  
 
In Chapter 4, thiazolo and thiazine bicyclic systems are synthezied from Biginelli 
DHPMs derivatives. Thiazolo and thiazine bicyclic scheme are synthesized from 
dihydropyrimidine derivatives and dibromo ethane or dibromo propane 
 235
correspondingly in the presence of potassium bicarbonate as a catalyst. Total 
eighteen compounds are synthesized with thiazolo bicyclic system and 5 
compounds as thiazine system. The synthesized compounds (AKS 551--582) are 
well characterized by IR, 1HNMR and Mass study and also by 13C technique.  
 
Chapter 5 covers synthesis and characterization of N-aryl tetrahydropyrimidine 
derivatives by Biginelli reaction. Introduction of phenyl carbamoyl moiety at C-3 
and/or C-5 position in dihydropyridine skeleton has showed diverse activity 
profile. For the synthesis of N-phenyl dihydropyrimidines, different N-phenyl 
ureas with substitutions (Phenyl, 3-methylphenyl, 2,4-dimethylphenyl) were 
synthesized. Acetoacetanilides with different halogen substitutions (4-chloro, 4-
flouro, 3-chloro-4-flouro) were synthesized. N-phenyl substituted DHPM 
derivatives were obtained by reacting N -(phenyl/3-methylphenyl/2,4-dimethyl) 
urea, (4-chloro, 4-flouro, 3-chloro-4-flouro)acetoacetanilide and substituted 
aromatic aldehyde. All newly synthesized compounds (AKS 901--920) are 
characterized by IR, 1H NMR and Mass spectral analysis. 
 
In Chapter 6, microwave assisted synthesis of oxo and a thioxo 
tetrahydropyrimidine derivative is covered. It was planned to develop various 
modified compounds associated with aliphatic chain at C4 position of 
dihydropyrimidines. Phenyl ring at C4 position of classical dihydropyrimidine was 
replaced with aliphatic chain. Present work deals with an aliphatic aldehyde 
(butyraldehyde) as a substrate to obtain a dihydropyrimidine skeleton without 
phenyl or heteroaryl ring at C4. Microwave irradiation technique was utilized and 
higher yields within shorter reaction time (10-15 minutes) were obtained. Ten new 
oxopyrimidines (AKS. 921-931) and eighteen thioxopyrimidine derivatives (AKS. 
923-940) are synthesized and characterized.  
 
Total 96 compounds are synthesized and characterized in the entire work. 
Representive Synthesized compounds are tested for anti microbial activity and 
further screening for antitubercular and anti viral activity is under investigation. 
The antimicrobial activity data are shown in last chapter  
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